Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,21487100,steady-state plasma exposure,A dose of 60 mg/kg in mice produced a human equivalent sorafenib steady-state plasma exposure of 10 μM.,Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21487100/),μM,10,297,DB00987,Cytarabine
,8453688,plasma levels,"ARA-C levels were not significantly changed in comparison with those obtained in a prior study of ARA-C with THU (ARA-C plasma levels at 3 h, 2630 +/- 1170 ng/ml).","Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453688/),ng,2630,345,DB00987,Cytarabine
greater,6850654,plasma final half-life,Cytarabine distribution was bi- or tri-compartmental; plasma final half-life was greater than 4 hrs in six patients.,High-dose cytarabine in acute leukemia: toxicity and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6850654/),h,4,4978,DB00987,Cytarabine
,26391155,t,"In NHL patients, cumulative higher trough concentrations over the eight administrations of the first cycle (TotC min, categorized by the median 58.71 mg/L) had significant prognostic value regarding the 5-year progression-free survival (PFS: 73.6 vs 46.5 %, P = 0.015) and 5-year overall survival (OS: 74.0 vs 52.2 %, P = 0.034).",Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26391155/),[mg] / [l],58.71,5582,DB00987,Cytarabine
,9835899,Css plasma concentrations,"The Css plasma concentrations of ara-C and ara-U averaged 10.33 +/- 0.81 microM and 139.14 +/- 17.8 microM, respectively.",Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9835899/),μM,10.33,12079,DB00987,Cytarabine
,9835899,Css plasma concentrations,"The Css plasma concentrations of ara-C and ara-U averaged 10.33 +/- 0.81 microM and 139.14 +/- 17.8 microM, respectively.",Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9835899/),μM,139.14,12080,DB00987,Cytarabine
,8926681,retention,"Ara-CTP retention, however, was significantly lower in T-ALL (37 +/- 15%, n = 8) compared to non-T-ALL (67 +/- 25%, n = 33; p < 0.003).",[Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926681/),%,37,18591,DB00987,Cytarabine
,8926681,retention,"Ara-CTP retention, however, was significantly lower in T-ALL (37 +/- 15%, n = 8) compared to non-T-ALL (67 +/- 25%, n = 33; p < 0.003).",[Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926681/),%,67,18592,DB00987,Cytarabine
,8926681,retention,"Ara-CTP retention was also significantly different in children with and without persistence of peripheral blast cells after one week of prednison treatment (71 +/- 30%, n = 9 and 53 +/- 19%, n = 21; p = 0.031) as well as in children with and without complete bone marrow remission on day 15 of the ALL-BFM treatment protocol (66 +/- 17%, n = 19 and 43 +/- 18%, n = 11; p = 0.018).",[Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926681/),%,71,18593,DB00987,Cytarabine
,8926681,retention,"Ara-CTP retention was also significantly different in children with and without persistence of peripheral blast cells after one week of prednison treatment (71 +/- 30%, n = 9 and 53 +/- 19%, n = 21; p = 0.031) as well as in children with and without complete bone marrow remission on day 15 of the ALL-BFM treatment protocol (66 +/- 17%, n = 19 and 43 +/- 18%, n = 11; p = 0.018).",[Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926681/),%,53,18594,DB00987,Cytarabine
,8926681,retention,"Ara-CTP retention was also significantly different in children with and without persistence of peripheral blast cells after one week of prednison treatment (71 +/- 30%, n = 9 and 53 +/- 19%, n = 21; p = 0.031) as well as in children with and without complete bone marrow remission on day 15 of the ALL-BFM treatment protocol (66 +/- 17%, n = 19 and 43 +/- 18%, n = 11; p = 0.018).",[Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926681/),%,66,18595,DB00987,Cytarabine
,8926681,retention,"Ara-CTP retention was also significantly different in children with and without persistence of peripheral blast cells after one week of prednison treatment (71 +/- 30%, n = 9 and 53 +/- 19%, n = 21; p = 0.031) as well as in children with and without complete bone marrow remission on day 15 of the ALL-BFM treatment protocol (66 +/- 17%, n = 19 and 43 +/- 18%, n = 11; p = 0.018).",[Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926681/),%,43,18596,DB00987,Cytarabine
,8926681,retention,"Ara-CTP retention was inversely correlated with the risk groups defined by the ALL-BFM treatment protocols (standard 79 +/- 29, intermediate 59 +/- 25, high risk 47 +/- 21%).",[Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926681/),,79,18597,DB00987,Cytarabine
,8926681,retention,"Ara-CTP retention was inversely correlated with the risk groups defined by the ALL-BFM treatment protocols (standard 79 +/- 29, intermediate 59 +/- 25, high risk 47 +/- 21%).",[Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926681/),,59,18598,DB00987,Cytarabine
,8926681,retention,"Ara-CTP retention was inversely correlated with the risk groups defined by the ALL-BFM treatment protocols (standard 79 +/- 29, intermediate 59 +/- 25, high risk 47 +/- 21%).",[Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926681/),,47,18599,DB00987,Cytarabine
,12560443,duration,"In addition, the mean duration of grade 4 neutropenia was similar in both groups (2.8 and 2.4 days, respectively).","Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12560443/),d,2.8,20431,DB00987,Cytarabine
,12560443,duration,"In addition, the mean duration of grade 4 neutropenia was similar in both groups (2.8 and 2.4 days, respectively).","Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12560443/),d,2.4,20432,DB00987,Cytarabine
,15824414,IC,"Although plasma pharmacokinetics did not correlate with disease response, the median IC of the antisense was higher in the CR patients compared with NRs (17.0 v 4.4 pmol/mg protein, respectively; P = .05).","Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15824414/),[pM] / [mg],17.0,22628,DB00987,Cytarabine
,15824414,IC,"Although plasma pharmacokinetics did not correlate with disease response, the median IC of the antisense was higher in the CR patients compared with NRs (17.0 v 4.4 pmol/mg protein, respectively; P = .05).","Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15824414/),[pM] / [mg],4.4,22629,DB00987,Cytarabine
,33172550,peak concentration,"In the PEG-rhG-CSF group, the peak concentration of PEG-rhG-CSF was 348.2 ng/mL (range 114.7-552.0 ng/mL), the time to peak was 48 hours (range 12-72 hours), and the half life was 14.1 hours (range 11.1-18.1 hours).",[Pharmacokinetics and pharmacodynamics of pegylated recombinant human granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: a prospective control trial]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33172550/),[ng] / [ml],348.2,22644,DB00987,Cytarabine
,33172550,time to peak,"In the PEG-rhG-CSF group, the peak concentration of PEG-rhG-CSF was 348.2 ng/mL (range 114.7-552.0 ng/mL), the time to peak was 48 hours (range 12-72 hours), and the half life was 14.1 hours (range 11.1-18.1 hours).",[Pharmacokinetics and pharmacodynamics of pegylated recombinant human granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: a prospective control trial]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33172550/),h,48,22645,DB00987,Cytarabine
,33172550,half life,"In the PEG-rhG-CSF group, the peak concentration of PEG-rhG-CSF was 348.2 ng/mL (range 114.7-552.0 ng/mL), the time to peak was 48 hours (range 12-72 hours), and the half life was 14.1 hours (range 11.1-18.1 hours).",[Pharmacokinetics and pharmacodynamics of pegylated recombinant human granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: a prospective control trial]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33172550/),h,14.1,22646,DB00987,Cytarabine
,9516951,maximum tolerated plasma concentrations,"The maximum tolerated plasma concentrations for this combination regimen was 10 microM fludarabine for 48 h followed by 72 h of 15 microM ara-C, which were achieved at dose level 3.",Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9516951/),μM,10,23245,DB00987,Cytarabine
,6945865,mean time,"3 Cytosine arabinoside levels declined rapidly after intravenous bolus and subcutaneous bolus injection, and fell below steady state infusion levels after a mean time of 40 min (intravenous bolus) and 100 min (subcutaneous injection).",The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6945865/),min,40,27868,DB00987,Cytarabine
,6945865,mean time,"3 Cytosine arabinoside levels declined rapidly after intravenous bolus and subcutaneous bolus injection, and fell below steady state infusion levels after a mean time of 40 min (intravenous bolus) and 100 min (subcutaneous injection).",The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6945865/),min,100,27869,DB00987,Cytarabine
,8220130,Plas,Plasma protein binding of etoposide is extensive (94%) and alterations of the non-proteinbound fraction affect pharmacokinetic behavior of the drug.,In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220130/),%,94,30213,DB00987,Cytarabine
,8220130,area under the concentration versus time curve AUC(0-infinity),The mean area under the concentration versus time curve AUC(0-infinity) in plasma was at the lower dose level 78.4 +/- 29.1 (mean +/- S.D.) micrograms/ml x h and 201.0 +/- 56.5 micrograms/ml x h at the higher dose level.,In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220130/),[μg] / [h·ml],78.4,30214,DB00987,Cytarabine
,8220130,area under the concentration versus time curve AUC(0-infinity),The mean area under the concentration versus time curve AUC(0-infinity) in plasma was at the lower dose level 78.4 +/- 29.1 (mean +/- S.D.) micrograms/ml x h and 201.0 +/- 56.5 micrograms/ml x h at the higher dose level.,In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220130/),[μg] / [h·ml],201.0,30215,DB00987,Cytarabine
,8220130,fraction of non-proteinbound,The fraction of non-proteinbound etoposide in plasma was 5.2 +/- 3.4 and 5.4 +/- 2.1% in the two treatment groups.,In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220130/),%,5.2,30216,DB00987,Cytarabine
,8220130,fraction of non-proteinbound,The fraction of non-proteinbound etoposide in plasma was 5.2 +/- 3.4 and 5.4 +/- 2.1% in the two treatment groups.,In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220130/),%,5.4,30217,DB00987,Cytarabine
,8220130,AUC(0-16h),"AUC(0-16h) in leukemic cells was 8.4 +/- 8.7 and 22.4 +/- 12.1 micrograms/ml x h at the two dose levels, respectively.",In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220130/),[μg] / [h·ml],8.4,30218,DB00987,Cytarabine
,8220130,AUC(0-16h),"AUC(0-16h) in leukemic cells was 8.4 +/- 8.7 and 22.4 +/- 12.1 micrograms/ml x h at the two dose levels, respectively.",In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220130/),[μg] / [h·ml],22.4,30219,DB00987,Cytarabine
,6204036,kc,"The resulting kc value (0.09 h-1, three rabbits) is similar to that for chemical hydrolysis (0.07 h-1) at 38.8 degrees C.",Pharmacokinetic prodrug modeling: in vitro and in vivo kinetics and mechanisms of ancitabine bioconversion to cytarabine. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6204036/),1/[h],0.09,30809,DB00987,Cytarabine
,6204036,kc,"The resulting kc value (0.09 h-1, three rabbits) is similar to that for chemical hydrolysis (0.07 h-1) at 38.8 degrees C.",Pharmacokinetic prodrug modeling: in vitro and in vivo kinetics and mechanisms of ancitabine bioconversion to cytarabine. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6204036/),1/[h],0.07,30810,DB00987,Cytarabine
,30892988,time to first response,"Fifty-four percent achieved complete remission (CR)/CR with incomplete blood count recovery (median time to first response, 1.4 months).",Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30892988/),month,1.4,31184,DB00987,Cytarabine
,30892988,OS,"The median OS was 10.1 months (95% CI, 5.7 to 14.2), and median DOR was 8.1 months (95% CI, 5.3 to 14.9 months).",Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30892988/),month,10.1,31185,DB00987,Cytarabine
,30892988,DOR,"The median OS was 10.1 months (95% CI, 5.7 to 14.2), and median DOR was 8.1 months (95% CI, 5.3 to 14.9 months).",Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30892988/),month,8.1,31186,DB00987,Cytarabine
,30892988,DOR,"Among patients without prior HMA exposure, CR/CR with incomplete blood count recovery was achieved in 62%, median DOR was 14.8 months (95% CI, 5.5 months to not reached), and median OS was 13.5 months (95% CI, 7.0 to 18.4 months).",Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30892988/),month,14.8,31187,DB00987,Cytarabine
,30892988,OS,"Among patients without prior HMA exposure, CR/CR with incomplete blood count recovery was achieved in 62%, median DOR was 14.8 months (95% CI, 5.5 months to not reached), and median OS was 13.5 months (95% CI, 7.0 to 18.4 months).",Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30892988/),month,13,31188,DB00987,Cytarabine
,18607882,MTD,"The MTD was 200 mg/m(2)/day and 240 mg/m(2)/day for D1-5 q3w and D1-5 q4w, respectively.",Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18607882/),[mg] / [d·m(2)],200,35505,DB00987,Cytarabine
,18607882,MTD,"The MTD was 200 mg/m(2)/day and 240 mg/m(2)/day for D1-5 q3w and D1-5 q4w, respectively.",Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18607882/),[mg] / [d·m(2)],240,35506,DB00987,Cytarabine
,18607882,time to progression (TTP),One objective partial response (PR) with time to progression (TTP) of 22 months was reported in an advanced malignant melanoma patient.,Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18607882/),month,22,35507,DB00987,Cytarabine
,1917392,half-life,"In pharmacokinetic studies, the drug half-life in the vitreous cavity was 124 hr after intravitreal administration of 1.0 mg of FUMP in liposomes.",Liposome suppression of proliferative vitreoretinopathy. Rabbit model using antimetabolite encapsulated liposomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1917392/),h,124,35885,DB00987,Cytarabine
,1917392,half-life,"By contrast, the drug half-life after a single injection in nonliposome-treated controls was only 4.5 hr.",Liposome suppression of proliferative vitreoretinopathy. Rabbit model using antimetabolite encapsulated liposomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1917392/),h,4.5,35886,DB00987,Cytarabine
,9754986,half-life,"The half-life of ACNU was very short (0.2-1.1 h), whereas the half-lives of MTX and Ara-C were relatively long (2.81-13.5 h and 1.84 6.25 h, respectively).","Pharmacokinetics of nimustine, methotrexate, and cytosine arabinoside during cerebrospinal fluid perfusion chemotherapy in patients with disseminated brain tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754986/),h,0.2-1.1,36316,DB00987,Cytarabine
,9754986,half-lives,"The half-life of ACNU was very short (0.2-1.1 h), whereas the half-lives of MTX and Ara-C were relatively long (2.81-13.5 h and 1.84 6.25 h, respectively).","Pharmacokinetics of nimustine, methotrexate, and cytosine arabinoside during cerebrospinal fluid perfusion chemotherapy in patients with disseminated brain tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754986/),h,2.81-13.5,36317,DB00987,Cytarabine
,9754986,half-lives,"The half-life of ACNU was very short (0.2-1.1 h), whereas the half-lives of MTX and Ara-C were relatively long (2.81-13.5 h and 1.84 6.25 h, respectively).","Pharmacokinetics of nimustine, methotrexate, and cytosine arabinoside during cerebrospinal fluid perfusion chemotherapy in patients with disseminated brain tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754986/),h,1.84,36318,DB00987,Cytarabine
,20347037,clearance,"Clofarabine clearance was significantly reduced upon co-administration with, cimetidine (0.83+/-0.22-->0.32+/-0.058mL/min).",Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20347037/),[ml] / [min],0.83,43396,DB00987,Cytarabine
,20347037,clearance,"Clofarabine clearance was significantly reduced upon co-administration with, cimetidine (0.83+/-0.22-->0.32+/-0.058mL/min).",Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20347037/),[ml] / [min],0.32,43397,DB00987,Cytarabine
,20347037,clearance,"In vivo data correlated with IPK results as clofarabine clearance decreased 61% (20.2-7.80mL/min/kg), upon co-administration with cimetidine in rats.",Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20347037/),[ml] / [kg·min],20.2-7.80,43398,DB00987,Cytarabine
,6941040,drug dose required for 90% inhibition of CFU,CML CFUc were significantly more sensitive to Ara-C [drug dose required for 90% inhibition of CFUc growth (LD90) = 0.015 +/- 0.003 microgram/ml] than were normal CFUc (LD90 = 0.038 +/- 0.009 microgram/ml).,Sensitivity of myeloid progenitor cells in healthy subjects and patients with chronic myeloid leukemia to chemotherapeutic agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6941040/),[μg] / [ml],0.015,43815,DB00987,Cytarabine
,6941040,LD90,CML CFUc were significantly more sensitive to Ara-C [drug dose required for 90% inhibition of CFUc growth (LD90) = 0.015 +/- 0.003 microgram/ml] than were normal CFUc (LD90 = 0.038 +/- 0.009 microgram/ml).,Sensitivity of myeloid progenitor cells in healthy subjects and patients with chronic myeloid leukemia to chemotherapeutic agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6941040/),[μg] / [ml],0.038,43816,DB00987,Cytarabine
,7634384,concentration at steady-state (Css),The mean (standard deviation) ara-C concentration at steady-state (Css) and systemic clearance (Cl) were 0.30 (0.13) microM and 134 (71) l/h per m2 respectively.,Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7634384/),μM,0.30,46823,DB00987,Cytarabine
,7634384,systemic clearance (Cl),The mean (standard deviation) ara-C concentration at steady-state (Css) and systemic clearance (Cl) were 0.30 (0.13) microM and 134 (71) l/h per m2 respectively.,Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7634384/),[l] / [h·m2],134,46824,DB00987,Cytarabine
,7634384,Cl,"Males had a significantly faster ara-C Cl (139 vs 131 l/h per m2, P = 0.025) than females.",Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7634384/),[l] / [h·m2],139,46825,DB00987,Cytarabine
,7634384,Cl,"Males had a significantly faster ara-C Cl (139 vs 131 l/h per m2, P = 0.025) than females.",Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7634384/),[l] / [h·m2],131,46826,DB00987,Cytarabine
,7612064,Retention times,"Retention times of araU, araC, and araA are 3.9, 5.9 and 9.4 min, respectively.",Ion-pair liquid chromatography of cytarabine and uracil-arabinoside in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612064/),min,3.9,49357,DB00987,Cytarabine
,7612064,Retention times,"Retention times of araU, araC, and araA are 3.9, 5.9 and 9.4 min, respectively.",Ion-pair liquid chromatography of cytarabine and uracil-arabinoside in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612064/),min,5.9,49358,DB00987,Cytarabine
,7612064,Retention times,"Retention times of araU, araC, and araA are 3.9, 5.9 and 9.4 min, respectively.",Ion-pair liquid chromatography of cytarabine and uracil-arabinoside in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612064/),min,9.4,49359,DB00987,Cytarabine
,7612064,Detection limits,"Detection limits of araC and araU are 10 and 15 ng/ml, resp.",Ion-pair liquid chromatography of cytarabine and uracil-arabinoside in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612064/),[ng] / [ml],10,49360,DB00987,Cytarabine
,7612064,Detection limits,"Detection limits of araC and araU are 10 and 15 ng/ml, resp.",Ion-pair liquid chromatography of cytarabine and uracil-arabinoside in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612064/),[ng] / [ml],15,49361,DB00987,Cytarabine
,21282541,maximum-tolerated dose,The maximum-tolerated dose was 101 units/m(2).,First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21282541/),[units] / [m(2],101,49763,DB00987,Cytarabine
,21282541,half-life,"Median half-life was 31.1 hours (cytarabine) and 21.9 hours (daunorubicin), with both drugs and their metabolites detectable > 7 days after the last dose.",First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21282541/),h,31.1,49764,DB00987,Cytarabine
,21282541,half-life,"Median half-life was 31.1 hours (cytarabine) and 21.9 hours (daunorubicin), with both drugs and their metabolites detectable > 7 days after the last dose.",First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21282541/),h,21.9,49765,DB00987,Cytarabine
,7694271,half-life,"From the conjugate of araC with Gal-CMD, araC was released with a half-life of 36 hr in phosphate buffer (pH 7.4) and 23 hr in plasma.","Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7694271/),h,36,50159,DB00987,Cytarabine
,7694271,half-life,"From the conjugate of araC with Gal-CMD, araC was released with a half-life of 36 hr in phosphate buffer (pH 7.4) and 23 hr in plasma.","Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7694271/),h,23,50160,DB00987,Cytarabine
,16144928,DLT,"With the addition of ara-C, the DLT was reached at 540 microg/wk.",Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144928/),[μg] / [wk],540,55567,DB00987,Cytarabine
,16144928,serum peak concentration (C(max)),"The mean serum peak concentration (C(max)) of PEG-IFN increased from 9.4 to 28 ng/mL as the dose increased from 270 to 450 microg/wk, with no further increases in C(max) at higher dose levels.",Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144928/),[ng] / [ml],9.4,55568,DB00987,Cytarabine
,16144928,serum peak concentration (C(max)),"The mean serum peak concentration (C(max)) of PEG-IFN increased from 9.4 to 28 ng/mL as the dose increased from 270 to 450 microg/wk, with no further increases in C(max) at higher dose levels.",Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144928/),[ng] / [ml],28,55569,DB00987,Cytarabine
,16144928,area under the serum concentration-time curve (AUC),"The mean +/- SD area under the serum concentration-time curve (AUC) calculated after the first dose also increased from 1,022 +/- 694 to 3,343 +/- 2,728 ng hour/mL as dose was increased from 270 to 450 microg/wk, showing a dose-related increase in systemic exposure of PEG-IFN.",Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144928/),[h·ng] / [ml],"1,022",55570,DB00987,Cytarabine
,16144928,area under the serum concentration-time curve (AUC),"The mean +/- SD area under the serum concentration-time curve (AUC) calculated after the first dose also increased from 1,022 +/- 694 to 3,343 +/- 2,728 ng hour/mL as dose was increased from 270 to 450 microg/wk, showing a dose-related increase in systemic exposure of PEG-IFN.",Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144928/),[h·ng] / [ml],"3,343",55571,DB00987,Cytarabine
>,1301593,T1/2,The observed antitumor activity in L1210 cells is primarily associated with higher Ara-CTP pools and retention (T1/2 > 4 hr) in tumor cells as compared with normal bone marrow cells.,1-Beta-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301593/),h,4,58530,DB00987,Cytarabine
<,1301593,T1/2,"In the least responsive tumor (P-388), although Ara-CTP pools were sufficiently high, retention of the drug in tumor cells and in normal cells is poor with a T1/2 < 2 hr.",1-Beta-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301593/),h,2,58531,DB00987,Cytarabine
,8995498,CL,"The final parameter estimates were: CL = 2.59 x AGE x SA 1/h, Q = 2.01 x AGE x SA 1/h, Vd1 = 0.48 x AGE x SA1, and Vd2 = 38.1 x AGE x SA1.",NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8995498/),,2.59,59104,DB00987,Cytarabine
,8995498,Q,"The final parameter estimates were: CL = 2.59 x AGE x SA 1/h, Q = 2.01 x AGE x SA 1/h, Vd1 = 0.48 x AGE x SA1, and Vd2 = 38.1 x AGE x SA1.",NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8995498/),,2.01,59105,DB00987,Cytarabine
,8995498,Vd1,"The final parameter estimates were: CL = 2.59 x AGE x SA 1/h, Q = 2.01 x AGE x SA 1/h, Vd1 = 0.48 x AGE x SA1, and Vd2 = 38.1 x AGE x SA1.",NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8995498/),,0.48,59106,DB00987,Cytarabine
,8995498,Vd2,"The final parameter estimates were: CL = 2.59 x AGE x SA 1/h, Q = 2.01 x AGE x SA 1/h, Vd1 = 0.48 x AGE x SA1, and Vd2 = 38.1 x AGE x SA1.",NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8995498/),,38.1,59107,DB00987,Cytarabine
,1961042,peak plasma Ara-C levels at 3 h (Cp3h),"Pharmacokinetic studies revealed, for group I, mean peak plasma Ara-C levels at 3 h (Cp3h) of 1254 ng/ml, area under the curve (AUC) 4651 ng x h/ml, total body clearance (TBC) 32.65 l/h/m2, renal clearance (RC) 7.04 l/h/m2 with a mean of 12.36% of the injected amount of Ara-C excreted unchanged in urine over the first 24 h.",Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1961042/),[ng] / [ml],1254,59357,DB00987,Cytarabine
,1961042,area under the curve (AUC),"Pharmacokinetic studies revealed, for group I, mean peak plasma Ara-C levels at 3 h (Cp3h) of 1254 ng/ml, area under the curve (AUC) 4651 ng x h/ml, total body clearance (TBC) 32.65 l/h/m2, renal clearance (RC) 7.04 l/h/m2 with a mean of 12.36% of the injected amount of Ara-C excreted unchanged in urine over the first 24 h.",Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1961042/),[h·ng] / [ml],4651,59358,DB00987,Cytarabine
,1961042,total body clearance (TBC),"Pharmacokinetic studies revealed, for group I, mean peak plasma Ara-C levels at 3 h (Cp3h) of 1254 ng/ml, area under the curve (AUC) 4651 ng x h/ml, total body clearance (TBC) 32.65 l/h/m2, renal clearance (RC) 7.04 l/h/m2 with a mean of 12.36% of the injected amount of Ara-C excreted unchanged in urine over the first 24 h.",Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1961042/),[l] / [h·m2],32.65,59359,DB00987,Cytarabine
,1961042,renal clearance (RC),"Pharmacokinetic studies revealed, for group I, mean peak plasma Ara-C levels at 3 h (Cp3h) of 1254 ng/ml, area under the curve (AUC) 4651 ng x h/ml, total body clearance (TBC) 32.65 l/h/m2, renal clearance (RC) 7.04 l/h/m2 with a mean of 12.36% of the injected amount of Ara-C excreted unchanged in urine over the first 24 h.",Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1961042/),[l] / [h·m2],7.04,59360,DB00987,Cytarabine
,1961042,Cp3h,"The corresponding mean values for group II are Cp3h 3305 ng/ml, AUC 15080 ng x h/ml, TBC 20.48 l/h/m2, RC 7.02 l/h/m2 and 26.23%.",Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1961042/),[ng] / [ml],3305,59361,DB00987,Cytarabine
,1961042,AUC,"The corresponding mean values for group II are Cp3h 3305 ng/ml, AUC 15080 ng x h/ml, TBC 20.48 l/h/m2, RC 7.02 l/h/m2 and 26.23%.",Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1961042/),[h·ng] / [ml],15080,59362,DB00987,Cytarabine
,1961042,TBC,"The corresponding mean values for group II are Cp3h 3305 ng/ml, AUC 15080 ng x h/ml, TBC 20.48 l/h/m2, RC 7.02 l/h/m2 and 26.23%.",Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1961042/),[l] / [h·m2],20.48,59363,DB00987,Cytarabine
,1961042,RC,"The corresponding mean values for group II are Cp3h 3305 ng/ml, AUC 15080 ng x h/ml, TBC 20.48 l/h/m2, RC 7.02 l/h/m2 and 26.23%.",Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1961042/),[l] / [h·m2],7.02,59364,DB00987,Cytarabine
,1961042,RC,"The corresponding mean values for group II are Cp3h 3305 ng/ml, AUC 15080 ng x h/ml, TBC 20.48 l/h/m2, RC 7.02 l/h/m2 and 26.23%.",Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1961042/),%,26.23,59365,DB00987,Cytarabine
,1961042,Cp3h,"Pharmacokinetics for uracil arabinoside (Ara-U) in patients treated with Ara-C 200 mg/m2 plus THU, were comparable to values seen with Ara-C for Cp3h, AUC and 24 h urine, amounting to 3160 ng/ml, 21717 ng x h/ml and 23.62% whereas TBC was significantly lower (p less than 0.001) for Ara-U than for Ara-C (3.02 versus 20.48 l/h/m2).",Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1961042/),[ng] / [ml],3160,59366,DB00987,Cytarabine
,1961042,AUC,"Pharmacokinetics for uracil arabinoside (Ara-U) in patients treated with Ara-C 200 mg/m2 plus THU, were comparable to values seen with Ara-C for Cp3h, AUC and 24 h urine, amounting to 3160 ng/ml, 21717 ng x h/ml and 23.62% whereas TBC was significantly lower (p less than 0.001) for Ara-U than for Ara-C (3.02 versus 20.48 l/h/m2).",Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1961042/),[h·ng] / [ml],21717,59367,DB00987,Cytarabine
,1961042,24 h urine,"Pharmacokinetics for uracil arabinoside (Ara-U) in patients treated with Ara-C 200 mg/m2 plus THU, were comparable to values seen with Ara-C for Cp3h, AUC and 24 h urine, amounting to 3160 ng/ml, 21717 ng x h/ml and 23.62% whereas TBC was significantly lower (p less than 0.001) for Ara-U than for Ara-C (3.02 versus 20.48 l/h/m2).",Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1961042/),%,23.62,59368,DB00987,Cytarabine
,4031970,elimination half life,Mean Ara-C elimination half life of 140 minutes in CSF was eight times longer than that in plasma.,Central nervous system pharmacokinetics of high-dose cytosine arabinoside. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4031970/),min,140,60970,DB00987,Cytarabine
,4031970,peak mean CSF concentration,The peak mean CSF concentration of Ara-C (2.1 micrograms /ml) was about 7% of the plasma concentration (30 micrograms/ml).,Central nervous system pharmacokinetics of high-dose cytosine arabinoside. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4031970/),[μg] / [ml],2.1,60971,DB00987,Cytarabine
,16322302,maximal tolerated dose,"Dose-limiting toxicity occurred at 60 mg/m2/d with profound neutropenia >40 days duration, and maximal tolerated dose was 50 mg/m2/d.",Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16322302/),[mg] / [d·m2],50,61138,DB00987,Cytarabine
,16322302,Overall response rate,Overall response rate was 31% in 26 acute myelogenous leukemia and 12.5% in acute lymphoblastic leukemia.,Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16322302/),%,31,61139,DB00987,Cytarabine
,16322302,Overall response rate,Overall response rate was 31% in 26 acute myelogenous leukemia and 12.5% in acute lymphoblastic leukemia.,Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16322302/),%,12.5,61140,DB00987,Cytarabine
,10864038,half-lives,"The half-lives of Ara-C, MTX, and ACNU were 2.65, 3.52, and 0.71 h, respectively.","Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10864038/),h,2.65,61642,DB00987,Cytarabine
,10864038,half-lives,"The half-lives of Ara-C, MTX, and ACNU were 2.65, 3.52, and 0.71 h, respectively.","Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10864038/),h,3.52,61643,DB00987,Cytarabine
,10864038,half-lives,"The half-lives of Ara-C, MTX, and ACNU were 2.65, 3.52, and 0.71 h, respectively.","Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10864038/),h,0.71,61644,DB00987,Cytarabine
,10864038,concentrations,"The mean total and free VPA concentrations in plasma were 78.0+/-0.8 and 10.9-0.3 microg/ml, respectively.","Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10864038/),[μg] / [ml],10.9-0.3,61645,DB00987,Cytarabine
,34080695,peak CA concentration,"Median peak CA concentration for the SC protocol (3.40 µg/ml, range 1.60-9.70 µg/ml) was significantly higher than the CRI (1.09 µg/ml, range 0.77-1.67 µg/ml; p = .02).",Pharmacokinetics of a cytosine arabinoside subcutaneous protocol in dogs with meningoencephalomyelitis of unknown aetiology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34080695/),[μg] / [ml],3.40,64378,DB00987,Cytarabine
,34080695,peak CA concentration,"Median peak CA concentration for the SC protocol (3.40 µg/ml, range 1.60-9.70 µg/ml) was significantly higher than the CRI (1.09 µg/ml, range 0.77-1.67 µg/ml; p = .02).",Pharmacokinetics of a cytosine arabinoside subcutaneous protocol in dogs with meningoencephalomyelitis of unknown aetiology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34080695/),[μg] / [ml],1.09,64379,DB00987,Cytarabine
,34080695,CA1,"Median concentration at 1h and 8h following initiation of treatment was significantly higher for the SC protocol (CA1 2.28 µg/ml, range 0.97-2.67; CA8 1.83 µg/ml, range 0.77-2.84) compared to the CRI (CA1 0.01 µg/ml, range 0-0.45; CA8 0.74 µg/ml, range 0.67-1.11; p = .01).",Pharmacokinetics of a cytosine arabinoside subcutaneous protocol in dogs with meningoencephalomyelitis of unknown aetiology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34080695/),[μg] / [ml],2.28,64380,DB00987,Cytarabine
,34080695,CA1,"Median concentration at 1h and 8h following initiation of treatment was significantly higher for the SC protocol (CA1 2.28 µg/ml, range 0.97-2.67; CA8 1.83 µg/ml, range 0.77-2.84) compared to the CRI (CA1 0.01 µg/ml, range 0-0.45; CA8 0.74 µg/ml, range 0.67-1.11; p = .01).",Pharmacokinetics of a cytosine arabinoside subcutaneous protocol in dogs with meningoencephalomyelitis of unknown aetiology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34080695/),[μg] / [ml],0.01,64381,DB00987,Cytarabine
,34080695,CA8,"Median concentration at 1h and 8h following initiation of treatment was significantly higher for the SC protocol (CA1 2.28 µg/ml, range 0.97-2.67; CA8 1.83 µg/ml, range 0.77-2.84) compared to the CRI (CA1 0.01 µg/ml, range 0-0.45; CA8 0.74 µg/ml, range 0.67-1.11; p = .01).",Pharmacokinetics of a cytosine arabinoside subcutaneous protocol in dogs with meningoencephalomyelitis of unknown aetiology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34080695/),[μg] / [ml],0.74,64382,DB00987,Cytarabine
,23585305,ﬂow rate,"The supernatant was separated on a reversed phase C18 column with a mobile phase of 10 mM KH2PO4 buffer solution (pH 6.3) containing 10 mM perchloric acid using isocratic elution (at ﬂow rate 1.5 mL/min), and detected using an ultraviolet detector at 280 nm.",Determination of mizoribine in human plasma using high-performance liquid chromatography: application to a pharmacokinetic study in Chinese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585305/),[ml] / [min],1.5,70546,DB00987,Cytarabine
,9853980,CR rate,The CR rate after two courses with this regimen was 77%.,High single dose of mitoxantrone and cytarabine in acute non-lymphocytic leukemia: a pharmacokinetic and clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853980/),%,77,71027,DB00987,Cytarabine
,8102639,overall response rate,"Twenty-six (62%) patients achieved a complete remission (CR) or restored chronic phase and three patients achieved a partial remission (PR) for an overall response rate of 69% (95% confidence interval, 54% to 84%).",Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8102639/),%,69,71305,DB00987,Cytarabine
,8229133,MTD,"The MTD was 75 mg of DTC 101, and seven of nine patients manifested cytologic responses.",Extended CSF cytarabine exposure following intrathecal administration of DTC 101. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229133/),mg,75,71472,DB00987,Cytarabine
,9316874,affinity,Binding of NOAC incorporated into liposomes to erythrocytes (Ec) was saturated at 63 nmol/10(9) Ec and binding analysis resulted in a weak affinity of 3 x 10(3) liters/mol and 4 x 10(7) binding sites per Ec.,"Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-beta-D-arabinofuranosylcytosine, a new anticancer drug. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316874/),[l] / [mol],3 x,73416,DB00987,Cytarabine
,9316874,affinity,Binding of NOAC incorporated into liposomes to erythrocytes (Ec) was saturated at 63 nmol/10(9) Ec and binding analysis resulted in a weak affinity of 3 x 10(3) liters/mol and 4 x 10(7) binding sites per Ec.,"Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-beta-D-arabinofuranosylcytosine, a new anticancer drug. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316874/),,4 x,73417,DB00987,Cytarabine
,9316874,partition coefficient D(Ec),"The Ec partition coefficient D(Ec) was approximately 4, which demonstrates the high accumulation of NOAC in Ec membranes.","Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-beta-D-arabinofuranosylcytosine, a new anticancer drug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316874/),,4,73418,DB00987,Cytarabine
,9316874,fraction f(b),The calculated fraction f(b) of drug bound to plasma proteins was 30%.,"Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-beta-D-arabinofuranosylcytosine, a new anticancer drug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316874/),%,30,73419,DB00987,Cytarabine
,9316874,distribution half-life t1/2alpha,The biodistribution of liposomal NOAC in ICR mice after intravenous application revealed a biphasic blood concentration versus time curve with a distribution half-life t1/2alpha of 23 min and an elimination half-life t1/2beta of 7 h.,"Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-beta-D-arabinofuranosylcytosine, a new anticancer drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316874/),min,23,73420,DB00987,Cytarabine
,9316874,elimination half-life t1/2beta,The biodistribution of liposomal NOAC in ICR mice after intravenous application revealed a biphasic blood concentration versus time curve with a distribution half-life t1/2alpha of 23 min and an elimination half-life t1/2beta of 7 h.,"Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-beta-D-arabinofuranosylcytosine, a new anticancer drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316874/),h,7,73421,DB00987,Cytarabine
,9316874,elimination half-life,The drug was distributed mainly into the liver with an organ load of 69% and with an elimination half-life of 8 h.,"Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-beta-D-arabinofuranosylcytosine, a new anticancer drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316874/),h,8,73422,DB00987,Cytarabine
,12439044,clearance rate,"The average clearance rate, reflecting systemic clearance and clearance by continuous venovenous hemofiltration and hemodialysis, was 12.4 L/hour per m for the first 3 days of 2-CdA therapy.",Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12439044/),[l] / [h·m],12.4,74076,DB00987,Cytarabine
,6668493,Apparent steady state plasma levels,Apparent steady state plasma levels of ara-C during 13 infusions averaged 115 +/- 32 microM.,"Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668493/),μM,115,77494,DB00987,Cytarabine
,6668493,distribution half-life,The apparent postinfusion kinetics of ara-C were triexponential with a distribution half-life of 16 minutes and elimination half-lives of 1.8 hours and six hours.,"Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668493/),min,16,77495,DB00987,Cytarabine
,6668493,elimination half-lives,The apparent postinfusion kinetics of ara-C were triexponential with a distribution half-life of 16 minutes and elimination half-lives of 1.8 hours and six hours.,"Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668493/),h,1.8,77496,DB00987,Cytarabine
,6668493,elimination half-lives,The apparent postinfusion kinetics of ara-C were triexponential with a distribution half-life of 16 minutes and elimination half-lives of 1.8 hours and six hours.,"Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668493/),h,six,77497,DB00987,Cytarabine
,6668493,Total clearance,Total clearance averaged 86 L per hour and mean residence time averaged 0.47 hours.,"Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668493/),[l] / [h],86,77498,DB00987,Cytarabine
,6668493,mean residence time,Total clearance averaged 86 L per hour and mean residence time averaged 0.47 hours.,"Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668493/),h,0.47,77499,DB00987,Cytarabine
,6668493,Peak levels,Peak levels of ara-U averaged 310 microM and the metabolite had an average apparent elimination half-life of 3.75 hours.,"Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668493/),μM,310,77500,DB00987,Cytarabine
,6668493,apparent elimination half-life,Peak levels of ara-U averaged 310 microM and the metabolite had an average apparent elimination half-life of 3.75 hours.,"Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668493/),h,3.75,77501,DB00987,Cytarabine
,18836794,half-life,"Under the conditions of renal impairment, AraU half-life was about 75 h and the AUC was about 12-fold higher than for patients with normal renal function.",AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18836794/),h,75,77988,DB00987,Cytarabine
,8442704,initial half-life,The ventricular concentration of free cytarabine released from DTC 101 into cerebrospinal fluid decreased biexponentially with an initial half-life of 7.2 +/- 1.7 (+/- SEM) hours and a terminal half-life of 140 +/- 49 hours.,Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8442704/),h,7.2,81839,DB00987,Cytarabine
,8442704,terminal half-life,The ventricular concentration of free cytarabine released from DTC 101 into cerebrospinal fluid decreased biexponentially with an initial half-life of 7.2 +/- 1.7 (+/- SEM) hours and a terminal half-life of 140 +/- 49 hours.,Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8442704/),h,140,81840,DB00987,Cytarabine
,8442704,duration of response,"The duration of response ranged from 2 to more than 14 weeks, with a median of over 11 weeks.",Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8442704/),,2 to more,81841,DB00987,Cytarabine
,10456485,area under the concentration time-curve (AUC),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],558.26,85527,DB00987,Cytarabine
,10456485,area under the concentration time-curve (AUC),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],315.44,85528,DB00987,Cytarabine
,10456485,area under the concentration time-curve (AUC),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],2896.60,85529,DB00987,Cytarabine
,10456485,area under the concentration time-curve (AUC),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],1028.49,85530,DB00987,Cytarabine
,10456485,total body clearance (CL),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[l] / [(m)^2·h],83.51,85531,DB00987,Cytarabine
,10456485,total body clearance (CL),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[l] / [(m)^2·h],139.65,85532,DB00987,Cytarabine
,10456485,exposure,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],331.29,85533,DB00987,Cytarabine
,10456485,exposure,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],315.44,85534,DB00987,Cytarabine
,10456485,total body exposure,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],2030.32,85535,DB00987,Cytarabine
,10456485,total body exposure,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],1028.49,85536,DB00987,Cytarabine
,10456485,AUC,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],2030.32,85537,DB00987,Cytarabine
,10456485,AUC,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],2896.60,85538,DB00987,Cytarabine
,18821152,t(1/2),Pharmacokinetic studies of CGPCLL resulted in higher t(1/2) (28.86 h) and AUC 2526.88 mug/mL h compared with cytarabine-loaded liposomal suspension (CLLS) and C-GP containing free cytarabine (CGPFC) in rats.,Chitosan-based thermosensitive hydrogel containing liposomes for sustained delivery of cytarabine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18821152/),h,28.86,86165,DB00987,Cytarabine
,18821152,AUC,Pharmacokinetic studies of CGPCLL resulted in higher t(1/2) (28.86 h) and AUC 2526.88 mug/mL h compared with cytarabine-loaded liposomal suspension (CLLS) and C-GP containing free cytarabine (CGPFC) in rats.,Chitosan-based thermosensitive hydrogel containing liposomes for sustained delivery of cytarabine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18821152/),[μg] / [h·ml],2526.88,86166,DB00987,Cytarabine
,17171362,Cmax,The intracellular accumulation of ara-CTP was significantly lower in normal lymphocytes (Cmax 47.7-60.9 pmol/10(6) cells) compared to leukemic cell lines (Cmax 11-1128 pmol/10(6) cells) and leukemic cells of our patients (Cmax 85.9-631 pmol/10(6) cells).,Pharmacology of intracellular cytosine-arabinoside-5'-triphosphate in malignant cells of pediatric patients with initial or relapsed leukemia and in normal lymphocytes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17171362/),[pM] / [10(6)·cells],47.7-60.9,86471,DB00987,Cytarabine
,17171362,Cmax,The intracellular accumulation of ara-CTP was significantly lower in normal lymphocytes (Cmax 47.7-60.9 pmol/10(6) cells) compared to leukemic cell lines (Cmax 11-1128 pmol/10(6) cells) and leukemic cells of our patients (Cmax 85.9-631 pmol/10(6) cells).,Pharmacology of intracellular cytosine-arabinoside-5'-triphosphate in malignant cells of pediatric patients with initial or relapsed leukemia and in normal lymphocytes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17171362/),[pM] / [10(6)·cells],11-1128,86472,DB00987,Cytarabine
,17171362,Cmax,The intracellular accumulation of ara-CTP was significantly lower in normal lymphocytes (Cmax 47.7-60.9 pmol/10(6) cells) compared to leukemic cell lines (Cmax 11-1128 pmol/10(6) cells) and leukemic cells of our patients (Cmax 85.9-631 pmol/10(6) cells).,Pharmacology of intracellular cytosine-arabinoside-5'-triphosphate in malignant cells of pediatric patients with initial or relapsed leukemia and in normal lymphocytes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17171362/),[pM] / [10(6)·cells],85.9-631,86473,DB00987,Cytarabine
,10885585,systemic clearance,"Following intravenous administration at 30 to 450 mg/m2, DMDC has low systemic clearance (10 to 15 L/h/m2), moderate volume of distribution (nominally similar to total body water) and a short elimination half-life of between 2 and 6 hours.","Clinical pharmacokinetics of 2'-deoxy-2'-methylidenecytidine (DMDC), a deoxycytidine analogue antineoplastic agent. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885585/),[l] / [h·m2],10 to 15,87076,DB00987,Cytarabine
,10885585,elimination half-life,"Following intravenous administration at 30 to 450 mg/m2, DMDC has low systemic clearance (10 to 15 L/h/m2), moderate volume of distribution (nominally similar to total body water) and a short elimination half-life of between 2 and 6 hours.","Clinical pharmacokinetics of 2'-deoxy-2'-methylidenecytidine (DMDC), a deoxycytidine analogue antineoplastic agent. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885585/),h,2 and 6,87077,DB00987,Cytarabine
,10885585,maximum DMDC plasma concentrations,"Following oral administration of DMDC at 12 to 50 mg/m2, mean maximum DMDC plasma concentrations are within the 100 to 400 microg/L range and are generally reached within 2 hours.","Clinical pharmacokinetics of 2'-deoxy-2'-methylidenecytidine (DMDC), a deoxycytidine analogue antineoplastic agent. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885585/),[μg] / [l],100 to 400,87078,DB00987,Cytarabine
,10885585,Oral bioavailability,"Oral bioavailability of DMDC is in the order of 40%, largely as a result of first-pass metabolism in the gut and liver.","Clinical pharmacokinetics of 2'-deoxy-2'-methylidenecytidine (DMDC), a deoxycytidine analogue antineoplastic agent. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885585/),%,40,87079,DB00987,Cytarabine
,21516131,liver target index,"The conjugates 6 and 16 showed high specificity in targeting the liver (liver target index 34.9 and 16.3, respectively) and good absorption in vivo, as compared with cytarabine.",Novel liver-specific cholic acid-cytarabine conjugates with potent antitumor activities: Synthesis and biological characterization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21516131/),,34.9,87545,DB00987,Cytarabine
,21516131,liver target index,"The conjugates 6 and 16 showed high specificity in targeting the liver (liver target index 34.9 and 16.3, respectively) and good absorption in vivo, as compared with cytarabine.",Novel liver-specific cholic acid-cytarabine conjugates with potent antitumor activities: Synthesis and biological characterization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21516131/),,16.3,87546,DB00987,Cytarabine
,8988727,duration of complete remission,"The median duration of complete remission was 4 months (range, 1-14 months) whereas overall survival time lasted for a median of 4.5 months (range, 1-30+ months).",High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8988727/),month,4,87863,DB00987,Cytarabine
,8988727,overall survival time,"The median duration of complete remission was 4 months (range, 1-14 months) whereas overall survival time lasted for a median of 4.5 months (range, 1-30+ months).",High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8988727/),month,4.5,87864,DB00987,Cytarabine
>,8640171,AUC,Eighteen of 51 (35.3%) evaluable patients had an AUC > 1500 mumol x min/l; 10 of whom received doses reduced proportionally to achieve an AUC = 1200 mumol x min/l starting with the 10th to 15th dose.,Association of busulfan area under the curve with veno-occlusive disease following BMT. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8640171/),[min·μM] / [l],1500,89824,DB00987,Cytarabine
,8640171,AUC,Eighteen of 51 (35.3%) evaluable patients had an AUC > 1500 mumol x min/l; 10 of whom received doses reduced proportionally to achieve an AUC = 1200 mumol x min/l starting with the 10th to 15th dose.,Association of busulfan area under the curve with veno-occlusive disease following BMT. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8640171/),[min·μM] / [l],1200,89825,DB00987,Cytarabine
>,8640171,AUC,Six of 18 (33.3%) patients with an initial AUC > 1500 mumol x min/l developed VOD vs one of 33 (3.0%) patients with an initial AUC < 1500 mumol x min/l (relative risk = 11.1; P = 0.0056).,Association of busulfan area under the curve with veno-occlusive disease following BMT. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8640171/),[min·μM] / [l],1500,89826,DB00987,Cytarabine
<,8640171,AUC,Six of 18 (33.3%) patients with an initial AUC > 1500 mumol x min/l developed VOD vs one of 33 (3.0%) patients with an initial AUC < 1500 mumol x min/l (relative risk = 11.1; P = 0.0056).,Association of busulfan area under the curve with veno-occlusive disease following BMT. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8640171/),[min·μM] / [l],1500,89827,DB00987,Cytarabine
,6572569,area under the curve (AUC),The mean area under the curve (AUC) was 1147 +/- 230 ng/ml for the IV infusion and 1017 +/- 238 ng/ml for the SC infusion.,Subcutaneous infusion of cytosine arabinoside. A practical alternative to intravenous infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6572569/),[ng] / [ml],1147,91671,DB00987,Cytarabine
,6572569,area under the curve (AUC),The mean area under the curve (AUC) was 1147 +/- 230 ng/ml for the IV infusion and 1017 +/- 238 ng/ml for the SC infusion.,Subcutaneous infusion of cytosine arabinoside. A practical alternative to intravenous infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6572569/),[ng] / [ml],1017,91672,DB00987,Cytarabine
,3607782,half-life,The total amount of the drug in the peritoneal cavity decreased with a 21-hour half-life.,Multivesicular liposomes containing cytarabine entrapped in the presence of hydrochloric acid for intracavitary chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3607782/),h,21,92851,DB00987,Cytarabine
,6433796,peak ventricular concentration,"The peak ventricular concentration of MTX, which was administered by Ommaya reservoir, at a dose of 15mg/m2, was 2.5 +/- 0.9 X 10(-4)M, and remained as a level of 10(-6)M for 72 hours with a half-life of 10.5 hours.",[Pharmacokinetics of intrathecal chemotherapy and clinical problems]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6433796/),M,2.5,93257,DB00987,Cytarabine
,6433796,half-life,"The peak ventricular concentration of MTX, which was administered by Ommaya reservoir, at a dose of 15mg/m2, was 2.5 +/- 0.9 X 10(-4)M, and remained as a level of 10(-6)M for 72 hours with a half-life of 10.5 hours.",[Pharmacokinetics of intrathecal chemotherapy and clinical problems]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6433796/),h,10.5,93258,DB00987,Cytarabine
,2797645,Survival,Survival of control mice injected with 10(4) murine ovarian teratocarcinoma was 28 days.,Synergistic effect of combined intraperitoneal cisplatin and cytosine arabinoside in a murine ovarian cancer model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2797645/),d,28,94140,DB00987,Cytarabine
,15571270,maximum tolerated dose (MTD),Phase I studies among 32 patients with acute leukemia defined a maximum tolerated dose (MTD) of 40 mg/m2/d given as a one hour infusion daily for 5 days.,Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15571270/),[mg] / [d·m2],40,95777,DB00987,Cytarabine
,15571270,overall response rate,"Twenty patients (32%) achieved complete response (CR), 1 had a partial response (PR), and 9 had a CR but without platelet recovery (CRp), for an overall response rate of 48%.",Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15571270/),%,48,95778,DB00987,Cytarabine
,19342996,concentration,The median TGN concentration in non-DS children above 2 years of age was 2.30 micromol/mmol Hb (range 0.57-25.3).,Thioguanine pharmacokinetics in induction therapy of children with acute myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19342996/),[μM] / [hb·mM],2.30,97683,DB00987,Cytarabine
,2791191,peak plasma level,"The peak plasma level was 22.9 +/- 6.4 ng/ml, and the predicted time to reach the peak level was 2.5 +/- 1.0 h.",Clinical pharmacology of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in patients with hematologic malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791191/),[ng] / [ml],22.9,99900,DB00987,Cytarabine
,2791191,time to reach the peak level,"The peak plasma level was 22.9 +/- 6.4 ng/ml, and the predicted time to reach the peak level was 2.5 +/- 1.0 h.",Clinical pharmacology of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in patients with hematologic malignancies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791191/),h,2.5,99901,DB00987,Cytarabine
,2791191,elimination half-life,The elimination half-life was 3.8 +/- 2.7 h.,Clinical pharmacology of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in patients with hematologic malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791191/),h,3.8,99902,DB00987,Cytarabine
,2791191,peak concentration,"Plasma ara-U was detectable for at least 24 h, with a peak concentration of 376 ng/ml at 6 h.",Clinical pharmacology of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in patients with hematologic malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791191/),[ng] / [ml],376,99903,DB00987,Cytarabine
below,2791191,excretion,Urinary PLAC excretion was below the limit of detection (5 ng/ml) in all cases.,Clinical pharmacology of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in patients with hematologic malignancies. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791191/),[ng] / [ml],5,99904,DB00987,Cytarabine
,26696583,elimination half-life,The median MTX elimination half-life was 21.7 h (range 9.4-204.4).,The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26696583/),h,21.7,105605,DB00987,Cytarabine
,6654641,cumulative urinary excretion,"The cumulative urinary excretion over 12 hours was 67% and 70% for the subconjunctivally and intravenously injected animals, respectively, and peak serum levels were 0.061 mM and 0.170 mM, respectively.",Subconjunctival versus intravenous cytosine arabinoside: effect of route of administration and ocular toxicity. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654641/),%,67,106266,DB00987,Cytarabine
,6654641,cumulative urinary excretion,"The cumulative urinary excretion over 12 hours was 67% and 70% for the subconjunctivally and intravenously injected animals, respectively, and peak serum levels were 0.061 mM and 0.170 mM, respectively.",Subconjunctival versus intravenous cytosine arabinoside: effect of route of administration and ocular toxicity. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654641/),%,70,106267,DB00987,Cytarabine
,6654641,peak serum levels,"The cumulative urinary excretion over 12 hours was 67% and 70% for the subconjunctivally and intravenously injected animals, respectively, and peak serum levels were 0.061 mM and 0.170 mM, respectively.",Subconjunctival versus intravenous cytosine arabinoside: effect of route of administration and ocular toxicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654641/),mM,0.061,106268,DB00987,Cytarabine
,6654641,peak serum levels,"The cumulative urinary excretion over 12 hours was 67% and 70% for the subconjunctivally and intravenously injected animals, respectively, and peak serum levels were 0.061 mM and 0.170 mM, respectively.",Subconjunctival versus intravenous cytosine arabinoside: effect of route of administration and ocular toxicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654641/),mM,0.170,106269,DB00987,Cytarabine
,3702507,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) in patients with non-hematological solid tumors was assumed to be 5 mg kg-1 daily X 5 days.,Phase I clinical and pharmacokinetic study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3702507/),[mg] / [kg],5,108677,DB00987,Cytarabine
,3702507,half-lives of the initial phase (t1/2 alpha),"The plasma disappearance curve of BHAC looked biphasic, and when 4 mg kg-1 of BHAC were administered the half-lives of the initial phase (t1/2 alpha) and the second phase (t1/2 beta) were calculated as 0.798 and 5.76 h respectively.",Phase I clinical and pharmacokinetic study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3702507/),h,0.798,108678,DB00987,Cytarabine
,3702507,second phase (t1/2 beta),"The plasma disappearance curve of BHAC looked biphasic, and when 4 mg kg-1 of BHAC were administered the half-lives of the initial phase (t1/2 alpha) and the second phase (t1/2 beta) were calculated as 0.798 and 5.76 h respectively.",Phase I clinical and pharmacokinetic study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3702507/),h,5.76,108679,DB00987,Cytarabine
,8453629,initial,"Following a single 2-mg dose, the Depo/Ara-C concentration decreased biexponentially with initial and terminal half-lives of 14.6 and 156 h, respectively.",Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453629/),h,14.6,110843,DB00987,Cytarabine
,8453629,terminal half-lives,"Following a single 2-mg dose, the Depo/Ara-C concentration decreased biexponentially with initial and terminal half-lives of 14.6 and 156 h, respectively.",Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453629/),h,156,110844,DB00987,Cytarabine
,8453629,minimal cytotoxic level,The free drug concentration remained above the reported minimal cytotoxic level of 0.1 micrograms/ml (0.4 microM) for more than 672 h (28 days).,Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453629/),[μg] / [ml],0.1,110845,DB00987,Cytarabine
,8453629,minimal cytotoxic level,The free drug concentration remained above the reported minimal cytotoxic level of 0.1 micrograms/ml (0.4 microM) for more than 672 h (28 days).,Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453629/),μM,0.4,110846,DB00987,Cytarabine
,8453629,half-life,"In contrast, the half-life of ara-C following an intralumbar bolus dose of unencapsulated drug in a single animal was 0.74 h.",Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453629/),h,0.74,110847,DB00987,Cytarabine
,14981964,peak,The plasma ara-C reached a peak (61.2 +/- 52.7 microM) that far surpassed the saturating level for intracellular activation of the drug.,Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14981964/),μM,61.2,112607,DB00987,Cytarabine
,14981964,half-life,The plasma ara-U reached its peak (139.8 +/- 40.0 microM) and was maintained with a half-life of 277 +/- 76 min.,Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14981964/),min,277,112608,DB00987,Cytarabine
<,31454720,half-life,"The quantitative determination of Ara-C in plasma is challenging due the required sensitivity because of the short half-life of this drug (i.e., <10 min) and the metabolic instability in biological matrix upon sampling possibly resulting in erratic values.",Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31454720/),min,10,113656,DB00987,Cytarabine
,7596174,lag time,Ara-CMP-Stearate dose-independent parameters: lag time = 1.04 h (0.57); tmax = 5.72 h (0.30); t1/2 = 9.4 h (0.36).,Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596174/),h,1.04,115342,DB00987,Cytarabine
,7596174,tmax,Ara-CMP-Stearate dose-independent parameters: lag time = 1.04 h (0.57); tmax = 5.72 h (0.30); t1/2 = 9.4 h (0.36).,Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596174/),h,5.72,115343,DB00987,Cytarabine
,7596174,t1/2,Ara-CMP-Stearate dose-independent parameters: lag time = 1.04 h (0.57); tmax = 5.72 h (0.30); t1/2 = 9.4 h (0.36).,Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596174/),h,9.4,115344,DB00987,Cytarabine
,7596174,AUC,Dose-dependent parameters: at 100 mg: AUC = 1099 ng/h/ml (0.31); concentration(max) = 53.8 ng/ml (0.28); at 200 mg: AUC = 2753 ng/h/ml (0.32); concentration(max) = 154.8 ng/ml (0.46); at 300 mg: AUC = 2940 ng/h/ml (0.66); concentration(max) = 160.0 ng/ml (0.59).,Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596174/),[ng] / [h·ml],1099,115345,DB00987,Cytarabine
,7596174,concentration(max),Dose-dependent parameters: at 100 mg: AUC = 1099 ng/h/ml (0.31); concentration(max) = 53.8 ng/ml (0.28); at 200 mg: AUC = 2753 ng/h/ml (0.32); concentration(max) = 154.8 ng/ml (0.46); at 300 mg: AUC = 2940 ng/h/ml (0.66); concentration(max) = 160.0 ng/ml (0.59).,Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596174/),[ng] / [ml],53.8,115346,DB00987,Cytarabine
,7596174,AUC,Dose-dependent parameters: at 100 mg: AUC = 1099 ng/h/ml (0.31); concentration(max) = 53.8 ng/ml (0.28); at 200 mg: AUC = 2753 ng/h/ml (0.32); concentration(max) = 154.8 ng/ml (0.46); at 300 mg: AUC = 2940 ng/h/ml (0.66); concentration(max) = 160.0 ng/ml (0.59).,Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596174/),[ng] / [h·ml],2753,115347,DB00987,Cytarabine
,7596174,concentration(max),Dose-dependent parameters: at 100 mg: AUC = 1099 ng/h/ml (0.31); concentration(max) = 53.8 ng/ml (0.28); at 200 mg: AUC = 2753 ng/h/ml (0.32); concentration(max) = 154.8 ng/ml (0.46); at 300 mg: AUC = 2940 ng/h/ml (0.66); concentration(max) = 160.0 ng/ml (0.59).,Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596174/),[ng] / [ml],154.8,115348,DB00987,Cytarabine
,7596174,AUC,Dose-dependent parameters: at 100 mg: AUC = 1099 ng/h/ml (0.31); concentration(max) = 53.8 ng/ml (0.28); at 200 mg: AUC = 2753 ng/h/ml (0.32); concentration(max) = 154.8 ng/ml (0.46); at 300 mg: AUC = 2940 ng/h/ml (0.66); concentration(max) = 160.0 ng/ml (0.59).,Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596174/),[ng] / [h·ml],2940,115349,DB00987,Cytarabine
,7596174,concentration(max),Dose-dependent parameters: at 100 mg: AUC = 1099 ng/h/ml (0.31); concentration(max) = 53.8 ng/ml (0.28); at 200 mg: AUC = 2753 ng/h/ml (0.32); concentration(max) = 154.8 ng/ml (0.46); at 300 mg: AUC = 2940 ng/h/ml (0.66); concentration(max) = 160.0 ng/ml (0.59).,Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596174/),[ng] / [ml],160.0,115350,DB00987,Cytarabine
,7596174,limit of detection,No Ara-CMP-Stearate was detected in urine samples (limit of detection = 500 pg/ml).,Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596174/),[pg] / [ml],500,115351,DB00987,Cytarabine
,7596174,t1/2,Pharmacokinetic parameters of Ara-C following Ara-CMP-Stearate application showed the following characteristics: t1/2 = 24.3 h (0.39); AUC (100 mg) = 262 ng/h/ml (0.93); AUC (200 mg) = 502 ng/h/ml (0.87); AUC (300 mg) = 898 ng/h/ml (1.07).,Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596174/),h,24.3,115352,DB00987,Cytarabine
,7596174,AUC,Pharmacokinetic parameters of Ara-C following Ara-CMP-Stearate application showed the following characteristics: t1/2 = 24.3 h (0.39); AUC (100 mg) = 262 ng/h/ml (0.93); AUC (200 mg) = 502 ng/h/ml (0.87); AUC (300 mg) = 898 ng/h/ml (1.07).,Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596174/),[ng] / [h·ml],262,115353,DB00987,Cytarabine
,7596174,AUC,Pharmacokinetic parameters of Ara-C following Ara-CMP-Stearate application showed the following characteristics: t1/2 = 24.3 h (0.39); AUC (100 mg) = 262 ng/h/ml (0.93); AUC (200 mg) = 502 ng/h/ml (0.87); AUC (300 mg) = 898 ng/h/ml (1.07).,Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596174/),[ng] / [h·ml],502,115354,DB00987,Cytarabine
,7596174,AUC,Pharmacokinetic parameters of Ara-C following Ara-CMP-Stearate application showed the following characteristics: t1/2 = 24.3 h (0.39); AUC (100 mg) = 262 ng/h/ml (0.93); AUC (200 mg) = 502 ng/h/ml (0.87); AUC (300 mg) = 898 ng/h/ml (1.07).,Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596174/),[ng] / [h·ml],898,115355,DB00987,Cytarabine
,7082832,ratios,"CSF/serum ara-C ratios ranged from 0.14 to 0.91 (mean, 0.58).",Pharmacokinetics of continuous intravenous and subcutaneous infusions of cytosine arabinoside. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7082832/),,0.58,117856,DB00987,Cytarabine
,7661730,maximum concentration,"The mean pharmacokinetic parameters of free cytarabine in the lumbar and ventricular CSF compartments were as follows: maximum concentration, 226 and 6.06 mg/L; half-life, 277 and 130 hours; and area under the concentration vs time curve, 4120 and 598 micrograms/h per milliliter, respectively.",Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7661730/),[mg] / [l],226,118733,DB00987,Cytarabine
,7661730,maximum concentration,"The mean pharmacokinetic parameters of free cytarabine in the lumbar and ventricular CSF compartments were as follows: maximum concentration, 226 and 6.06 mg/L; half-life, 277 and 130 hours; and area under the concentration vs time curve, 4120 and 598 micrograms/h per milliliter, respectively.",Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7661730/),[mg] / [l],6.06,118734,DB00987,Cytarabine
,7661730,half-life,"The mean pharmacokinetic parameters of free cytarabine in the lumbar and ventricular CSF compartments were as follows: maximum concentration, 226 and 6.06 mg/L; half-life, 277 and 130 hours; and area under the concentration vs time curve, 4120 and 598 micrograms/h per milliliter, respectively.",Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7661730/),h,277,118735,DB00987,Cytarabine
,7661730,half-life,"The mean pharmacokinetic parameters of free cytarabine in the lumbar and ventricular CSF compartments were as follows: maximum concentration, 226 and 6.06 mg/L; half-life, 277 and 130 hours; and area under the concentration vs time curve, 4120 and 598 micrograms/h per milliliter, respectively.",Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7661730/),h,130,118736,DB00987,Cytarabine
,7661730,area under the concentration vs time curve,"The mean pharmacokinetic parameters of free cytarabine in the lumbar and ventricular CSF compartments were as follows: maximum concentration, 226 and 6.06 mg/L; half-life, 277 and 130 hours; and area under the concentration vs time curve, 4120 and 598 micrograms/h per milliliter, respectively.",Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7661730/),[μg] / [h·milliliter],4120,118737,DB00987,Cytarabine
,7661730,area under the concentration vs time curve,"The mean pharmacokinetic parameters of free cytarabine in the lumbar and ventricular CSF compartments were as follows: maximum concentration, 226 and 6.06 mg/L; half-life, 277 and 130 hours; and area under the concentration vs time curve, 4120 and 598 micrograms/h per milliliter, respectively.",Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7661730/),[μg] / [h·milliliter],598,118738,DB00987,Cytarabine
,6850647,initial half-life,"In seven patients given BHAC (200 mg/body weight; 2.97 to 4.26 mg/kg) i.v. for 90 min, the plasma disappearance curve of BHAC was biphasic with a mean initial half-life of 0.37 hr and a mean second half-life of 5.27 hr.",Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6850647/),h,0.37,120115,DB00987,Cytarabine
,6850647,second half-life,"In seven patients given BHAC (200 mg/body weight; 2.97 to 4.26 mg/kg) i.v. for 90 min, the plasma disappearance curve of BHAC was biphasic with a mean initial half-life of 0.37 hr and a mean second half-life of 5.27 hr.",Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6850647/),h,5.27,120116,DB00987,Cytarabine
,6850647,apparent volume of the central compartment,"The apparent volume of the central compartment and the apparent volume of distribution were 0.047 and 0.316 liter/kg, respectively; the systemic clearance was 0.051 liter/hr/kg.",Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6850647/),[l] / [kg],0.047,120117,DB00987,Cytarabine
,6850647,apparent volume of distribution,"The apparent volume of the central compartment and the apparent volume of distribution were 0.047 and 0.316 liter/kg, respectively; the systemic clearance was 0.051 liter/hr/kg.",Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6850647/),[l] / [kg],0.316,120118,DB00987,Cytarabine
,6850647,systemic clearance,"The apparent volume of the central compartment and the apparent volume of distribution were 0.047 and 0.316 liter/kg, respectively; the systemic clearance was 0.051 liter/hr/kg.",Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6850647/),[l] / [h·kg],0.051,120119,DB00987,Cytarabine
less,6850647,excretion,Urinary BHAC excretion was less than 0.2 micrograms/ml of the sensitivity limit in all samples.,Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6850647/),[μg] / [ml],0.2,120120,DB00987,Cytarabine
,1453772,t1/2,During conventional-dose AraC therapy little interpatient variation was observed in AraCTP retention times in leukemic blasts from 5 patients with t1/2 values ranging from 1.70 to 2.50 h (median 2.14 h).,Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1453772/),h,1.70 to 2.50,120369,DB00987,Cytarabine
,1453772,t1/2,During conventional-dose AraC therapy little interpatient variation was observed in AraCTP retention times in leukemic blasts from 5 patients with t1/2 values ranging from 1.70 to 2.50 h (median 2.14 h).,Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1453772/),h,2.14,120370,DB00987,Cytarabine
,1453772,t1/2,"Substantial differences in AraCTP retention times were revealed, however, during 3 h infusions of either 1.0 or 3.0 g/m2 AraC in leukemic blasts from 10 patients with t1/2 values between 1.60 to 7.63 h (median 2.42 h).",Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1453772/),h,1.60 to 7.63,120371,DB00987,Cytarabine
,1453772,t1/2,"Substantial differences in AraCTP retention times were revealed, however, during 3 h infusions of either 1.0 or 3.0 g/m2 AraC in leukemic blasts from 10 patients with t1/2 values between 1.60 to 7.63 h (median 2.42 h).",Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1453772/),h,2.42,120372,DB00987,Cytarabine
,1453772,t1/2,"In contrast, AraCTP retention times were relatively uniform in normal mononuclear blood cells from 11 patients with t1/2 values of 3.34 to 5.29 h (median 3.85 h).",Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1453772/),h,3.34 to 5.29,120373,DB00987,Cytarabine
,1453772,t1/2,"In contrast, AraCTP retention times were relatively uniform in normal mononuclear blood cells from 11 patients with t1/2 values of 3.34 to 5.29 h (median 3.85 h).",Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1453772/),h,3.85,120374,DB00987,Cytarabine
,1453772,retention times,Similar findings emerged after in vitro exposure of normal bone marrow cells from six healthy volunteers to 20 mumol/l AraC for 3 h revealing a > 10% decrease of intracellular AraCTP within the first post-treatment hour in all cases with AraCTP retention times of 2.29 to 8.63 h (median 3.20 h).,Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1453772/),h,2.29 to 8.63,120375,DB00987,Cytarabine
,1453772,retention times,Similar findings emerged after in vitro exposure of normal bone marrow cells from six healthy volunteers to 20 mumol/l AraC for 3 h revealing a > 10% decrease of intracellular AraCTP within the first post-treatment hour in all cases with AraCTP retention times of 2.29 to 8.63 h (median 3.20 h).,Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1453772/),h,3.20,120376,DB00987,Cytarabine
,291436,Plasma clearance,"Plasma clearance was 3.9 to 18.1 l/min as measured by the GC-MS method, and terminal half-lives varied from 7--107 min.",Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/291436/),[l] / [min],3.9 to 18.1,120564,DB00987,Cytarabine
,291436,terminal half-lives,"Plasma clearance was 3.9 to 18.1 l/min as measured by the GC-MS method, and terminal half-lives varied from 7--107 min.",Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/291436/),min,7--107,120565,DB00987,Cytarabine
,291436,Plasma clearances,"Plasma clearances were much lower than after a bolus, 0.39 to 5.25 l/min.",Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/291436/),[l] / [min],0.39 to 5.25,120566,DB00987,Cytarabine
,24969912,overall response rate,"Of the 8 PCNSL patients, 4 (50%) achieved CR and 3 (38%) PR, an overall response rate of 88%.","Fotemustine, teniposide and dexamethasone in treating patients with CNS lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24969912/),%,88,121433,DB00987,Cytarabine
,24969912,overall response rate,Of the 8 SCNSL patients the overall response rate was 63% (CR+PR:38%+25%).,"Fotemustine, teniposide and dexamethasone in treating patients with CNS lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24969912/),%,63,121434,DB00987,Cytarabine
,24969912,overall response rate,Of the 8 SCNSL patients the overall response rate was 63% (CR+PR:38%+25%).,"Fotemustine, teniposide and dexamethasone in treating patients with CNS lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24969912/),%,38,121435,DB00987,Cytarabine
,266428,plasma half-life (t1/2),The plasma half-life (t1/2) of Ara-C of the first phase varied from 1.2 to 1.9 min (mean 1.6).,Pharmacokinetics of cytosine arabinoside in acute myeloid leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/266428/),min,1.6,121705,DB00987,Cytarabine
,266428,t1/2 of the second phase,The t1/2 of the second phase varied from 8.8 to 18.9 min.,Pharmacokinetics of cytosine arabinoside in acute myeloid leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/266428/),min,8.8 to 18.9,121706,DB00987,Cytarabine
,266428,second-phase t1/2,There was poor treatment response in five patients with second-phase t1/2 of Ara-C ranging from 6.6 to 10.7 min whereas there was complete remission in nine patients with t1/2 exceeding 12.7 min.,Pharmacokinetics of cytosine arabinoside in acute myeloid leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/266428/),min,6.6 to 10.7,121707,DB00987,Cytarabine
exceeding,266428,t1/2,There was poor treatment response in five patients with second-phase t1/2 of Ara-C ranging from 6.6 to 10.7 min whereas there was complete remission in nine patients with t1/2 exceeding 12.7 min.,Pharmacokinetics of cytosine arabinoside in acute myeloid leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/266428/),min,12.7,121708,DB00987,Cytarabine
,19698017,plasma half-life,"The agent, administered orally, has approximately 98% oral bioavailability, achieves maximum plasma concentration approximately 2-4 hours after ingestion, and has a plasma half-life of approximately 18 hours.",Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19698017/),h,18,123857,DB00987,Cytarabine
,19698017,trough plasma concentration,"The patient's trough plasma concentration before surgery (1558 ng/ml) was consistent with those found in the literature (>/= 1000 ng/ml), whereas her trough concentrations after surgery were 46-60% lower (629-836 ng/ml) than the preoperative value.",Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19698017/),[ng] / [ml],1558,123858,DB00987,Cytarabine
,19698017,trough concentrations,"The patient's trough plasma concentration before surgery (1558 ng/ml) was consistent with those found in the literature (>/= 1000 ng/ml), whereas her trough concentrations after surgery were 46-60% lower (629-836 ng/ml) than the preoperative value.",Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19698017/),[ng] / [ml],629-836,123859,DB00987,Cytarabine
,21768474,binding constant,"In vitro, the N-oxide potently inhibited FLT3-internal tandem duplication (ITD; binding constant, 70 nmol/L) and the viability of five AML cell lines.",Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21768474/),[nM] / [l],70,125556,DB00987,Cytarabine
less,3471322,steady-state plasma ara-C concentrations,"However, when the infusion rate was further reduced to 0.4 or 0.3 g/m2 over 2 h, resulting in steady-state plasma ara-C concentrations of less than 7 microM, the accumulation rate of ara-CTP was substantially reduced as was the ara-CTP intracellular AUC.",Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471322/),,7,125839,DB00987,Cytarabine
,15018979,percentage of incorporation efficiency,"Thus, microspheres with 46+/-4 microg drug/mg microspheres and 50+/-5 microg drug/mg microspheres were obtained, which means a percentage of incorporation efficiency of 42+/-4% and 25+/-2%, respectively.",Cytarabine release from comatrices of albumin microspheres in a poly(lactide-co-glycolide) film: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15018979/),%,42,125909,DB00987,Cytarabine
,15018979,percentage of incorporation efficiency,"Thus, microspheres with 46+/-4 microg drug/mg microspheres and 50+/-5 microg drug/mg microspheres were obtained, which means a percentage of incorporation efficiency of 42+/-4% and 25+/-2%, respectively.",Cytarabine release from comatrices of albumin microspheres in a poly(lactide-co-glycolide) film: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15018979/),%,25,125910,DB00987,Cytarabine
,7104969,At steady state plasma concentrations,At steady state plasma concentrations of ARA-C were 32-97 microM (8-24 micrograms/ml).,Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104969/),μM,32-97,126679,DB00987,Cytarabine
,7104969,At steady state plasma concentrations,At steady state plasma concentrations of ARA-C were 32-97 microM (8-24 micrograms/ml).,Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104969/),[μg] / [ml],8-24,126680,DB00987,Cytarabine
,7104969,terminal half-life (t50%),ARA-C disappeared from the plasma mono- or biphasic with a terminal half-life (t50%) of 7.8-12.6 minutes.,Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104969/),min,7.8-12.6,126681,DB00987,Cytarabine
,7104969,total clearance (Cl),"The total clearance (Cl) of ARA-C varied between 1.7 and 2.9 liters/kg . h, and the distribution volume (Vss) between 0.44 and 0.86 liters/kg.",Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104969/),[l] / [h·kg],1.7 and 2.9,126682,DB00987,Cytarabine
,7104969,distribution volume (Vss),"The total clearance (Cl) of ARA-C varied between 1.7 and 2.9 liters/kg . h, and the distribution volume (Vss) between 0.44 and 0.86 liters/kg.",Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104969/),[l] / [kg],0.44 and 0.86,126683,DB00987,Cytarabine
,11920222,complete response rate,The complete response rate was 49% overall and similar in both cohorts.,Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920222/),%,49,129252,DB00987,Cytarabine
,11920222,overall survival,The median overall survival of patients was 333 days in cohort 1 compared to 98 days in cohort 2.,Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920222/),d,333,129253,DB00987,Cytarabine
,11920222,overall survival,The median overall survival of patients was 333 days in cohort 1 compared to 98 days in cohort 2.,Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920222/),d,98,129254,DB00987,Cytarabine
,11920222,maximum tolerated dose,The maximum tolerated dose of DNR was established as 35 mg/m(2).,Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920222/),[mg] / [m],35,129255,DB00987,Cytarabine
,17256136,terminal half-life,"The mean terminal half-life measured for IDA in this group of patients (14.9 h) was not significantly different from the mean value observed after standard dose (13.9 h, P=0.72).",High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17256136/),h,14.9,129332,DB00987,Cytarabine
,17256136,terminal half-life,"The mean terminal half-life measured for IDA in this group of patients (14.9 h) was not significantly different from the mean value observed after standard dose (13.9 h, P=0.72).",High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17256136/),h,13.9,129333,DB00987,Cytarabine
,17256136,ol t1/2,"IDAol t1/2 was also similar after HD-IDA (46.2 h) and standard dose (39.4 h, P=0.79).",High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17256136/),h,46.2,129334,DB00987,Cytarabine
,17256136,ol t1/2,"IDAol t1/2 was also similar after HD-IDA (46.2 h) and standard dose (39.4 h, P=0.79).",High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17256136/),h,39.4,129335,DB00987,Cytarabine
,10677637,alpha,"After IV administration, the alpha and beta plasma half-lives were 1.9 and 46.5 min, respectively.","Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677637/),min,1.9,132175,DB00987,Cytarabine
,10677637,beta plasma half-lives,"After IV administration, the alpha and beta plasma half-lives were 1.9 and 46.5 min, respectively.","Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677637/),min,46.5,132176,DB00987,Cytarabine
,10677637,blood-to-brain transfer constant,"The blood-to-brain transfer constant of AraC was 2.5+/-1.4 microliter g(-1) min(-1), compatible with high water solubility.","Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677637/),[μl] / [g·min],2.5,132177,DB00987,Cytarabine
,10677637,rate loss constant,"The rate loss constant from brain was 0.002+/-0.0004 min(-1), suggesting that AraC was accumulating in brain cells.","Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677637/),1/[min],0.002,132178,DB00987,Cytarabine
,3471699,peak levels,Pharmacokinetic studies revealed that mean basal levels achieved with continuous infusion prior to high-dose ara-C were 10(2) ng/ml and peak levels were of the order of 10(4) ng/ml.,Cytosine arabinoside in the management of recurrent leukaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471699/),[ng] / [ml],10(4,136630,DB00987,Cytarabine
,1503923,clearance,"Median methotrexate clearance tended to be lower in four infants (0.26-0.99 years) vs 108 children (1-19 years): 80 vs 103 ml min-1 m-2, respectively (P = 0.01).",Disposition of antineoplastic agents in the very young child. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503923/),[ml] / [(m)^2·min],80,139441,DB00987,Cytarabine
,1503923,clearance,"Median methotrexate clearance tended to be lower in four infants (0.26-0.99 years) vs 108 children (1-19 years): 80 vs 103 ml min-1 m-2, respectively (P = 0.01).",Disposition of antineoplastic agents in the very young child. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503923/),[ml] / [(m)^2·min],103,139442,DB00987,Cytarabine
,32990804,area under the curve (AUCIVlast),"Cytarabine in vitro area under the curve (AUCIVlast) was 22-fold higher in AML samples as compared to CTRL samples (AML mean (standard deviation (SD)), 51,829 (27,004) h ng/mL; CTRL mean (SD), 2356 (1250) h ng/mL, p = 0.00019).",Slower degradation rate of cytarabine in blood samples from acute myeloid leukemia by comparison with control samples. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32990804/),[h·ng] / [ml],"51,829",141182,DB00987,Cytarabine
,32990804,area under the curve (AUCIVlast),"Cytarabine in vitro area under the curve (AUCIVlast) was 22-fold higher in AML samples as compared to CTRL samples (AML mean (standard deviation (SD)), 51,829 (27,004) h ng/mL; CTRL mean (SD), 2356 (1250) h ng/mL, p = 0.00019).",Slower degradation rate of cytarabine in blood samples from acute myeloid leukemia by comparison with control samples. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32990804/),[h·ng] / [ml],2356,141183,DB00987,Cytarabine
,32990804,degradation half-life (t1/2,"This increase was associated with a prolonged in vitro degradation half-life (t1/2IVdeg AML mean (SD), 15 (11.8) h; CTRL mean (SD), 0.36 (0.37) h, p = 0.0033).",Slower degradation rate of cytarabine in blood samples from acute myeloid leukemia by comparison with control samples. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32990804/),h,15,141184,DB00987,Cytarabine
,32990804,degradation half-life (t1/2,"This increase was associated with a prolonged in vitro degradation half-life (t1/2IVdeg AML mean (SD), 15 (11.8) h; CTRL mean (SD), 0.36 (0.37) h, p = 0.0033).",Slower degradation rate of cytarabine in blood samples from acute myeloid leukemia by comparison with control samples. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32990804/),h,0.36,141185,DB00987,Cytarabine
,9402748,overall response rate,Thirty-five patients (53%) achieved CR and 9 PR for an overall response rate of 67%.,Idarubicin in induction treatment of acute myeloid leukemia in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402748/),%,67,142609,DB00987,Cytarabine
,9402748,Overall survival,"Overall survival and disease free survival were 14 and 13 months, respectively.",Idarubicin in induction treatment of acute myeloid leukemia in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402748/),month,14,142610,DB00987,Cytarabine
,9402748,disease free survival,"Overall survival and disease free survival were 14 and 13 months, respectively.",Idarubicin in induction treatment of acute myeloid leukemia in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402748/),month,13,142611,DB00987,Cytarabine
,31541945,overall response rate,"The overall response rate was 60.9%, 43.5% achieved a complete remission (CR), and 17.4% achieved CR with incomplete count recovery.",Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31541945/),%,60.9,143054,DB00987,Cytarabine
,4053067,steady-state concentration,A steady-state concentration of ara-C in plasma (94 +/- 32 microM) was reached by the end of the 2-h infusion.,Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4053067/),μM,94,143427,DB00987,Cytarabine
,4053067,initial,"Its elimination was biphasic with an initial and terminal t1/2 of 0.44 +/- 0.10 h and 2.8 +/- 0.9 h, respectively.",Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4053067/),h,0.44,143428,DB00987,Cytarabine
,4053067,terminal t1/2,"Its elimination was biphasic with an initial and terminal t1/2 of 0.44 +/- 0.10 h and 2.8 +/- 0.9 h, respectively.",Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4053067/),h,2.8,143429,DB00987,Cytarabine
,4053067,t1/2,"ara-CTP elimination was monophasic with a median t1/2 of 3.4 h (range, 1.25 to 18.9 h).",Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4053067/),h,3.4,143430,DB00987,Cytarabine
,9068927,oral bioavailability,"The oral bioavailability of cladribine is 37 to 51%, and that of subcutaneous administration is 100%.",The clinical pharmacokinetics of cladribine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068927/),%,37 to 51,143470,DB00987,Cytarabine
,9068927,oral bioavailability,"The oral bioavailability of cladribine is 37 to 51%, and that of subcutaneous administration is 100%.",The clinical pharmacokinetics of cladribine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068927/),%,100,143471,DB00987,Cytarabine
,9068927,terminal half-life,The terminal half-life varies from 5.7 to 19.7 hours and the apparent volume of distribution from 54 to 357 L/m2.,The clinical pharmacokinetics of cladribine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068927/),h,5.7 to 19.7,143472,DB00987,Cytarabine
,9068927,apparent volume of distribution,The terminal half-life varies from 5.7 to 19.7 hours and the apparent volume of distribution from 54 to 357 L/m2.,The clinical pharmacokinetics of cladribine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068927/),[l] / [m2],54 to 357,143473,DB00987,Cytarabine
,9068927,half-lives,The intracellular concentration of these metabolites is several hundred-fold higher than that of cladribine in plasma and they are retained in leukaemia cells with half-lives between 9 and > 30 hours depending on diagnosis and sampling schedule.,The clinical pharmacokinetics of cladribine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068927/),h,9 and > 30,143474,DB00987,Cytarabine
,16478631,C(max),Mean Triapine C(max) and AUC were 1.13 microg/mL and 251.5 minmicrog/mL.,Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16478631/),[μg] / [ml],1.13,145805,DB00987,Cytarabine
,16478631,AUC,Mean Triapine C(max) and AUC were 1.13 microg/mL and 251.5 minmicrog/mL.,Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16478631/),[minμg] / [ml],251.5,145806,DB00987,Cytarabine
,9402329,Minimum plasma araC concentrations,"Minimum plasma araC concentrations at the end of infusion were 10.5 micromol/l and 22.0 micromol/l at a dose of 1000 and 3000 mg/m2, respectively.",Pharmacokinetics of high-dose cytarabine and its deamination product--a reappraisal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402329/),[μM] / [l],10.5,150571,DB00987,Cytarabine
,9402329,Minimum plasma araC concentrations,"Minimum plasma araC concentrations at the end of infusion were 10.5 micromol/l and 22.0 micromol/l at a dose of 1000 and 3000 mg/m2, respectively.",Pharmacokinetics of high-dose cytarabine and its deamination product--a reappraisal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402329/),[μM] / [l],22.0,150572,DB00987,Cytarabine
>,9402329,araU/araC ratio,"In our European study population a ""fast"" deamination phenotype of cytarabine (araU/araC ratio > 14) was not be observed.",Pharmacokinetics of high-dose cytarabine and its deamination product--a reappraisal. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402329/),,14,150573,DB00987,Cytarabine
,7596061,peak plasma level (Cmax),"In the Ara-C s.c. patients, the peak plasma level (Cmax) of Ara-C was 103 ng/ml and the time to reach Cmax was 15 min.",[Plasma concentration of cytosine arabinoside (Ara-C) in the elderly patients with hematological malignancy treated by Ara-C or cytarabine ocfosfate (SPAC)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596061/),[ng] / [ml],103,151755,DB00987,Cytarabine
,7596061,time to reach Cmax,"In the Ara-C s.c. patients, the peak plasma level (Cmax) of Ara-C was 103 ng/ml and the time to reach Cmax was 15 min.",[Plasma concentration of cytosine arabinoside (Ara-C) in the elderly patients with hematological malignancy treated by Ara-C or cytarabine ocfosfate (SPAC)]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596061/),min,15,151756,DB00987,Cytarabine
,7596061,elimination half-like (t1/2),The elimination half-like (t1/2) was 25 min and no accumulation was detected after 14 days of consecutive Ara-C s.c. administrations.,[Plasma concentration of cytosine arabinoside (Ara-C) in the elderly patients with hematological malignancy treated by Ara-C or cytarabine ocfosfate (SPAC)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596061/),min,25,151757,DB00987,Cytarabine
,7596061,Cmax,"In the SPAC p.o. patients, Cmax of Ara-C was 3-8 ng/ml and it took 3-5 days to reach Cmax.",[Plasma concentration of cytosine arabinoside (Ara-C) in the elderly patients with hematological malignancy treated by Ara-C or cytarabine ocfosfate (SPAC)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596061/),[ng] / [ml],3-8,151758,DB00987,Cytarabine
,3383195,Km,"Several explanations for the different cellular accumulation of the drug triphosphates were established: (a) nucleoside transport studies demonstrated that the membrane permeation of dFdC was 65% more rapid than that of ara-C; (b) deoxycytidine kinase had a higher affinity for dFdC (Km = 3.6 microM) than for ara-C (Km = 8.8 microM), while the Km for deoxycytidine was 1.4 microM; (c) the elimination of intracellular dFdCTP was biphasic with t1/2 alpha = 3.9 and t1/2 beta greater than 16 h while the degradation of ara-CTP was monophasic and significantly faster (t1/2 = 0.7 h).","Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383195/),μM,3.6,151768,DB00987,Cytarabine
,3383195,Km,"Several explanations for the different cellular accumulation of the drug triphosphates were established: (a) nucleoside transport studies demonstrated that the membrane permeation of dFdC was 65% more rapid than that of ara-C; (b) deoxycytidine kinase had a higher affinity for dFdC (Km = 3.6 microM) than for ara-C (Km = 8.8 microM), while the Km for deoxycytidine was 1.4 microM; (c) the elimination of intracellular dFdCTP was biphasic with t1/2 alpha = 3.9 and t1/2 beta greater than 16 h while the degradation of ara-CTP was monophasic and significantly faster (t1/2 = 0.7 h).","Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383195/),μM,8.8,151769,DB00987,Cytarabine
,3383195,Km,"Several explanations for the different cellular accumulation of the drug triphosphates were established: (a) nucleoside transport studies demonstrated that the membrane permeation of dFdC was 65% more rapid than that of ara-C; (b) deoxycytidine kinase had a higher affinity for dFdC (Km = 3.6 microM) than for ara-C (Km = 8.8 microM), while the Km for deoxycytidine was 1.4 microM; (c) the elimination of intracellular dFdCTP was biphasic with t1/2 alpha = 3.9 and t1/2 beta greater than 16 h while the degradation of ara-CTP was monophasic and significantly faster (t1/2 = 0.7 h).","Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383195/),μM,1.4,151770,DB00987,Cytarabine
,3383195,t1/2 alpha,"Several explanations for the different cellular accumulation of the drug triphosphates were established: (a) nucleoside transport studies demonstrated that the membrane permeation of dFdC was 65% more rapid than that of ara-C; (b) deoxycytidine kinase had a higher affinity for dFdC (Km = 3.6 microM) than for ara-C (Km = 8.8 microM), while the Km for deoxycytidine was 1.4 microM; (c) the elimination of intracellular dFdCTP was biphasic with t1/2 alpha = 3.9 and t1/2 beta greater than 16 h while the degradation of ara-CTP was monophasic and significantly faster (t1/2 = 0.7 h).","Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383195/),,3.9,151771,DB00987,Cytarabine
greater,3383195,t1/2 beta,"Several explanations for the different cellular accumulation of the drug triphosphates were established: (a) nucleoside transport studies demonstrated that the membrane permeation of dFdC was 65% more rapid than that of ara-C; (b) deoxycytidine kinase had a higher affinity for dFdC (Km = 3.6 microM) than for ara-C (Km = 8.8 microM), while the Km for deoxycytidine was 1.4 microM; (c) the elimination of intracellular dFdCTP was biphasic with t1/2 alpha = 3.9 and t1/2 beta greater than 16 h while the degradation of ara-CTP was monophasic and significantly faster (t1/2 = 0.7 h).","Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383195/),h,16,151772,DB00987,Cytarabine
,3383195,t1/2,"Several explanations for the different cellular accumulation of the drug triphosphates were established: (a) nucleoside transport studies demonstrated that the membrane permeation of dFdC was 65% more rapid than that of ara-C; (b) deoxycytidine kinase had a higher affinity for dFdC (Km = 3.6 microM) than for ara-C (Km = 8.8 microM), while the Km for deoxycytidine was 1.4 microM; (c) the elimination of intracellular dFdCTP was biphasic with t1/2 alpha = 3.9 and t1/2 beta greater than 16 h while the degradation of ara-CTP was monophasic and significantly faster (t1/2 = 0.7 h).","Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383195/),h,0.7,151773,DB00987,Cytarabine
,6587957,t1/2,"Elimination of Ara-C from CSF followed a biphasic pattern, with an initial t1/2 of 1 hr and a terminal t1/2 of 3.4 hr.",Cytosine arabinoside cerebrospinal fluid kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587957/),h,1,153200,DB00987,Cytarabine
,6587957,terminal t1/2,"Elimination of Ara-C from CSF followed a biphasic pattern, with an initial t1/2 of 1 hr and a terminal t1/2 of 3.4 hr.",Cytosine arabinoside cerebrospinal fluid kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587957/),h,3.4,153201,DB00987,Cytarabine
,6587957,clearance from CSF,"Ara-C clearance from CSF was 0.42 ml/min, suggesting that drug elimination was primarily by CSF bulk flow.",Cytosine arabinoside cerebrospinal fluid kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587957/),[ml] / [min],0.42,153202,DB00987,Cytarabine
,6587957,ratio of the AUC,"The ratio of the AUC of Ara-U to the AUC of Ara-C was 0.08, indicating only minor metabolism of Ara-C to Ara-U in CSF, in contrast to that after systemic Ara-C.",Cytosine arabinoside cerebrospinal fluid kinetics. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587957/),,0.08,153203,DB00987,Cytarabine
,32104323,AUC0-10,"The main pharmacokinetic parameters for the OPC group and the co-administrative group were as follows: AUC0-10 (18,168.7 ± 2561.4) ng⋅h/ml and (13,448.5 ± 2544.73) ng⋅h/ml, AUC0-∞ (18,683.1 ± 3066.5) ng⋅h/ml and (13,721.1 ± 2683.0) ng⋅h/ml, C max (6654.8 ± 481.3) ng/ml and (4765.1 ± 928.9) ng/ml, respectively.",The effect of cephalexin in influencing the pharmacokinetics of a novel drug - 5'-valyl-cytarabine hydrochloride. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32104323/),[h·ng] / [ml],"18,168.7",154154,DB00987,Cytarabine
,32104323,AUC0-10,"The main pharmacokinetic parameters for the OPC group and the co-administrative group were as follows: AUC0-10 (18,168.7 ± 2561.4) ng⋅h/ml and (13,448.5 ± 2544.73) ng⋅h/ml, AUC0-∞ (18,683.1 ± 3066.5) ng⋅h/ml and (13,721.1 ± 2683.0) ng⋅h/ml, C max (6654.8 ± 481.3) ng/ml and (4765.1 ± 928.9) ng/ml, respectively.",The effect of cephalexin in influencing the pharmacokinetics of a novel drug - 5'-valyl-cytarabine hydrochloride. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32104323/),[h·ng] / [ml],"13,448.5",154155,DB00987,Cytarabine
,32104323,AUC0-∞,"The main pharmacokinetic parameters for the OPC group and the co-administrative group were as follows: AUC0-10 (18,168.7 ± 2561.4) ng⋅h/ml and (13,448.5 ± 2544.73) ng⋅h/ml, AUC0-∞ (18,683.1 ± 3066.5) ng⋅h/ml and (13,721.1 ± 2683.0) ng⋅h/ml, C max (6654.8 ± 481.3) ng/ml and (4765.1 ± 928.9) ng/ml, respectively.",The effect of cephalexin in influencing the pharmacokinetics of a novel drug - 5'-valyl-cytarabine hydrochloride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32104323/),[h·ng] / [ml],"18,683.1",154156,DB00987,Cytarabine
,32104323,AUC0-∞,"The main pharmacokinetic parameters for the OPC group and the co-administrative group were as follows: AUC0-10 (18,168.7 ± 2561.4) ng⋅h/ml and (13,448.5 ± 2544.73) ng⋅h/ml, AUC0-∞ (18,683.1 ± 3066.5) ng⋅h/ml and (13,721.1 ± 2683.0) ng⋅h/ml, C max (6654.8 ± 481.3) ng/ml and (4765.1 ± 928.9) ng/ml, respectively.",The effect of cephalexin in influencing the pharmacokinetics of a novel drug - 5'-valyl-cytarabine hydrochloride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32104323/),[h·ng] / [ml],"13,721.1",154157,DB00987,Cytarabine
,32104323,C max,"The main pharmacokinetic parameters for the OPC group and the co-administrative group were as follows: AUC0-10 (18,168.7 ± 2561.4) ng⋅h/ml and (13,448.5 ± 2544.73) ng⋅h/ml, AUC0-∞ (18,683.1 ± 3066.5) ng⋅h/ml and (13,721.1 ± 2683.0) ng⋅h/ml, C max (6654.8 ± 481.3) ng/ml and (4765.1 ± 928.9) ng/ml, respectively.",The effect of cephalexin in influencing the pharmacokinetics of a novel drug - 5'-valyl-cytarabine hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32104323/),[ng] / [ml],6654.8,154158,DB00987,Cytarabine
,32104323,C max,"The main pharmacokinetic parameters for the OPC group and the co-administrative group were as follows: AUC0-10 (18,168.7 ± 2561.4) ng⋅h/ml and (13,448.5 ± 2544.73) ng⋅h/ml, AUC0-∞ (18,683.1 ± 3066.5) ng⋅h/ml and (13,721.1 ± 2683.0) ng⋅h/ml, C max (6654.8 ± 481.3) ng/ml and (4765.1 ± 928.9) ng/ml, respectively.",The effect of cephalexin in influencing the pharmacokinetics of a novel drug - 5'-valyl-cytarabine hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32104323/),[ng] / [ml],4765.1,154159,DB00987,Cytarabine
,8491056,half-life (t1/2),"The pharmacokinetics of idarubicin follow a 2- or 3-compartment plasma disappearance with half-life (t1/2) values of 13 min, 2.4h and 16h, clearance approximately 60 L/h/m2 and volume of distribution at steady-state of 1,500 L/m2.",Clinical pharmacokinetics of idarubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491056/),min,13,154775,DB00987,Cytarabine
,8491056,half-life (t1/2),"The pharmacokinetics of idarubicin follow a 2- or 3-compartment plasma disappearance with half-life (t1/2) values of 13 min, 2.4h and 16h, clearance approximately 60 L/h/m2 and volume of distribution at steady-state of 1,500 L/m2.",Clinical pharmacokinetics of idarubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491056/),h,2.4,154776,DB00987,Cytarabine
,8491056,half-life (t1/2),"The pharmacokinetics of idarubicin follow a 2- or 3-compartment plasma disappearance with half-life (t1/2) values of 13 min, 2.4h and 16h, clearance approximately 60 L/h/m2 and volume of distribution at steady-state of 1,500 L/m2.",Clinical pharmacokinetics of idarubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491056/),h,16,154777,DB00987,Cytarabine
,8491056,clearance,"The pharmacokinetics of idarubicin follow a 2- or 3-compartment plasma disappearance with half-life (t1/2) values of 13 min, 2.4h and 16h, clearance approximately 60 L/h/m2 and volume of distribution at steady-state of 1,500 L/m2.",Clinical pharmacokinetics of idarubicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491056/),[l] / [h·m2],60,154778,DB00987,Cytarabine
,8491056,volume of distribution at steady-state,"The pharmacokinetics of idarubicin follow a 2- or 3-compartment plasma disappearance with half-life (t1/2) values of 13 min, 2.4h and 16h, clearance approximately 60 L/h/m2 and volume of distribution at steady-state of 1,500 L/m2.",Clinical pharmacokinetics of idarubicin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491056/),[l] / [m2],"1,500",154779,DB00987,Cytarabine
,8491056,elimination t1/2,Idarubicinol is characterised by a very long elimination t1/2 of 55h.,Clinical pharmacokinetics of idarubicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491056/),h,55,154780,DB00987,Cytarabine
>,8491056,ratio of meta,"The ratio of metabolite: parent drug area under the plasma concentration-time curve is often > 2 and is even higher after 2 or 3 daily injections of the drug, the normal drug protocol used in induction or consolidation treatments of acute leukaemias.",Clinical pharmacokinetics of idarubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491056/),,2,154781,DB00987,Cytarabine
,8491056,bioavailability,"The bioavailability of idarubicin is 20 to 25%, but if the activity of idarubicinol is taken into account, it is effectively about 40%.",Clinical pharmacokinetics of idarubicin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491056/),%,20 to 25,154782,DB00987,Cytarabine
,8491056,bioavailability,"The bioavailability of idarubicin is 20 to 25%, but if the activity of idarubicinol is taken into account, it is effectively about 40%.",Clinical pharmacokinetics of idarubicin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491056/),%,40,154783,DB00987,Cytarabine
,33798663,AUC,In vivo pharmacokinetics of the optimized DSPC/DSPE-PEG2000 liposomal flavopiridol formulation demonstrated a 30-fold increase in AUC (0.804 μg-hr/mL versus 26.92 μg-hr/mL) compared to the free flavopiridol formulation.,Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33798663/),[μg-hr] / [ml],0.804,154950,DB00987,Cytarabine
,33798663,AUC,In vivo pharmacokinetics of the optimized DSPC/DSPE-PEG2000 liposomal flavopiridol formulation demonstrated a 30-fold increase in AUC (0.804 μg-hr/mL versus 26.92 μg-hr/mL) compared to the free flavopiridol formulation.,Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33798663/),[μg-hr] / [ml],26.92,154951,DB00987,Cytarabine
,12165900,duration of first remission,The median duration of first remission was 0.9 years.,[Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12165900/),years,0.9,155606,DB00987,Cytarabine
,12165900,overall AUC,"The pharmacokinetic investigation showed a high overall AUC of 234.6 mg/l h at a dose of 60 mg/m (2), and a volume of distribution of 1.98 l/m (2), which is much lower in comparison to conventional Daunorubicin.",[Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12165900/),[mg] / [h·l],234.6,155607,DB00987,Cytarabine
,12165900,volume of distribution,"The pharmacokinetic investigation showed a high overall AUC of 234.6 mg/l h at a dose of 60 mg/m (2), and a volume of distribution of 1.98 l/m (2), which is much lower in comparison to conventional Daunorubicin.",[Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12165900/),[l·m] / [2],1.98,155608,DB00987,Cytarabine
,3152911,First-phase elimination half-lives (t1/2(alpha)),First-phase elimination half-lives (t1/2(alpha)) of MTX and 7-hydroxy-methotrexate (7-OH-MTX) after 21 infusions were 2.7 +/- 0.4 h and 6.5 +/- 1.8 h (mean +/- SD).,High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,2.7,155899,DB00987,Cytarabine
,3152911,First-phase elimination half-lives (t1/2(alpha)),First-phase elimination half-lives (t1/2(alpha)) of MTX and 7-hydroxy-methotrexate (7-OH-MTX) after 21 infusions were 2.7 +/- 0.4 h and 6.5 +/- 1.8 h (mean +/- SD).,High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,6.5,155900,DB00987,Cytarabine
,3152911,first-phase elimination half-lives (t1/2(alpha],"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,4.2,155901,DB00987,Cytarabine
,3152911,first-phase elimination half-lives (t1/2(alpha],"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,9.9,155902,DB00987,Cytarabine
,3152911,second-phase elimination half-lives (t1/2(beta)),"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,43,155903,DB00987,Cytarabine
,3152911,second-phase elimination half-lives (t1/2(beta)),"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,58,155904,DB00987,Cytarabine
,22888522,AUC(0-4),"The Ara-C dose for Group A was 3g/m2 x 2, and the AUC(0-4) was 5.131 +/- 0.936.",Sequential arabinosylcytosin with or without fludarabine in paracmastic patients with acute myeloid leukemia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22888522/),,5.131,157904,DB00987,Cytarabine
,22888522,AUC(0-4),"The Ara-C dose for Group B was 2g/m2 x 2, and the AUC(0-4) was 12.245 +/- 3.863.",Sequential arabinosylcytosin with or without fludarabine in paracmastic patients with acute myeloid leukemia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22888522/),,12.245,157905,DB00987,Cytarabine
>,31098682,half-lives,Estimated mean half-lives for total cytarabine and daunorubicin were > 30 h.,A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31098682/),h,30,161131,DB00987,Cytarabine
,11368437,maximum tolerated dose,The maximum tolerated dose of mitoxantrone was defined as 4.5 mg/m2/day.,"Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368437/),[mg] / [d·m2],4.5,161135,DB00987,Cytarabine
,11368437,overall survival,The median overall survival was 4 months.,"Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368437/),month,4,161136,DB00987,Cytarabine
,1733548,Peak plasma,"Peak plasma and CSF ara-C levels were 10.8 and 1.5 micrograms/ml, respectively.",Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1733548/),[μg] / [ml],10.8,161631,DB00987,Cytarabine
,1733548,CSF,"Peak plasma and CSF ara-C levels were 10.8 and 1.5 micrograms/ml, respectively.",Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1733548/),[μg] / [ml],10.8,161632,DB00987,Cytarabine
,1733548,ara-C,"Peak plasma and CSF ara-C levels were 10.8 and 1.5 micrograms/ml, respectively.",Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1733548/),[μg] / [ml],1.5,161633,DB00987,Cytarabine
,3479250,peak plasma concentration,The peak plasma concentration of ara-C ranged from 0.02 to 5.6 microM after the first dose of ara-C.,Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3479250/),μM,0.02 to 5.6,162293,DB00987,Cytarabine
,3479250,area under the concentration-time curve (AUC),"The area under the concentration-time curve (AUC) of ara-C in plasma ranged from 302 to 20,298 microMh after the first dose of ara-C.",Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3479250/),μMh,"302 to 20,298",162294,DB00987,Cytarabine
,3479250,"half-life of elimination (t1/2,el)","The half-life of elimination (t1/2,el) of ara-C from plasma was 2.4 +/- 1.5 h in three patients with acute nonlymphoblastic leukemia (ANLL) and 4.78 +/- 4.1 h in 9 patients with acute lymphoblastic leukemia (ALL).",Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3479250/),h,2.4,162295,DB00987,Cytarabine
,3479250,"half-life of elimination (t1/2,el)","The half-life of elimination (t1/2,el) of ara-C from plasma was 2.4 +/- 1.5 h in three patients with acute nonlymphoblastic leukemia (ANLL) and 4.78 +/- 4.1 h in 9 patients with acute lymphoblastic leukemia (ALL).",Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3479250/),h,4.78,162296,DB00987,Cytarabine
,3479250,intracellular peak concentration,"The intracellular peak concentration of ara-CTP in circulating blast cells averaged 432.2 +/- 14.5 microM and 544.3 +/- 330 microM in patients with ANLL and ALL, respectively.",Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3479250/),μM,432.2,162297,DB00987,Cytarabine
,3479250,intracellular peak concentration,"The intracellular peak concentration of ara-CTP in circulating blast cells averaged 432.2 +/- 14.5 microM and 544.3 +/- 330 microM in patients with ANLL and ALL, respectively.",Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3479250/),μM,544.3,162298,DB00987,Cytarabine
,3479250,"t1/2,el","The elimination kinetics of ara-CTP was monoexponential with t1/2,el of 3.30 +/- 0.8 h and 6.9 +/- 2.8 h in patients with ANLL and ALL.",Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3479250/),h,3.30,162299,DB00987,Cytarabine
,3479250,"t1/2,el","The elimination kinetics of ara-CTP was monoexponential with t1/2,el of 3.30 +/- 0.8 h and 6.9 +/- 2.8 h in patients with ANLL and ALL.",Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3479250/),h,6.9,162300,DB00987,Cytarabine
,3479250,AUC,"The AUC of ara-CTP in leukemic cells ranged from 1,073 to 14,751 microMh and it was not related to the AUC of ara-C in plasma.",Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3479250/),μMh,"1,073 to 14,751",162301,DB00987,Cytarabine
,3476358,area under the curve (AUC) 0-24 h,A large variability was observed with respect to (1) the plasma area under the curve (AUC) 0-24 h (range: 0.06-0.37 nmol X h/ml); (2) the white cell AUC 0-24 h (range: 0-441 nmol X h/10(9) cells); and (3) the 1 h bone marrow concentration (range: 0-27 nmol/10(9) cells).,Pharmacokinetics of daunorubicin as a determinant of response in acute myeloid leukemia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3476358/),[h·nM] / [ml],0.06-0.37,162790,DB00987,Cytarabine
,3476358,AUC 0-24 h,A large variability was observed with respect to (1) the plasma area under the curve (AUC) 0-24 h (range: 0.06-0.37 nmol X h/ml); (2) the white cell AUC 0-24 h (range: 0-441 nmol X h/10(9) cells); and (3) the 1 h bone marrow concentration (range: 0-27 nmol/10(9) cells).,Pharmacokinetics of daunorubicin as a determinant of response in acute myeloid leukemia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3476358/),[h·nM] / [10(9)·cells],0-441,162791,DB00987,Cytarabine
,16618945,complete response rate,"The complete response rate improved from 35% after fludarabine induction to 79.4% after alemtuzumab consolidation, including 19 patients (56%) who achieved MRD negativity.",Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16618945/),%,35,163691,DB00987,Cytarabine
,16618945,complete response rate,"The complete response rate improved from 35% after fludarabine induction to 79.4% after alemtuzumab consolidation, including 19 patients (56%) who achieved MRD negativity.",Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16618945/),%,79.4,163692,DB00987,Cytarabine
,7786781,half-life,"The apparent terminal half-life of IDAol was significantly longer in the elderly than in the younger patients (mean half-life 59.7 h versus 41.4 h, P < 0.05).",Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7786781/),h,59.7,164234,DB00987,Cytarabine
,7786781,half-life,"The apparent terminal half-life of IDAol was significantly longer in the elderly than in the younger patients (mean half-life 59.7 h versus 41.4 h, P < 0.05).",Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7786781/),h,41.4,164235,DB00987,Cytarabine
,31152020,complete response (CR)/incomplete count recovery (Cri) rate,The complete response (CR)/incomplete count recovery (Cri) rate was 32%.,Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152020/),%,32,164275,DB00987,Cytarabine
,31152020,overall survival,Median overall survival was 10 months: 23 months with CR/CRi versus 7.8 months without CR/CRi (log-rank P = 0.02).,Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152020/),month,10,164276,DB00987,Cytarabine
,31152020,overall survival,Median overall survival was 10 months: 23 months with CR/CRi versus 7.8 months without CR/CRi (log-rank P = 0.02).,Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152020/),month,23,164277,DB00987,Cytarabine
,31152020,overall survival,Median overall survival was 10 months: 23 months with CR/CRi versus 7.8 months without CR/CRi (log-rank P = 0.02).,Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152020/),month,7.8,164278,DB00987,Cytarabine
,31152020,relapse-free survival,Median relapse-free survival was 8.2 months.,Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152020/),month,8.2,164279,DB00987,Cytarabine
less,1770090,electro,The electrophoretic separation time is less than 5 min.,Determination of cytosine-beta-D-arabinoside in plasma using capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770090/),min,5,166090,DB00987,Cytarabine
,1770090,limit of,The limit of detection for ara-C in plasma is 0.5 microM (signal-to-noise ratio = 3).,Determination of cytosine-beta-D-arabinoside in plasma using capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770090/),μM,0.5,166091,DB00987,Cytarabine
,1770090,signal-to-noise ratio,The limit of detection for ara-C in plasma is 0.5 microM (signal-to-noise ratio = 3).,Determination of cytosine-beta-D-arabinoside in plasma using capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770090/),,3,166092,DB00987,Cytarabine
,2328297,plasma clearance,The plasma clearance of ara-C (8.16 +/- 2.43 ml min-1 kg-1) was significantly higher than the clearance of ara-U (5.66 +/- 2.59 ml min-1 kg-1).,The disposition of cytosine arabinoside and its metabolite after single doses to rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328297/),[ml] / [kg·min],8.16,167160,DB00987,Cytarabine
,2328297,clearance,The plasma clearance of ara-C (8.16 +/- 2.43 ml min-1 kg-1) was significantly higher than the clearance of ara-U (5.66 +/- 2.59 ml min-1 kg-1).,The disposition of cytosine arabinoside and its metabolite after single doses to rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328297/),[ml] / [kg·min],5.66,167161,DB00987,Cytarabine
,2328297,volume of distribution,The volume of distribution of ara-C was 0.64 +/- 0.16 l kg-1 (mean +/- SD) and was significantly smaller (p less than 0.05) than that of ara-U (1.22 +/- 0.70 l kg-1).,The disposition of cytosine arabinoside and its metabolite after single doses to rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328297/),[l] / [kg],0.64,167162,DB00987,Cytarabine
,2328297,volume of distribution,The volume of distribution of ara-C was 0.64 +/- 0.16 l kg-1 (mean +/- SD) and was significantly smaller (p less than 0.05) than that of ara-U (1.22 +/- 0.70 l kg-1).,The disposition of cytosine arabinoside and its metabolite after single doses to rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328297/),[l] / [kg],1.22,167163,DB00987,Cytarabine
,2328297,elimination rate constant,"As a result, the elimination rate constant of ara-C was significantly larger than that of ara-U (0.602 +/- 0.097 h-1 vs 0.258 +/- 0.05 l h-1).",The disposition of cytosine arabinoside and its metabolite after single doses to rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328297/),1/[h],0.602,167164,DB00987,Cytarabine
,2328297,elimination rate constant,"As a result, the elimination rate constant of ara-C was significantly larger than that of ara-U (0.602 +/- 0.097 h-1 vs 0.258 +/- 0.05 l h-1).",The disposition of cytosine arabinoside and its metabolite after single doses to rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328297/),[l] / [h],0.258,167165,DB00987,Cytarabine
,2328297,fraction of,"In the rabbits that received both treatments (n = 7), the fraction of the ara-C dose metabolized to ara-U (fm) was 0.53 +/- 0.20.",The disposition of cytosine arabinoside and its metabolite after single doses to rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328297/),,0.53,167166,DB00987,Cytarabine
,16941075,limit of detection,The limit of detection was 0.003 microg/mL cytarabine and 0.016 microg/ml for ara-U.,"A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16941075/),[μg] / [ml],0.003,168788,DB00987,Cytarabine
,16941075,limit of detection,The limit of detection was 0.003 microg/mL cytarabine and 0.016 microg/ml for ara-U.,"A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16941075/),[μg] / [ml],0.016,168789,DB00987,Cytarabine
,27641693,peak concentration (CMAX ),"The mean peak concentration (CMAX ) and area under the curve (AUC) after CRI administration were 1.70 ± 0.66 μg/mL and 11.39 ± 3.37 h·μg/mL, respectively, for dogs receiving cytarabine alone, 2.36 ± 0.35 μg/mL and 16.91 + 3.60 h·μg/mL for dogs administered cytarabine and concurrently on other drugs.",Plasma and serum concentrations of cytarabine administered via continuous intravenous infusion to dogs with meningoencephalomyelitis of unknown etiology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27641693/),[μg] / [ml],1.70,169099,DB00987,Cytarabine
,27641693,peak concentration (CMAX ),"The mean peak concentration (CMAX ) and area under the curve (AUC) after CRI administration were 1.70 ± 0.66 μg/mL and 11.39 ± 3.37 h·μg/mL, respectively, for dogs receiving cytarabine alone, 2.36 ± 0.35 μg/mL and 16.91 + 3.60 h·μg/mL for dogs administered cytarabine and concurrently on other drugs.",Plasma and serum concentrations of cytarabine administered via continuous intravenous infusion to dogs with meningoencephalomyelitis of unknown etiology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27641693/),[μg] / [ml],2.36,169100,DB00987,Cytarabine
,27641693,area under the curve (AUC),"The mean peak concentration (CMAX ) and area under the curve (AUC) after CRI administration were 1.70 ± 0.66 μg/mL and 11.39 ± 3.37 h·μg/mL, respectively, for dogs receiving cytarabine alone, 2.36 ± 0.35 μg/mL and 16.91 + 3.60 h·μg/mL for dogs administered cytarabine and concurrently on other drugs.",Plasma and serum concentrations of cytarabine administered via continuous intravenous infusion to dogs with meningoencephalomyelitis of unknown etiology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27641693/),[h·μg] / [ml],11.39,169101,DB00987,Cytarabine
,27641693,area under the curve (AUC),"The mean peak concentration (CMAX ) and area under the curve (AUC) after CRI administration were 1.70 ± 0.66 μg/mL and 11.39 ± 3.37 h·μg/mL, respectively, for dogs receiving cytarabine alone, 2.36 ± 0.35 μg/mL and 16.91 + 3.60 h·μg/mL for dogs administered cytarabine and concurrently on other drugs.",Plasma and serum concentrations of cytarabine administered via continuous intravenous infusion to dogs with meningoencephalomyelitis of unknown etiology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27641693/),[h·μg] / [ml],16.91,169102,DB00987,Cytarabine
,1737352,t1/2,"The median rate of ara-CTP elimination was slightly faster after fludarabine treatment (t1/2, 6.7 versus 5.8 h), suggesting that catabolism of ara-CTP was not responsible for the increased ara-CTP area under the curve.",Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1737352/),h,6.7,170083,DB00987,Cytarabine
,1737352,t1/2,"The median rate of ara-CTP elimination was slightly faster after fludarabine treatment (t1/2, 6.7 versus 5.8 h), suggesting that catabolism of ara-CTP was not responsible for the increased ara-CTP area under the curve.",Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1737352/),h,5.8,170084,DB00987,Cytarabine
,28174232,fraction unbound,Flavopiridol fraction unbound was 10.9% and not different between schedules.,Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28174232/),%,10.9,171040,DB00987,Cytarabine
≥,28174232,AUC,"Clinical response was associated with AUC ≥ 780 h*ng/mL for newly diagnosed patients and AUC ≥ 1,690 h*ng/mL for relapsed/refractory patients.",Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28174232/),[h·ng] / [ml],780,171041,DB00987,Cytarabine
≥,28174232,AUC,"Clinical response was associated with AUC ≥ 780 h*ng/mL for newly diagnosed patients and AUC ≥ 1,690 h*ng/mL for relapsed/refractory patients.",Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28174232/),[h·ng] / [ml],"1,690",171042,DB00987,Cytarabine
,6766563,half-life,The plasma disappearance curve of BH-AC is biphasic; the half-life of the initial phase is 40 min and that of the second phase is 120 min.,Pharmacologic and clinical studies of N4-behenoyl-1-beta-D-arabinofuranosylcytosine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6766563/),min,40,172891,DB00987,Cytarabine
,6766563,half-life,The plasma disappearance curve of BH-AC is biphasic; the half-life of the initial phase is 40 min and that of the second phase is 120 min.,Pharmacologic and clinical studies of N4-behenoyl-1-beta-D-arabinofuranosylcytosine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6766563/),min,120,172892,DB00987,Cytarabine
,6766563,plasma t 1/2,The plasma-clearance study of BH-AC in 13 patients showed essentially a pattern similar to that in monkeys; the plasma t 1/2 of 60 min in the first phase and of 180 min in the second.,Pharmacologic and clinical studies of N4-behenoyl-1-beta-D-arabinofuranosylcytosine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6766563/),min,60,172893,DB00987,Cytarabine
,6766563,plasma t 1/2,The plasma-clearance study of BH-AC in 13 patients showed essentially a pattern similar to that in monkeys; the plasma t 1/2 of 60 min in the first phase and of 180 min in the second.,Pharmacologic and clinical studies of N4-behenoyl-1-beta-D-arabinofuranosylcytosine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6766563/),min,180,172894,DB00987,Cytarabine
<,32750494,tissue:plasma ratios,"In preclinical species, this article demonstrated (1) similar release of cytarabine and daunorubicin by CPX-351 in plasma; (2) similar patterns of metabolism of cytarabine and daunorubicin following administration of CPX-351 versus non-liposomal cytarabine/daunorubicin combination; (3) prolonged tissue exposure to CPX-351; (4) dramatically different tissue distribution of cytarabine and daunorubicin following administration of CPX-351 versus non-liposomal combination (tissue:plasma ratios generally <1 versus >1, respectively); and (5) dramatically lower unbound plasma and tissue concentrations of cytarabine and daunorubicin following administration of CPX-351 versus non-liposomal combination.","Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32750494/),,1,173266,DB00987,Cytarabine
>,32750494,tissue:plasma ratios,"In preclinical species, this article demonstrated (1) similar release of cytarabine and daunorubicin by CPX-351 in plasma; (2) similar patterns of metabolism of cytarabine and daunorubicin following administration of CPX-351 versus non-liposomal cytarabine/daunorubicin combination; (3) prolonged tissue exposure to CPX-351; (4) dramatically different tissue distribution of cytarabine and daunorubicin following administration of CPX-351 versus non-liposomal combination (tissue:plasma ratios generally <1 versus >1, respectively); and (5) dramatically lower unbound plasma and tissue concentrations of cytarabine and daunorubicin following administration of CPX-351 versus non-liposomal combination.","Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32750494/),,1,173267,DB00987,Cytarabine
,22840315,plasma ratio,The plasma ratio of 5:1 was maintained at all dose levels.,"Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22840315/),,5,174331,DB00987,Cytarabine
,8618451,terminal half-life,The average terminal half-life was 30.5h for idarubicin and 66.9 h for idarubicinol.,Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618451/),h,30.5,174570,DB00987,Cytarabine
,8618451,terminal half-life,The average terminal half-life was 30.5h for idarubicin and 66.9 h for idarubicinol.,Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618451/),h,66.9,174571,DB00987,Cytarabine
,8618451,AUC,The AUC for idarubicin and its main metabolite idarubicinol revealed a substantial interpatient variation with AUC values ranging from 25.7 to 114 ng x h/ml (average 58.1 ng x h/ml) for idarubicin and from 109.4 - 445.2 ng x h/ml (average 287.3 ng x h/ml) for idarubicinol.,Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618451/),[h·ng] / [ml],25.7 to 114,174572,DB00987,Cytarabine
,8618451,AUC,The AUC for idarubicin and its main metabolite idarubicinol revealed a substantial interpatient variation with AUC values ranging from 25.7 to 114 ng x h/ml (average 58.1 ng x h/ml) for idarubicin and from 109.4 - 445.2 ng x h/ml (average 287.3 ng x h/ml) for idarubicinol.,Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618451/),[h·ng] / [ml],58.1,174573,DB00987,Cytarabine
,8618451,AUC,The AUC for idarubicin and its main metabolite idarubicinol revealed a substantial interpatient variation with AUC values ranging from 25.7 to 114 ng x h/ml (average 58.1 ng x h/ml) for idarubicin and from 109.4 - 445.2 ng x h/ml (average 287.3 ng x h/ml) for idarubicinol.,Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618451/),[h·ng] / [ml],287.3,174574,DB00987,Cytarabine
,2720678,survival,A total dose of 7.35 g/kg/day for 2 days was nontoxic; the mean survival of control (saline treated) leukemic mice was 12.2 +/- 1.8 days and 11.7 +/- 2.0 days for the HiDAU-treated leukemic mice.,Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720678/),d,12.2,175420,DB00987,Cytarabine
,2720678,survival,A total dose of 7.35 g/kg/day for 2 days was nontoxic; the mean survival of control (saline treated) leukemic mice was 12.2 +/- 1.8 days and 11.7 +/- 2.0 days for the HiDAU-treated leukemic mice.,Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720678/),d,11.7,175421,DB00987,Cytarabine
,24129691,elimination half-life,"The average elimination half-life values in children aged 3-10 years and in those aged >10 years, treated with liposomal cytarabine 35 mg and 50 mg, respectively, were 40.9 and 43.7 h for free cytarabine and 31.5 and 36.4 h for encapsulated cytarabine in CSF.",Pharmacokinetics and toxicity of intrathecal liposomal cytarabine in children and adolescents following age-adapted dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24129691/),h,40.9,177876,DB00987,Cytarabine
,24129691,elimination half-life,"The average elimination half-life values in children aged 3-10 years and in those aged >10 years, treated with liposomal cytarabine 35 mg and 50 mg, respectively, were 40.9 and 43.7 h for free cytarabine and 31.5 and 36.4 h for encapsulated cytarabine in CSF.",Pharmacokinetics and toxicity of intrathecal liposomal cytarabine in children and adolescents following age-adapted dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24129691/),h,43.7,177877,DB00987,Cytarabine
,24129691,elimination half-life,"The average elimination half-life values in children aged 3-10 years and in those aged >10 years, treated with liposomal cytarabine 35 mg and 50 mg, respectively, were 40.9 and 43.7 h for free cytarabine and 31.5 and 36.4 h for encapsulated cytarabine in CSF.",Pharmacokinetics and toxicity of intrathecal liposomal cytarabine in children and adolescents following age-adapted dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24129691/),h,31.5,177878,DB00987,Cytarabine
,24129691,elimination half-life,"The average elimination half-life values in children aged 3-10 years and in those aged >10 years, treated with liposomal cytarabine 35 mg and 50 mg, respectively, were 40.9 and 43.7 h for free cytarabine and 31.5 and 36.4 h for encapsulated cytarabine in CSF.",Pharmacokinetics and toxicity of intrathecal liposomal cytarabine in children and adolescents following age-adapted dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24129691/),h,36.4,177879,DB00987,Cytarabine
,31490575,maximal concentrations,"The mean maximal concentrations in this study were 4,230, 9,293, and 16,675 ng/ml for a single dose of 50, 100, and 200 mg/m2 , respectively.",The pharmacokinetics of cytarabine administered at three distinct subcutaneous dosing protocols in dogs with meningoencephalomyelitis of unknown origin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31490575/),[ng] / [ml],"4,230",183642,DB00987,Cytarabine
,31490575,maximal concentrations,"The mean maximal concentrations in this study were 4,230, 9,293, and 16,675 ng/ml for a single dose of 50, 100, and 200 mg/m2 , respectively.",The pharmacokinetics of cytarabine administered at three distinct subcutaneous dosing protocols in dogs with meningoencephalomyelitis of unknown origin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31490575/),[ng] / [ml],"9,293",183643,DB00987,Cytarabine
,31490575,maximal concentrations,"The mean maximal concentrations in this study were 4,230, 9,293, and 16,675 ng/ml for a single dose of 50, 100, and 200 mg/m2 , respectively.",The pharmacokinetics of cytarabine administered at three distinct subcutaneous dosing protocols in dogs with meningoencephalomyelitis of unknown origin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31490575/),[ng] / [ml],"16,675",183644,DB00987,Cytarabine
,31490575,area under the concentration versus time curve,"Drug exposure was similar regardless of the dosing protocol when the total dose was analyzed, with an area under the concentration versus time curve of 37,026, 38,465, and 32,510 ng × hr/ml for 50, 100, and 200 mg/m2 , respectively.",The pharmacokinetics of cytarabine administered at three distinct subcutaneous dosing protocols in dogs with meningoencephalomyelitis of unknown origin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31490575/),[h·ng] / [ml],"37,026",183645,DB00987,Cytarabine
,31490575,area under the concentration versus time curve,"Drug exposure was similar regardless of the dosing protocol when the total dose was analyzed, with an area under the concentration versus time curve of 37,026, 38,465, and 32,510 ng × hr/ml for 50, 100, and 200 mg/m2 , respectively.",The pharmacokinetics of cytarabine administered at three distinct subcutaneous dosing protocols in dogs with meningoencephalomyelitis of unknown origin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31490575/),[h·ng] / [ml],"38,465",183646,DB00987,Cytarabine
,31490575,area under the concentration versus time curve,"Drug exposure was similar regardless of the dosing protocol when the total dose was analyzed, with an area under the concentration versus time curve of 37,026, 38,465, and 32,510 ng × hr/ml for 50, 100, and 200 mg/m2 , respectively.",The pharmacokinetics of cytarabine administered at three distinct subcutaneous dosing protocols in dogs with meningoencephalomyelitis of unknown origin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31490575/),[h·ng] / [ml],"32,510",183647,DB00987,Cytarabine
,17325899,Overall response rate,"Overall response rate was 58%, with 37% complete and 21% partial responses.","A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17325899/),%,58,184793,DB00987,Cytarabine
,17325899,time to progression,"Median time to progression and overall median survival were 5.7 months and 14.5 months, respectively.","A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17325899/),month,5.7,184794,DB00987,Cytarabine
,17325899,overall median survival,"Median time to progression and overall median survival were 5.7 months and 14.5 months, respectively.","A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17325899/),month,14.5,184795,DB00987,Cytarabine
,9401941,bioavailability,"When given orally a rather low amount of the delivered NOAC was absorbed as the unchanged drug, resulting in a bioavailability of 1.1% from the plasma and 12.9% from whole blood.",Pharmacokinetics of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in plasma and whole blood after intravenous and oral administration to mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9401941/),%,1.1,186235,DB00987,Cytarabine
,9401941,bioavailability,"When given orally a rather low amount of the delivered NOAC was absorbed as the unchanged drug, resulting in a bioavailability of 1.1% from the plasma and 12.9% from whole blood.",Pharmacokinetics of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in plasma and whole blood after intravenous and oral administration to mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9401941/),%,12.9,186236,DB00987,Cytarabine
,9401941,mean residence time,The mean residence time of NOAC after intravenous administration was 3.5 h in plasma and 6 h in whole blood giving NOAC a terminal half-life in blood substantially longer than that of cytosine arabinoside.,Pharmacokinetics of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in plasma and whole blood after intravenous and oral administration to mice. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9401941/),h,3.5,186237,DB00987,Cytarabine
,9401941,mean residence time,The mean residence time of NOAC after intravenous administration was 3.5 h in plasma and 6 h in whole blood giving NOAC a terminal half-life in blood substantially longer than that of cytosine arabinoside.,Pharmacokinetics of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in plasma and whole blood after intravenous and oral administration to mice. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9401941/),h,6,186238,DB00987,Cytarabine
,9401941,mean residence time,After oral administration the mean residence time was 18 h in plasma and whole blood.,Pharmacokinetics of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in plasma and whole blood after intravenous and oral administration to mice. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9401941/),h,18,186239,DB00987,Cytarabine
,1733557,t1/2,"DP significantly increased the mean t1/2 for [3H]-ara-CTP from 102 to 136 min (P less than 0.01), but this effect was much less pronounced than that obtained for total tritium and the increase was quite variable (0-70%; median, 19%).",Modulation of the cellular pharmacokinetics of ara-CTP in human leukemic blasts by dipyridamole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1733557/),min,102 to 136,186537,DB00987,Cytarabine
,10363985,survival rate,"With this system, the survival rate of the cell line K562 treated with ara-C, relative to that of untreated control cells, was 7.1%, as determined by a clonogenic culture technique using a clinically intermediate dose of ara-C (1.0 g/m2; 2-h infusion).",Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363985/),%,7.1,187589,DB00987,Cytarabine
,10363985,relative cell survival rates,"When the area under the serum concentration-time curve (AUC) was kept constant at infusion times of 2, 4, 8, and 16 h with a regular dose of ara-C (100-mg/m2 infusion), the relative cell survival rates were 75, 72, 34, and 14%, respectively.",Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363985/),%,75,187590,DB00987,Cytarabine
,10363985,relative cell survival rates,"When the area under the serum concentration-time curve (AUC) was kept constant at infusion times of 2, 4, 8, and 16 h with a regular dose of ara-C (100-mg/m2 infusion), the relative cell survival rates were 75, 72, 34, and 14%, respectively.",Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363985/),%,72,187591,DB00987,Cytarabine
,10363985,relative cell survival rates,"When the area under the serum concentration-time curve (AUC) was kept constant at infusion times of 2, 4, 8, and 16 h with a regular dose of ara-C (100-mg/m2 infusion), the relative cell survival rates were 75, 72, 34, and 14%, respectively.",Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363985/),%,34,187592,DB00987,Cytarabine
,10363985,relative cell survival rates,"When the area under the serum concentration-time curve (AUC) was kept constant at infusion times of 2, 4, 8, and 16 h with a regular dose of ara-C (100-mg/m2 infusion), the relative cell survival rates were 75, 72, 34, and 14%, respectively.",Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363985/),%,14,187593,DB00987,Cytarabine
,10363985,relative survival rates [maximal concentrations (Cmaxs)],"For the simulations of the administration of 50 mg/m2 daunorubicin for 0.5-, 2-, 4-, and 8-h infusions, the relative survival rates [maximal concentrations (Cmaxs)] were 37.4% (0.24 microM), 49.7% (0.089 microM), 72.1% (0.055 microM), and 82.2% (0.032 microM), respectively.",Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363985/),%,37.4,187594,DB00987,Cytarabine
,10363985,relative survival rates [maximal concentrations (Cmaxs)],"For the simulations of the administration of 50 mg/m2 daunorubicin for 0.5-, 2-, 4-, and 8-h infusions, the relative survival rates [maximal concentrations (Cmaxs)] were 37.4% (0.24 microM), 49.7% (0.089 microM), 72.1% (0.055 microM), and 82.2% (0.032 microM), respectively.",Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363985/),μ,0.24,187595,DB00987,Cytarabine
,10363985,relative survival rates [maximal concentrations (Cmaxs)],"For the simulations of the administration of 50 mg/m2 daunorubicin for 0.5-, 2-, 4-, and 8-h infusions, the relative survival rates [maximal concentrations (Cmaxs)] were 37.4% (0.24 microM), 49.7% (0.089 microM), 72.1% (0.055 microM), and 82.2% (0.032 microM), respectively.",Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363985/),%,49.7,187596,DB00987,Cytarabine
,10363985,relative survival rates [maximal concentrations (Cmaxs)],"For the simulations of the administration of 50 mg/m2 daunorubicin for 0.5-, 2-, 4-, and 8-h infusions, the relative survival rates [maximal concentrations (Cmaxs)] were 37.4% (0.24 microM), 49.7% (0.089 microM), 72.1% (0.055 microM), and 82.2% (0.032 microM), respectively.",Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363985/),%,72.1,187597,DB00987,Cytarabine
,10363985,relative survival rates [maximal concentrations (Cmaxs)],"For the simulations of the administration of 50 mg/m2 daunorubicin for 0.5-, 2-, 4-, and 8-h infusions, the relative survival rates [maximal concentrations (Cmaxs)] were 37.4% (0.24 microM), 49.7% (0.089 microM), 72.1% (0.055 microM), and 82.2% (0.032 microM), respectively.",Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363985/),%,82.2,187598,DB00987,Cytarabine
,10363985,relative survival rates (Cmaxs),"With the conventional culture system, the relative survival rates (Cmaxs) following daunorubicin treatment were 7.6% (0.48 microM), 18.6% (0.12 microM), 63.7% (0.06 microM), and 92.0% (0.03 microM) when the drug exposure times were 0.5, 2, 4, and 8 h, respectively, with a constant C x T.",Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363985/),%,7.6,187599,DB00987,Cytarabine
,10363985,relative survival rates (Cmaxs),"With the conventional culture system, the relative survival rates (Cmaxs) following daunorubicin treatment were 7.6% (0.48 microM), 18.6% (0.12 microM), 63.7% (0.06 microM), and 92.0% (0.03 microM) when the drug exposure times were 0.5, 2, 4, and 8 h, respectively, with a constant C x T.",Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363985/),%,18.6,187600,DB00987,Cytarabine
,10363985,relative survival rates (Cmaxs),"With the conventional culture system, the relative survival rates (Cmaxs) following daunorubicin treatment were 7.6% (0.48 microM), 18.6% (0.12 microM), 63.7% (0.06 microM), and 92.0% (0.03 microM) when the drug exposure times were 0.5, 2, 4, and 8 h, respectively, with a constant C x T.",Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363985/),%,63.7,187601,DB00987,Cytarabine
,10363985,relative survival rates (Cmaxs),"With the conventional culture system, the relative survival rates (Cmaxs) following daunorubicin treatment were 7.6% (0.48 microM), 18.6% (0.12 microM), 63.7% (0.06 microM), and 92.0% (0.03 microM) when the drug exposure times were 0.5, 2, 4, and 8 h, respectively, with a constant C x T.",Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363985/),%,92.0,187602,DB00987,Cytarabine
,16010591,half-lives,"The AUC and Cmax of both irinotecan and its active metabolite SN38 increased linearly in proportion to dose, and the mean half-lives of irinotecan conversion to SN38 and SN38 elimination were 6.2 h (CV 171%) and 7.2 h (CV 48%).",Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16010591/),h,6.2,188040,DB00987,Cytarabine
,16010591,half-lives,"The AUC and Cmax of both irinotecan and its active metabolite SN38 increased linearly in proportion to dose, and the mean half-lives of irinotecan conversion to SN38 and SN38 elimination were 6.2 h (CV 171%) and 7.2 h (CV 48%).",Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16010591/),h,7.2,188041,DB00987,Cytarabine
,2304422,t1/2,"In contrast to the comparatively short retention of ara-C in the CSF (t1/2 1.8 to 2.9 hours), there was a high accumulation and an extremely long retention of ara-CTP in the leukemic cells (t1/2 8.1 to 36 hours).",Pharmacokinetics of cytosine arabinoside in cerebrospinal fluid and of its metabolite in leukemic cells. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2304422/),h,1.8 to 2.9,188115,DB00987,Cytarabine
,2304422,t1/2,"In contrast to the comparatively short retention of ara-C in the CSF (t1/2 1.8 to 2.9 hours), there was a high accumulation and an extremely long retention of ara-CTP in the leukemic cells (t1/2 8.1 to 36 hours).",Pharmacokinetics of cytosine arabinoside in cerebrospinal fluid and of its metabolite in leukemic cells. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2304422/),h,8.1 to 36,188116,DB00987,Cytarabine
,16597550,elimination half-life,Plasma pharmacokinetics were dose-linear with an elimination half-life of 2.2 h.,Safety assessment of 4'-thio-beta-D-arabinofuranosylcytosine in the beagle dog suggests a drug-induced centrally mediated effect on the hypothalamic-pituitary-adrenal axis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16597550/),h,2.2,188462,DB00987,Cytarabine
,15645422,IC(50),"Potent in vitro anti-proliferative effects were observed against pancreatic (Capan-1, MIA-PaCa-2, BxPC-3) and ovarian (SK-OV-3, OVCAR-3, ES-2) cancer cell lines with IC(50) of 0.01-0.2 microM.",Anti-tumor efficacy of the nucleoside analog 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl) cytosine (4'-thio-FAC) in human pancreatic and ovarian tumor xenograft models. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15645422/),μM,0.01-0.2,188564,DB00987,Cytarabine
,11127942,peak Ara-C level,The median peak Ara-C level in CSF was 16.69+/-6.30 mM (SD).,Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127942/),mM,16.69,189462,DB00987,Cytarabine
,11127942,half life for elimination,The half life for elimination was 1.45+/-0.61 h (SD) There was no drug accumulation between courses.,Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127942/),h,1.45,189463,DB00987,Cytarabine
,8261429,peak plasma level (Cmax),"The peak plasma level (Cmax) was 322 +/- 218 nM, and the predicted time to reach Cmax (Tmax) was 6.5 +/- 4.5 h, while the elimination half-life (t1/2) was very long (32.0 +/- 8.4 h).","Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261429/),nM,322,189816,DB00987,Cytarabine
,8261429,time to reach Cmax (Tmax),"The peak plasma level (Cmax) was 322 +/- 218 nM, and the predicted time to reach Cmax (Tmax) was 6.5 +/- 4.5 h, while the elimination half-life (t1/2) was very long (32.0 +/- 8.4 h).","Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261429/),h,6.5,189817,DB00987,Cytarabine
,8261429,elimination half-life (t1/2),"The peak plasma level (Cmax) was 322 +/- 218 nM, and the predicted time to reach Cmax (Tmax) was 6.5 +/- 4.5 h, while the elimination half-life (t1/2) was very long (32.0 +/- 8.4 h).","Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261429/),h,32.0,189818,DB00987,Cytarabine
,8261429,Cmax,"The plasma ara-C level increased slowly to a Cmax of 26.3 +/- 12.7 nM (Tmax, 13.3 +/- 4.7 h) after stearyl-ara-CMP administration.","Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261429/),nM,26.3,189819,DB00987,Cytarabine
,8261429,Tmax,"The plasma ara-C level increased slowly to a Cmax of 26.3 +/- 12.7 nM (Tmax, 13.3 +/- 4.7 h) after stearyl-ara-CMP administration.","Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261429/),h,13.3,189820,DB00987,Cytarabine
,8261429,Cmax,"For ara-U, the Cmax, Tmax, and t1/2 were 483 +/- 315 nM, 23.6 +/- 4.0 h, and 19.6 +/- 5.3 h, respectively.","Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261429/),nM,483,189821,DB00987,Cytarabine
,8261429,Tmax,"For ara-U, the Cmax, Tmax, and t1/2 were 483 +/- 315 nM, 23.6 +/- 4.0 h, and 19.6 +/- 5.3 h, respectively.","Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261429/),h,23.6,189822,DB00987,Cytarabine
,8261429,t1/2,"For ara-U, the Cmax, Tmax, and t1/2 were 483 +/- 315 nM, 23.6 +/- 4.0 h, and 19.6 +/- 5.3 h, respectively.","Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261429/),h,19.6,189823,DB00987,Cytarabine
,8410125,time to complete remission (CR),"Myelosuppression was universal and the median time to complete remission (CR) was 28 days (range, 19 to 77).",Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8410125/),d,28,191834,DB00987,Cytarabine
,12955470,survival time,"Injections of 10 mg/kg troxacitabine i.p. daily for 5 days in combination with araC at 10 mg/kg led to an increase in median survival time of 58 days compared to 49.5 and 53.5 days for araC and troxacitabine, respectively, given as single agents.",Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955470/),d,58,193614,DB00987,Cytarabine
,12955470,survival time,"Injections of 10 mg/kg troxacitabine i.p. daily for 5 days in combination with araC at 10 mg/kg led to an increase in median survival time of 58 days compared to 49.5 and 53.5 days for araC and troxacitabine, respectively, given as single agents.",Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955470/),d,49.5,193615,DB00987,Cytarabine
,12955470,survival time,"Injections of 10 mg/kg troxacitabine i.p. daily for 5 days in combination with araC at 10 mg/kg led to an increase in median survival time of 58 days compared to 49.5 and 53.5 days for araC and troxacitabine, respectively, given as single agents.",Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955470/),d,53.5,193616,DB00987,Cytarabine
,31770437,maximal tolerated dose,The maximal tolerated dose was 6 g/m2 per day.,"BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31770437/),[g] / [m2],6,194015,DB00987,Cytarabine
,31770437,Overall response rate,Overall response rate was 29.6%.,"BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31770437/),%,29.6,194016,DB00987,Cytarabine
,31770437,overall response,"A subgroup analysis of newly diagnosed patients with AML, de novo or secondary to myelodysplastic syndrome, unfit for standard induction (median age 78), demonstrated overall response of 45.5%.","BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31770437/),%,45.5,194017,DB00987,Cytarabine
,31770437,overall survival,The median overall survival was 6.5 months and was not reached in patients achieving complete remission.,"BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31770437/),month,6.5,194018,DB00987,Cytarabine
,32442344,maximum plasma concentration,"Subcutaneous LC administration resulted in a maximum plasma concentration of 26.3 to 59.78 ng/mL, time to reach maximum plasma concentration of 2 hours, area under the concentration-time curve to last measurable concentration of 669.3 to 1126 h × ng/mL, and plasma bioavailability (%F) of 19.6% to 31.3%.",Pharmacokinetics of multivesicular liposomal encapsulated cytarabine when administered subcutaneously in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32442344/),[ng] / [ml],26.3 to 59.78,194395,DB00987,Cytarabine
,32442344,time to reach maximum plasma concentration,"Subcutaneous LC administration resulted in a maximum plasma concentration of 26.3 to 59.78 ng/mL, time to reach maximum plasma concentration of 2 hours, area under the concentration-time curve to last measurable concentration of 669.3 to 1126 h × ng/mL, and plasma bioavailability (%F) of 19.6% to 31.3%.",Pharmacokinetics of multivesicular liposomal encapsulated cytarabine when administered subcutaneously in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32442344/),h,2,194396,DB00987,Cytarabine
,32442344,area under the concentration-time curve to last measurable concentration,"Subcutaneous LC administration resulted in a maximum plasma concentration of 26.3 to 59.78 ng/mL, time to reach maximum plasma concentration of 2 hours, area under the concentration-time curve to last measurable concentration of 669.3 to 1126 h × ng/mL, and plasma bioavailability (%F) of 19.6% to 31.3%.",Pharmacokinetics of multivesicular liposomal encapsulated cytarabine when administered subcutaneously in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32442344/),[h·ng] / [ml],669.3 to 1126,194397,DB00987,Cytarabine
,32442344,plasma bioavailability (%F),"Subcutaneous LC administration resulted in a maximum plasma concentration of 26.3 to 59.78 ng/mL, time to reach maximum plasma concentration of 2 hours, area under the concentration-time curve to last measurable concentration of 669.3 to 1126 h × ng/mL, and plasma bioavailability (%F) of 19.6% to 31.3%.",Pharmacokinetics of multivesicular liposomal encapsulated cytarabine when administered subcutaneously in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32442344/),%,19.6,194398,DB00987,Cytarabine
,32442344,plasma bioavailability (%F),"Subcutaneous LC administration resulted in a maximum plasma concentration of 26.3 to 59.78 ng/mL, time to reach maximum plasma concentration of 2 hours, area under the concentration-time curve to last measurable concentration of 669.3 to 1126 h × ng/mL, and plasma bioavailability (%F) of 19.6% to 31.3%.",Pharmacokinetics of multivesicular liposomal encapsulated cytarabine when administered subcutaneously in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32442344/),%,31.3,194399,DB00987,Cytarabine
,2324584,penetration,Pharmacokinetic study revealed high peaks of Ara-C concentration in plasma (6.2 microM immediately after the end of the infusion) and high degree of its penetration into the CNS (5.6 microM at 3 hr after the end of the infusion) suggesting the effective and perhaps a uniform level of Ara-C is achieved throughout the CNS by this therapy.,[Clinical effect and pharmacokinetics of intermediate dose Ara-C therapy in a patient with acute non-lymphocytic leukemia with two CNS recurrences]. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2324584/),μM,5.6,194604,DB00987,Cytarabine
,6896013,alpha,"In initial studies, which examined the cerebrospinal fluid (CSF) pharmacokinetics of intrathecally (i.t.) administered THU, the drug was found to be slowly cleared from the CSF with alpha and beta half-lives of 1 and 8 hr, respectively.",Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6896013/),h,1,194886,DB00987,Cytarabine
,6896013,beta half-lives,"In initial studies, which examined the cerebrospinal fluid (CSF) pharmacokinetics of intrathecally (i.t.) administered THU, the drug was found to be slowly cleared from the CSF with alpha and beta half-lives of 1 and 8 hr, respectively.",Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6896013/),h,8,194887,DB00987,Cytarabine
,6896013,alpha,"ara-C given alone was cleared from CSF with alpha and beta half-lives of 27.5 +/- 6.7 and 115.6 +/- 0.4 (S.D.) min, respectively.",Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6896013/),min,27.5,194888,DB00987,Cytarabine
,6896013,beta half-lives,"ara-C given alone was cleared from CSF with alpha and beta half-lives of 27.5 +/- 6.7 and 115.6 +/- 0.4 (S.D.) min, respectively.",Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6896013/),min,115.6,194889,DB00987,Cytarabine
,6896013,alpha,"Pretreatment with i.v. THU resulted in alpha and beta half-lives of 10.4 +/- 1.5 and 85.7 +/- 11.1, respectively, whereas concomitant administration of i.t. THU resulted in a single half-life of 96 +/- 0.7.",Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6896013/),,10.4,194890,DB00987,Cytarabine
,6896013,beta half-lives,"Pretreatment with i.v. THU resulted in alpha and beta half-lives of 10.4 +/- 1.5 and 85.7 +/- 11.1, respectively, whereas concomitant administration of i.t. THU resulted in a single half-life of 96 +/- 0.7.",Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6896013/),,85.7,194891,DB00987,Cytarabine
,6896013,half-life,"Pretreatment with i.v. THU resulted in alpha and beta half-lives of 10.4 +/- 1.5 and 85.7 +/- 11.1, respectively, whereas concomitant administration of i.t. THU resulted in a single half-life of 96 +/- 0.7.",Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6896013/),,96,194892,DB00987,Cytarabine
,6896013,clearance rates,"The mean calculated clearance rates for ara-C alone, ara-C plus i.v. THU, and ara-C plus i.t. THU were 7.5, 6.2, and 4.2 ml/hr, respectively.",Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6896013/),[ml] / [h],7.5,194893,DB00987,Cytarabine
,6896013,clearance rates,"The mean calculated clearance rates for ara-C alone, ara-C plus i.v. THU, and ara-C plus i.t. THU were 7.5, 6.2, and 4.2 ml/hr, respectively.",Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6896013/),[ml] / [h],6.2,194894,DB00987,Cytarabine
,6896013,clearance rates,"The mean calculated clearance rates for ara-C alone, ara-C plus i.v. THU, and ara-C plus i.t. THU were 7.5, 6.2, and 4.2 ml/hr, respectively.",Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6896013/),[ml] / [h],4.2,194895,DB00987,Cytarabine
,1933871,duration of complete responses,The duration of complete responses ranged from 7 to 22 weeks.,"Intrathecal 6-mercaptopurine: preclinical pharmacology, phase I/II trial, and pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1933871/),weeks,7 to 22,197934,DB00987,Cytarabine
,2908850,peak plasma ara-C concentration,"The peak plasma ara-C concentration of ara-C ranged from 57 to 199 microM with an average concentration of 103 +/- 49 microM; the half-lives of distribution (t1/2, alpha) and elimination (t1/2, beta) averaged 17 +/- 7 min and 4.04 +/- 3.1 h, respectively.",Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908850/),μM,57 to 199,198955,DB00987,Cytarabine
,2908850,"half-lives of distribution (t1/2, alpha)","The peak plasma ara-C concentration of ara-C ranged from 57 to 199 microM with an average concentration of 103 +/- 49 microM; the half-lives of distribution (t1/2, alpha) and elimination (t1/2, beta) averaged 17 +/- 7 min and 4.04 +/- 3.1 h, respectively.",Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908850/),min,17,198956,DB00987,Cytarabine
,2908850,"elimination (t1/2, beta)","The peak plasma ara-C concentration of ara-C ranged from 57 to 199 microM with an average concentration of 103 +/- 49 microM; the half-lives of distribution (t1/2, alpha) and elimination (t1/2, beta) averaged 17 +/- 7 min and 4.04 +/- 3.1 h, respectively.",Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908850/),h,4.04,198957,DB00987,Cytarabine
,2908850,area under the plasma concentration time curve from 0 to 12 h (AUC0----12 h),"The mean area under the plasma concentration time curve from 0 to 12 h (AUC0----12 h) of ara-C averaged 386.8 +/- 328.0 microMh (mean, +/- SD, n = 8).",Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908850/),μMh,386.8,198958,DB00987,Cytarabine
,2908850,peak concentration,"The peak concentration of uracil arabinoside averaged 501 +/- 123 microM, and it was eliminated with a t1/2, el of 2.3 +/- 0.6 h.",Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908850/),μM,501,198959,DB00987,Cytarabine
,2908850,"t1/2, el","The peak concentration of uracil arabinoside averaged 501 +/- 123 microM, and it was eliminated with a t1/2, el of 2.3 +/- 0.6 h.",Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908850/),h,2.3,198960,DB00987,Cytarabine
,2908850,Css,"The patients then received an individualized loading bolus (mean = 0.5 g/m2) followed by a continuous infusion regimen of ara-C (mean = 130 mg/m2/h), to achieve a Css in the range of 20 to 35 microM.",Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908850/),μM,20 to 35,198961,DB00987,Cytarabine
,2908850,AUC,"The percentage of variation of correlation of the AUC following the loading bolus plus the continuous infusion from 12 to 72 h was only 12.4% (mean = 2158 microMh, n = 8), whereas the percentage of variation of correlation of the AUC after the test dose of ara-C in the same patients was 84.8%.(ABSTRACT TRUNCATED AT 400 WORDS)",Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908850/),μMh,2158,198962,DB00987,Cytarabine
,1537079,t1/2 beta,"The mean values for the calculated pharmacokinetic parameters were: t1/2 beta, 256 +/- 38 min; mean residence time (MRT), 346 +/- 47 min; AUC, 4,972 +/- 629 micrograms min ml-1 (normalized to a dose of 100 mg/m2); volume of distribution at steady state (Vdss), 6.6 +/- 1.2 l/m2; and clearance (CL), 20.4 +/- 2.4 ml min-1 m-2.",Pharmacokinetics of high-dose etoposide after short-term infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1537079/),min,256,199424,DB00987,Cytarabine
,1537079,mean residence time (MRT),"The mean values for the calculated pharmacokinetic parameters were: t1/2 beta, 256 +/- 38 min; mean residence time (MRT), 346 +/- 47 min; AUC, 4,972 +/- 629 micrograms min ml-1 (normalized to a dose of 100 mg/m2); volume of distribution at steady state (Vdss), 6.6 +/- 1.2 l/m2; and clearance (CL), 20.4 +/- 2.4 ml min-1 m-2.",Pharmacokinetics of high-dose etoposide after short-term infusion. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1537079/),min,346,199425,DB00987,Cytarabine
,1537079,AUC,"The mean values for the calculated pharmacokinetic parameters were: t1/2 beta, 256 +/- 38 min; mean residence time (MRT), 346 +/- 47 min; AUC, 4,972 +/- 629 micrograms min ml-1 (normalized to a dose of 100 mg/m2); volume of distribution at steady state (Vdss), 6.6 +/- 1.2 l/m2; and clearance (CL), 20.4 +/- 2.4 ml min-1 m-2.",Pharmacokinetics of high-dose etoposide after short-term infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1537079/),[min·μg] / [ml],"4,972",199426,DB00987,Cytarabine
,1537079,volume of distribution at steady state (Vdss),"The mean values for the calculated pharmacokinetic parameters were: t1/2 beta, 256 +/- 38 min; mean residence time (MRT), 346 +/- 47 min; AUC, 4,972 +/- 629 micrograms min ml-1 (normalized to a dose of 100 mg/m2); volume of distribution at steady state (Vdss), 6.6 +/- 1.2 l/m2; and clearance (CL), 20.4 +/- 2.4 ml min-1 m-2.",Pharmacokinetics of high-dose etoposide after short-term infusion. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1537079/),[l] / [m2],6.6,199427,DB00987,Cytarabine
,1537079,clearance (CL),"The mean values for the calculated pharmacokinetic parameters were: t1/2 beta, 256 +/- 38 min; mean residence time (MRT), 346 +/- 47 min; AUC, 4,972 +/- 629 micrograms min ml-1 (normalized to a dose of 100 mg/m2); volume of distribution at steady state (Vdss), 6.6 +/- 1.2 l/m2; and clearance (CL), 20.4 +/- 2.4 ml min-1 m-2.",Pharmacokinetics of high-dose etoposide after short-term infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1537079/),[ml] / [(m)^2·min],20.4,199428,DB00987,Cytarabine
,1742843,plasma distribution half-life,"After an i.v. bolus of ara-C, the mean plasma distribution half-life was 7.1 +/- 4.5 min and the mean elimination half-life was 69 +/- 28 min.",Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742843/),min,7.1,201374,DB00987,Cytarabine
,1742843,elimination half-life,"After an i.v. bolus of ara-C, the mean plasma distribution half-life was 7.1 +/- 4.5 min and the mean elimination half-life was 69 +/- 28 min.",Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742843/),min,69,201375,DB00987,Cytarabine
,1742843,plasma clearance,The mean plasma clearance was 227 +/- 125 ml min-1 m-2.,Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742843/),[ml] / [(m)^2·min],227,201376,DB00987,Cytarabine
,1742843,peak concentration,"The peak concentration of ara-C in the CSF was 29 +/- 11 microM, which occurred at 57 +/- 13 min after the ara-C bolus.",Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742843/),μM,29,201377,DB00987,Cytarabine
,1742843,elimination half-life,The CSF elimination half-life was 113 +/- 26 min.,Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742843/),min,113,201378,DB00987,Cytarabine
,1742843,plasma steady-state concentration,"During a 12-h infusion of ara-C (50 mg m-2 h-1), the plasma steady-state concentration was 14.1 +/- 4.2 microM, the CSF steady-state concentration was 8.3 +/- 1.1 microM, and the CSF: plasma ratio was 0.62 +/- 0.14.",Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742843/),μM,14.1,201379,DB00987,Cytarabine
,1742843,steady-state concentration,"During a 12-h infusion of ara-C (50 mg m-2 h-1), the plasma steady-state concentration was 14.1 +/- 4.2 microM, the CSF steady-state concentration was 8.3 +/- 1.1 microM, and the CSF: plasma ratio was 0.62 +/- 0.14.",Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742843/),μM,8.3,201380,DB00987,Cytarabine
,1742843,CSF: plasma ratio,"During a 12-h infusion of ara-C (50 mg m-2 h-1), the plasma steady-state concentration was 14.1 +/- 4.2 microM, the CSF steady-state concentration was 8.3 +/- 1.1 microM, and the CSF: plasma ratio was 0.62 +/- 0.14.",Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742843/),,0.62,201381,DB00987,Cytarabine
,1742843,plasma elimination half-life,The plasma elimination half-life was 64 +/- 19 min and the plasma clearance was 214 +/- 69 ml min-1 m-2.,Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742843/),min,64,201382,DB00987,Cytarabine
,1742843,plasma clearance,The plasma elimination half-life was 64 +/- 19 min and the plasma clearance was 214 +/- 69 ml min-1 m-2.,Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742843/),[ml] / [(m)^2·min],214,201383,DB00987,Cytarabine
,1742843,elimination half-life,The CSF elimination half-life was 165 +/- 28 min.,Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742843/),min,165,201384,DB00987,Cytarabine
,22943060,Terminal half-life (T(1/2) ),"Terminal half-life (T(1/2) ) of cytarabine was 1.35 ± 0.3 and 1.15 ± 0.13 h after SC administration and CRI, respectively.",The pharmacokinetics of cytarabine in dogs when administered via subcutaneous and continuous intravenous infusion routes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943060/),h,1.35,202019,DB00987,Cytarabine
,22943060,Terminal half-life (T(1/2) ),"Terminal half-life (T(1/2) ) of cytarabine was 1.35 ± 0.3 and 1.15 ± 0.13 h after SC administration and CRI, respectively.",The pharmacokinetics of cytarabine in dogs when administered via subcutaneous and continuous intravenous infusion routes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943060/),h,1.15,202020,DB00987,Cytarabine
,22943060,peak concentration (Cmax ),"Mean peak concentration (Cmax ) was 2.88 and 2.80 μg/mL for SC and CRI administration, respectively.",The pharmacokinetics of cytarabine in dogs when administered via subcutaneous and continuous intravenous infusion routes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943060/),[μg] / [ml],2.88,202021,DB00987,Cytarabine
,22943060,peak concentration (Cmax ),"Mean peak concentration (Cmax ) was 2.88 and 2.80 μg/mL for SC and CRI administration, respectively.",The pharmacokinetics of cytarabine in dogs when administered via subcutaneous and continuous intravenous infusion routes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943060/),[μg] / [ml],2.80,202022,DB00987,Cytarabine
,22943060,Volume of distribution,Volume of distribution was 0.66 ± 0.07 l/kg.,The pharmacokinetics of cytarabine in dogs when administered via subcutaneous and continuous intravenous infusion routes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943060/),[l] / [kg],0.66,202023,DB00987,Cytarabine
,10602895,AUC,"This degradation results in highly different AraC exposures for different cells (e.g., AUC of 960 ng per h/ml in REH versus 4048 ng per h/ml in BLIN cells) in spite of identical starting concentrations of the drug.","Cytidine deaminase - the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cells. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10602895/),[ng] / [h·ml],960,206837,DB00987,Cytarabine
,10602895,AUC,"This degradation results in highly different AraC exposures for different cells (e.g., AUC of 960 ng per h/ml in REH versus 4048 ng per h/ml in BLIN cells) in spite of identical starting concentrations of the drug.","Cytidine deaminase - the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cells. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10602895/),[ng] / [h·ml],4048,206838,DB00987,Cytarabine
,15661261,MTD,The MTD of idarubicin in this combination was 8 mg/(m(2) day) with a DLT of oral mucositis.,"A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),[mg] / [d·m(2)],8,208630,DB00987,Cytarabine
,15661261,complete remission rate,"The complete remission rate (on an intent-to-treat basis) for this regimen was 33%, with a median duration of 6 months.","A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),%,33,208631,DB00987,Cytarabine
,15661261,clearance,"The clearance of idarubicin was 140 +/- 200 and 181 +/- 94.3 l/h for idarubicin alone and with PSC-833, respectively.","A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),[l] / [h],140,208632,DB00987,Cytarabine
,15661261,clearance,"The clearance of idarubicin was 140 +/- 200 and 181 +/- 94.3 l/h for idarubicin alone and with PSC-833, respectively.","A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),[l] / [h],181,208633,DB00987,Cytarabine
,15661261,volume of distribution of the central compartment,"The volume of distribution of the central compartment was 423 +/- 443 and 337 +/- 394 l for idarubicin alone and in combination with PSC-833, respectively.","A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),l,423,208634,DB00987,Cytarabine
,15661261,volume of distribution of the central compartment,"The volume of distribution of the central compartment was 423 +/- 443 and 337 +/- 394 l for idarubicin alone and in combination with PSC-833, respectively.","A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),l,337,208635,DB00987,Cytarabine
,7719461,minimum detectable amount,The minimum detectable amount is 2.5 pmol in a 50-microliters volume.,Alkylsulphonic acid ion pairing with radial compression columns for determining plasma or cerebrospinal fluid 1-beta-D-arabinofuranosylcytosine in pediatric pharmacokinetic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7719461/),pM,2.5,211277,DB00987,Cytarabine
,3864533,steady state plasma levels,"Mean steady state plasma levels of 7.7 +/- 4.7 ng/ml (31.7 +/- 19.3 nM) (n = 189) and a range 0.6 (2.5 nM) (lower limit of assay) to 29.7 ng/ml (122.1 nM), with significant inter- and intra-patient variations, were reached within about 2.7 h.",Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3864533/),[ng] / [ml],7.7,215319,DB00987,Cytarabine
,3864533,steady state plasma levels,"Mean steady state plasma levels of 7.7 +/- 4.7 ng/ml (31.7 +/- 19.3 nM) (n = 189) and a range 0.6 (2.5 nM) (lower limit of assay) to 29.7 ng/ml (122.1 nM), with significant inter- and intra-patient variations, were reached within about 2.7 h.",Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3864533/),nM,31.7,215320,DB00987,Cytarabine
,3864533,steady state plasma levels,"Mean steady state plasma levels of 7.7 +/- 4.7 ng/ml (31.7 +/- 19.3 nM) (n = 189) and a range 0.6 (2.5 nM) (lower limit of assay) to 29.7 ng/ml (122.1 nM), with significant inter- and intra-patient variations, were reached within about 2.7 h.",Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3864533/),nM,0.6,215321,DB00987,Cytarabine
,3864533,steady state plasma levels,"Mean steady state plasma levels of 7.7 +/- 4.7 ng/ml (31.7 +/- 19.3 nM) (n = 189) and a range 0.6 (2.5 nM) (lower limit of assay) to 29.7 ng/ml (122.1 nM), with significant inter- and intra-patient variations, were reached within about 2.7 h.",Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3864533/),[ng] / [ml],29.7,215322,DB00987,Cytarabine
,3864533,t1/2 alpha,"The plasma levels of ara-C decreased rapidly, with a t1/2 alpha of about 12 min following discontinuation of the infusion, followed by a very slow t 1/2 beta of about 19 h.",Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3864533/),min,12,215323,DB00987,Cytarabine
,3864533,t 1/2 beta,"The plasma levels of ara-C decreased rapidly, with a t1/2 alpha of about 12 min following discontinuation of the infusion, followed by a very slow t 1/2 beta of about 19 h.",Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3864533/),h,19,215324,DB00987,Cytarabine
,3864533,area under the curve,"Other parameters (mean values of 10 or 11 patients) were: area under the curve, 182.1 +/- 64.8 ng X day/ml; total body clearance, 188.7 +/- 54.8 liters/h; renal clearance, 3.1 +/- 1.4 liters/h; volume of distribution at steady state, 53,913 +/- 17,626 liters; and recovery of ara-C in urine, 1.43 +/- 0.69% (n = 226) of daily administered ara-C.",Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3864533/),[d·ng] / [ml],182.1,215325,DB00987,Cytarabine
,3864533,total body clearance,"Other parameters (mean values of 10 or 11 patients) were: area under the curve, 182.1 +/- 64.8 ng X day/ml; total body clearance, 188.7 +/- 54.8 liters/h; renal clearance, 3.1 +/- 1.4 liters/h; volume of distribution at steady state, 53,913 +/- 17,626 liters; and recovery of ara-C in urine, 1.43 +/- 0.69% (n = 226) of daily administered ara-C.",Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3864533/),[l] / [h],188.7,215326,DB00987,Cytarabine
,3864533,renal clearance,"Other parameters (mean values of 10 or 11 patients) were: area under the curve, 182.1 +/- 64.8 ng X day/ml; total body clearance, 188.7 +/- 54.8 liters/h; renal clearance, 3.1 +/- 1.4 liters/h; volume of distribution at steady state, 53,913 +/- 17,626 liters; and recovery of ara-C in urine, 1.43 +/- 0.69% (n = 226) of daily administered ara-C.",Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3864533/),[l] / [h],3.1,215327,DB00987,Cytarabine
,3864533,volume of distribution at steady state,"Other parameters (mean values of 10 or 11 patients) were: area under the curve, 182.1 +/- 64.8 ng X day/ml; total body clearance, 188.7 +/- 54.8 liters/h; renal clearance, 3.1 +/- 1.4 liters/h; volume of distribution at steady state, 53,913 +/- 17,626 liters; and recovery of ara-C in urine, 1.43 +/- 0.69% (n = 226) of daily administered ara-C.",Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3864533/),l,"53,913",215328,DB00987,Cytarabine
,18316568,total body clearance,"Pharmacokinetic studies revealed that the total body clearance of bortezomib decreased significantly (P < 0.01, N = 26) between the first (mean +/- SD, 41.9 +/- 17.1 L/h/m(2)) and third (18.4 +/- 7.0 L/h/m(2)) doses.",Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18316568/),[h·l] / [m(2],41.9,215866,DB00987,Cytarabine
,18316568,total body clearance,"Pharmacokinetic studies revealed that the total body clearance of bortezomib decreased significantly (P < 0.01, N = 26) between the first (mean +/- SD, 41.9 +/- 17.1 L/h/m(2)) and third (18.4 +/- 7.0 L/h/m(2)) doses.",Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18316568/),[h·l] / [m(2],18.4,215867,DB00987,Cytarabine
,27377011,t1/2,The N(4)-ursodeoxycholic acid conjugate of cytarabine (compound 5) exhibited optimal stability (t1/2=90min) in vitro and a 3.9-fold prolonged half-life of cytarabine in vivo.,Transporter-targeted cholic acid-cytarabine conjugates for improved oral absorption. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27377011/),min,90,219066,DB00987,Cytarabine
,20858843,MTD,The MTD of (213)Bi-lintuzumab was 37 MB/kg; myelosuppression lasting >35 days was dose limiting.,Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20858843/),[Mb] / [kg],37,219474,DB00987,Cytarabine
,20858843,response duration,"The median response duration was 6 months (range, 2-12).",Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20858843/),month,6,219475,DB00987,Cytarabine
,6616454,half-life,"Due to rapid peripheral deamination (230 nm ara-C/hr/ml plasma), the half-life of ara-C in plasma after a 140-mg/kg i.v. 1-hr infusion was short (3.7 min).",Cerebrospinal fluid and plasma pharmacokinetics of high doses of 1-beta-D-arabinofuranosylcytosine in nonhuman primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6616454/),min,3.7,220422,DB00987,Cytarabine
less,6616454,Peak plasma concentrations,"Peak plasma concentrations of ara-C, ranging between less than 0.1 and 49 micrograms/ml, were dose dependent (ara-C, 15 to 140 mg/kg).",Cerebrospinal fluid and plasma pharmacokinetics of high doses of 1-beta-D-arabinofuranosylcytosine in nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6616454/),[μg] / [ml],0,220423,DB00987,Cytarabine
,6616454,peak lumbar CSF levels,"Intraventricular administration of 50 and 250 mg of ara-C resulted in peak lumbar CSF levels of 435 and 2235 micrograms/ml, respectively, at about 155 and 80 min postinjection.",Cerebrospinal fluid and plasma pharmacokinetics of high doses of 1-beta-D-arabinofuranosylcytosine in nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6616454/),[μg] / [ml],435,220424,DB00987,Cytarabine
,6616454,peak lumbar CSF levels,"Intraventricular administration of 50 and 250 mg of ara-C resulted in peak lumbar CSF levels of 435 and 2235 micrograms/ml, respectively, at about 155 and 80 min postinjection.",Cerebrospinal fluid and plasma pharmacokinetics of high doses of 1-beta-D-arabinofuranosylcytosine in nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6616454/),[μg] / [ml],2235,220425,DB00987,Cytarabine
,6616454,half-life,The half-life of ara-C in CSF ranged between 50 and 60 min.,Cerebrospinal fluid and plasma pharmacokinetics of high doses of 1-beta-D-arabinofuranosylcytosine in nonhuman primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6616454/),min,50 and 60,220426,DB00987,Cytarabine
,6616454,peak lumbar ara-U levels,Administration of 50 mg of ara-U intraventricularly resulted in peak lumbar ara-U levels of 595 micrograms/ml at about 180 min with a prolonged clearance.,Cerebrospinal fluid and plasma pharmacokinetics of high doses of 1-beta-D-arabinofuranosylcytosine in nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6616454/),[μg] / [ml],595,220427,DB00987,Cytarabine
,15963092,apparent clearance (CL),"Population mean estimates (95% confidence interval) at day 1 for apparent clearance (CL) and apparent volume of distribution (V) of imatinib were 14 (13-15) l h(-1) and 252 (237-267) l, respectively.",Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15963092/),[l] / [h],14,221371,DB00987,Cytarabine
,15963092,apparent volume of distribution (V),"Population mean estimates (95% confidence interval) at day 1 for apparent clearance (CL) and apparent volume of distribution (V) of imatinib were 14 (13-15) l h(-1) and 252 (237-267) l, respectively.",Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15963092/),l,252,221372,DB00987,Cytarabine
,8857548,t1/2,"Substantial differences in AraCTP retention times were revealed, during 3-h infusions of either 1.0 or 3.0 g/m2 AraC in leukemic blasts from 10 patients with t1/2 values of 1.60-7.63 h (median, 2.42 h).",Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8857548/),h,1.60-7.63,221550,DB00987,Cytarabine
,8857548,t1/2,"Substantial differences in AraCTP retention times were revealed, during 3-h infusions of either 1.0 or 3.0 g/m2 AraC in leukemic blasts from 10 patients with t1/2 values of 1.60-7.63 h (median, 2.42 h).",Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8857548/),h,2.42,221551,DB00987,Cytarabine
,8857548,t1/2,"In contrast, AraCTP retention times were relatively uniform in normal mononuclear blood cells from 11 patients, with t1/2 values of 3.34-5.29 h (median, 3.85 h).",Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8857548/),h,3.34-5.29,221552,DB00987,Cytarabine
,8857548,t1/2,"In contrast, AraCTP retention times were relatively uniform in normal mononuclear blood cells from 11 patients, with t1/2 values of 3.34-5.29 h (median, 3.85 h).",Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8857548/),h,3.85,221553,DB00987,Cytarabine
,21699456,AUC,"There was substantial inter-individual variability in MTX AUC (median: 795.5 µM*h/L, range 44.8-8326.44).",Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21699456/),[h·μM] / [l],795.5,224886,DB00987,Cytarabine
,3478543,terminal rate of elimination (t1/2),The median terminal rate of elimination (t1/2) of F-ara-A was 8.4 hr compared to 2.2 hr for ara-C.,Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3478543/),h,8.4,226337,DB00987,Cytarabine
,3478543,terminal rate of elimination (t1/2),The median terminal rate of elimination (t1/2) of F-ara-A was 8.4 hr compared to 2.2 hr for ara-C.,Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3478543/),h,2.2,226338,DB00987,Cytarabine
,3478543,t1/2,The median t1/2 for F-ara-ATP in CLB was 12.2 hr relative to 1.9 hr for ara-CTP.,Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3478543/),h,12.2,226339,DB00987,Cytarabine
,3478543,t1/2,The median t1/2 for F-ara-ATP in CLB was 12.2 hr relative to 1.9 hr for ara-CTP.,Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3478543/),h,1.9,226340,DB00987,Cytarabine
,9766508,half-lives,Cytosine arabinoside (AraC) is rapidly inactivated via systemic deamination with half-lives ranging from 1 h (i.v.) to 4 h (s.c.) -- and cannot be applied orally due to its hydrophilic properties.,Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766508/),h,1,228336,DB00987,Cytarabine
,9766508,half-lives,Cytosine arabinoside (AraC) is rapidly inactivated via systemic deamination with half-lives ranging from 1 h (i.v.) to 4 h (s.c.) -- and cannot be applied orally due to its hydrophilic properties.,Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766508/),h,4,228337,DB00987,Cytarabine
,9766508,half-life,"Time of maximum concentration (h), half-life (h) and area under the curve (ng x h/ml, at the 1200 mg dose level) were as follows (VC variation coefficient) YNK01: 1.0 (0.58), 10.1 (0.43), 12622 (0.65); AraC: 23.2 (0.57), 22.6 (0.36), 3496 (0.76); AraU: 19.2 (0.58) 22.3 (0.33) 15441 (0.66).",Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766508/),[h·ng] / [ml],23.2,228338,DB00987,Cytarabine
,9766508,half-life,"Time of maximum concentration (h), half-life (h) and area under the curve (ng x h/ml, at the 1200 mg dose level) were as follows (VC variation coefficient) YNK01: 1.0 (0.58), 10.1 (0.43), 12622 (0.65); AraC: 23.2 (0.57), 22.6 (0.36), 3496 (0.76); AraU: 19.2 (0.58) 22.3 (0.33) 15441 (0.66).",Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766508/),[h·ng] / [ml],22.6,228339,DB00987,Cytarabine
,9766508,half-life,"Time of maximum concentration (h), half-life (h) and area under the curve (ng x h/ml, at the 1200 mg dose level) were as follows (VC variation coefficient) YNK01: 1.0 (0.58), 10.1 (0.43), 12622 (0.65); AraC: 23.2 (0.57), 22.6 (0.36), 3496 (0.76); AraU: 19.2 (0.58) 22.3 (0.33) 15441 (0.66).",Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766508/),[h·ng] / [ml],3496,228340,DB00987,Cytarabine
,9766508,half-life,"Time of maximum concentration (h), half-life (h) and area under the curve (ng x h/ml, at the 1200 mg dose level) were as follows (VC variation coefficient) YNK01: 1.0 (0.58), 10.1 (0.43), 12622 (0.65); AraC: 23.2 (0.57), 22.6 (0.36), 3496 (0.76); AraU: 19.2 (0.58) 22.3 (0.33) 15441 (0.66).",Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766508/),[h·ng] / [ml],19.2,228341,DB00987,Cytarabine
,9766508,half-life,"Time of maximum concentration (h), half-life (h) and area under the curve (ng x h/ml, at the 1200 mg dose level) were as follows (VC variation coefficient) YNK01: 1.0 (0.58), 10.1 (0.43), 12622 (0.65); AraC: 23.2 (0.57), 22.6 (0.36), 3496 (0.76); AraU: 19.2 (0.58) 22.3 (0.33) 15441 (0.66).",Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766508/),[h·ng] / [ml],22.3,228342,DB00987,Cytarabine
,9766508,area under the curve,"Time of maximum concentration (h), half-life (h) and area under the curve (ng x h/ml, at the 1200 mg dose level) were as follows (VC variation coefficient) YNK01: 1.0 (0.58), 10.1 (0.43), 12622 (0.65); AraC: 23.2 (0.57), 22.6 (0.36), 3496 (0.76); AraU: 19.2 (0.58) 22.3 (0.33) 15441 (0.66).",Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766508/),[h·ng] / [ml],10.1,228343,DB00987,Cytarabine
,9766508,area under the curve,"Time of maximum concentration (h), half-life (h) and area under the curve (ng x h/ml, at the 1200 mg dose level) were as follows (VC variation coefficient) YNK01: 1.0 (0.58), 10.1 (0.43), 12622 (0.65); AraC: 23.2 (0.57), 22.6 (0.36), 3496 (0.76); AraU: 19.2 (0.58) 22.3 (0.33) 15441 (0.66).",Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766508/),[h·ng] / [ml],12622,228344,DB00987,Cytarabine
,9766508,area under the curve,"Time of maximum concentration (h), half-life (h) and area under the curve (ng x h/ml, at the 1200 mg dose level) were as follows (VC variation coefficient) YNK01: 1.0 (0.58), 10.1 (0.43), 12622 (0.65); AraC: 23.2 (0.57), 22.6 (0.36), 3496 (0.76); AraU: 19.2 (0.58) 22.3 (0.33) 15441 (0.66).",Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766508/),[h·ng] / [ml],23.2,228345,DB00987,Cytarabine
,9766508,area under the curve,"Time of maximum concentration (h), half-life (h) and area under the curve (ng x h/ml, at the 1200 mg dose level) were as follows (VC variation coefficient) YNK01: 1.0 (0.58), 10.1 (0.43), 12622 (0.65); AraC: 23.2 (0.57), 22.6 (0.36), 3496 (0.76); AraU: 19.2 (0.58) 22.3 (0.33) 15441 (0.66).",Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766508/),[h·ng] / [ml],22.6,228346,DB00987,Cytarabine
,9766508,area under the curve,"Time of maximum concentration (h), half-life (h) and area under the curve (ng x h/ml, at the 1200 mg dose level) were as follows (VC variation coefficient) YNK01: 1.0 (0.58), 10.1 (0.43), 12622 (0.65); AraC: 23.2 (0.57), 22.6 (0.36), 3496 (0.76); AraU: 19.2 (0.58) 22.3 (0.33) 15441 (0.66).",Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766508/),[h·ng] / [ml],3496,228347,DB00987,Cytarabine
,9766508,area under the curve,"Time of maximum concentration (h), half-life (h) and area under the curve (ng x h/ml, at the 1200 mg dose level) were as follows (VC variation coefficient) YNK01: 1.0 (0.58), 10.1 (0.43), 12622 (0.65); AraC: 23.2 (0.57), 22.6 (0.36), 3496 (0.76); AraU: 19.2 (0.58) 22.3 (0.33) 15441 (0.66).",Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766508/),[h·ng] / [ml],19.2,228348,DB00987,Cytarabine
,9766508,area under the curve,"Time of maximum concentration (h), half-life (h) and area under the curve (ng x h/ml, at the 1200 mg dose level) were as follows (VC variation coefficient) YNK01: 1.0 (0.58), 10.1 (0.43), 12622 (0.65); AraC: 23.2 (0.57), 22.6 (0.36), 3496 (0.76); AraU: 19.2 (0.58) 22.3 (0.33) 15441 (0.66).",Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766508/),[h·ng] / [ml],22.3,228349,DB00987,Cytarabine
,9766508,area under the curve,"Time of maximum concentration (h), half-life (h) and area under the curve (ng x h/ml, at the 1200 mg dose level) were as follows (VC variation coefficient) YNK01: 1.0 (0.58), 10.1 (0.43), 12622 (0.65); AraC: 23.2 (0.57), 22.6 (0.36), 3496 (0.76); AraU: 19.2 (0.58) 22.3 (0.33) 15441 (0.66).",Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766508/),[h·ng] / [ml],15441,228350,DB00987,Cytarabine
,7795790,recoveries,"The recoveries for plasma samples ranged from 56.4 to 64.1%, regardless of drug concentrations.",Highly sensitive high-performance liquid chromatographic assay for 1-beta-D-arabinofuranosylcytosine-5'-stearyl phosphate (cytarabine-ocfosfate). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7795790/),%,56.4 to 64.1,229475,DB00987,Cytarabine
,7795790,inter-assay recovery,The inter-assay recovery (ten measurements over ten days) at a plasma concentration of 50 ng/ml was 57% with a C.V. of 8.25%.,Highly sensitive high-performance liquid chromatographic assay for 1-beta-D-arabinofuranosylcytosine-5'-stearyl phosphate (cytarabine-ocfosfate). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7795790/),%,57,229476,DB00987,Cytarabine
,7795790,C.V.,The inter-assay recovery (ten measurements over ten days) at a plasma concentration of 50 ng/ml was 57% with a C.V. of 8.25%.,Highly sensitive high-performance liquid chromatographic assay for 1-beta-D-arabinofuranosylcytosine-5'-stearyl phosphate (cytarabine-ocfosfate). ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7795790/),%,8.25,229477,DB00987,Cytarabine
,29034009,negativity,MRD negativity at end-induction was 85% in Arm A versus 67% in Arm B patients.,"A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29034009/),,85,230890,DB00987,Cytarabine
,29034009,negativity,MRD negativity at end-induction was 85% in Arm A versus 67% in Arm B patients.,"A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29034009/),,67,230891,DB00987,Cytarabine
,8132852,initial-phase half-life (t1/2 alpha),The plasma concentration of BHAC reached a maximum (173.4 +/- 75.3 micrograms/mL) at the end of the infusion and then declined in a biphasic pattern with an initial-phase half-life (t1/2 alpha) of 1.00 +/- .36 hours and a second-phase half-life (t1/2 beta) of 4.28 +/- 2.35 hours.,Plasma and leukemic cell pharmacokinetics of high-dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute leukemia patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8132852/),h,1.00,231844,DB00987,Cytarabine
,8132852,second-phase half-life (t1/2 beta),The plasma concentration of BHAC reached a maximum (173.4 +/- 75.3 micrograms/mL) at the end of the infusion and then declined in a biphasic pattern with an initial-phase half-life (t1/2 alpha) of 1.00 +/- .36 hours and a second-phase half-life (t1/2 beta) of 4.28 +/- 2.35 hours.,Plasma and leukemic cell pharmacokinetics of high-dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute leukemia patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8132852/),h,4.28,231845,DB00987,Cytarabine
,8132852,t1/2 alpha,That of ara-C similarly reached a maximum (102.2 +/- 39.9 mg/mL) at the end of the infusion and then declined with t1/2 alpha of 1.37 +/- 1.11 hours and t1/2 beta of 11.2 +/- 4.31 hours.,Plasma and leukemic cell pharmacokinetics of high-dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute leukemia patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8132852/),h,1.37,231846,DB00987,Cytarabine
,8132852,t1/2 beta,That of ara-C similarly reached a maximum (102.2 +/- 39.9 mg/mL) at the end of the infusion and then declined with t1/2 alpha of 1.37 +/- 1.11 hours and t1/2 beta of 11.2 +/- 4.31 hours.,Plasma and leukemic cell pharmacokinetics of high-dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute leukemia patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8132852/),h,11.2,231847,DB00987,Cytarabine
,8132852,t1/2,"Intracellular ara-CTP concentration increased in a linear-accumulation manner for the first 4 hours after the infusion, reached a maximum of .081 +/- .112 micrograms/10(7) cells at approximately 7 hours, and then declined very slowly in accordance with a one-compartment model with t1/2 of 13.56 +/- 9.62 hours.",Plasma and leukemic cell pharmacokinetics of high-dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute leukemia patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8132852/),h,13.56,231848,DB00987,Cytarabine
,19115956,IC(50),"Glycylsarcosine (gly-sar, a typical substrate of PepT1) uptake by Caco-2 cells can be inhibited by 2 in a concentration-dependent manner, and IC(50) for 2 was 2.18 +/- 0.12 mM.","Synthesis, transport and pharmacokinetics of 5'-amino acid ester prodrugs of 1-beta-D-arabinofuranosylcytosine. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19115956/),mM,2.18,233947,DB00987,Cytarabine
,19115956,oral absolute bioavailability,"The oral absolute bioavailability of 1 was 60.0% and 21.8% after 2 and 1 were orally administered to rats 30 mg/kg, respectively.","Synthesis, transport and pharmacokinetics of 5'-amino acid ester prodrugs of 1-beta-D-arabinofuranosylcytosine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19115956/),%,60.0,233948,DB00987,Cytarabine
,19115956,oral absolute bioavailability,"The oral absolute bioavailability of 1 was 60.0% and 21.8% after 2 and 1 were orally administered to rats 30 mg/kg, respectively.","Synthesis, transport and pharmacokinetics of 5'-amino acid ester prodrugs of 1-beta-D-arabinofuranosylcytosine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19115956/),%,21.8,233949,DB00987,Cytarabine
,19115956,1/ara-U ratio,"Oral administration of 2 resulted in an increased 1/ara-U ratio (2.76) in the blood, much higher than that (1.25) after 1 orally taken.","Synthesis, transport and pharmacokinetics of 5'-amino acid ester prodrugs of 1-beta-D-arabinofuranosylcytosine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19115956/),,2.76,233950,DB00987,Cytarabine
,19115956,1/ara-U ratio,"Oral administration of 2 resulted in an increased 1/ara-U ratio (2.76) in the blood, much higher than that (1.25) after 1 orally taken.","Synthesis, transport and pharmacokinetics of 5'-amino acid ester prodrugs of 1-beta-D-arabinofuranosylcytosine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19115956/),,1.25,233951,DB00987,Cytarabine
,3592717,half-lives of the initial phase (t1/2 alpha),The half-lives of the initial phase (t1/2 alpha) and the second phase (t1/2 beta) by the administration (1 hr iv infusion) of 700 mg/m2 were 1.08 and 3.65 h respectively.,[Clinical and pharmacokinetic studies of high dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592717/),h,1.08,234677,DB00987,Cytarabine
,3592717,second phase (t1/2 beta),The half-lives of the initial phase (t1/2 alpha) and the second phase (t1/2 beta) by the administration (1 hr iv infusion) of 700 mg/m2 were 1.08 and 3.65 h respectively.,[Clinical and pharmacokinetic studies of high dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592717/),h,1.08,234678,DB00987,Cytarabine
,3592717,second phase (t1/2 beta),The half-lives of the initial phase (t1/2 alpha) and the second phase (t1/2 beta) by the administration (1 hr iv infusion) of 700 mg/m2 were 1.08 and 3.65 h respectively.,[Clinical and pharmacokinetic studies of high dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592717/),h,3.65,234679,DB00987,Cytarabine
,3592717,Cmax,The plasma 1-beta-D-arabinofuranosylcytosine was detected for 12-24 hr after infusion (Cmax: 0.26 microgram/ml).,[Clinical and pharmacokinetic studies of high dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592717/),[μg] / [ml],0.26,234680,DB00987,Cytarabine
,29761906,Plasma drug concentrations,Plasma drug concentrations ranged from 0.05 to 2.8 μg/ml.,"The pharmacokinetics of cytarabine administered subcutaneously, combined with prednisone, in dogs with meningoencephalomyelitis of unknown etiology. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29761906/),[μg] / [ml],0.05 to 2.8,235292,DB00987,Cytarabine
,29761906,elimination half-life,"The population estimate (CV%) for elimination half-life and Tmax of cytarabine in dogs was 1.09 (21.93) hr and 0.55 (51.03) hr, respectively.","The pharmacokinetics of cytarabine administered subcutaneously, combined with prednisone, in dogs with meningoencephalomyelitis of unknown etiology. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29761906/),h,1.09,235293,DB00987,Cytarabine
,29761906,Tmax,"The population estimate (CV%) for elimination half-life and Tmax of cytarabine in dogs was 1.09 (21.93) hr and 0.55 (51.03) hr, respectively.","The pharmacokinetics of cytarabine administered subcutaneously, combined with prednisone, in dogs with meningoencephalomyelitis of unknown etiology. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29761906/),h,0.55,235294,DB00987,Cytarabine
,29761906,volume of distribution per fraction absorbed,The volume of distribution per fraction absorbed was 976.31 (10.85%) ml/kg.,"The pharmacokinetics of cytarabine administered subcutaneously, combined with prednisone, in dogs with meningoencephalomyelitis of unknown etiology. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29761906/),[ml] / [kg],976.31,235295,DB00987,Cytarabine
,8890711,half-life,"Recent pharmacokinetic studies have revealed a prolonged release of the cytotoxic agent cytosine arabinoside (araC) from hepatocytes into the systemic circulation, resulting in a half-life of approximately 24 h for araC.","Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8890711/),h,24,241594,DB00987,Cytarabine
,34416320,Overall response rate,"Overall response rate was 75%, and 56% of patients had non-hematological severe toxicities, including one lethal toxicity.",Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34416320/),%,75,243600,DB00987,Cytarabine
,34416320,clearance (Cl,Results showed that liposomal CPX-351 led to sustained exposure with reduced clearance (Cl = 0.16 L/h) and prolonged half-life (T1/2 = 28 h).,Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34416320/),[l] / [h],0.16,243601,DB00987,Cytarabine
,34416320,half-life (T1/2,Results showed that liposomal CPX-351 led to sustained exposure with reduced clearance (Cl = 0.16 L/h) and prolonged half-life (T1/2 = 28 h).,Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34416320/),h,28,243602,DB00987,Cytarabine
,34416320,AUC,"Seven out of 9 patients were PM with a strong impact on the PK parameters, i.e., PM patients showing higher cytarabine levels as compared with EM patients (AUC: 5536 vs. 1784 ng/mL.h), sustained plasma exposure (T1/2: 33.9 vs. 13.7 h), and reduced clearance (Cl: 0.12 vs. 0.29 L/h).",Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34416320/),[ng] / [h·ml],5536,243603,DB00987,Cytarabine
,34416320,AUC,"Seven out of 9 patients were PM with a strong impact on the PK parameters, i.e., PM patients showing higher cytarabine levels as compared with EM patients (AUC: 5536 vs. 1784 ng/mL.h), sustained plasma exposure (T1/2: 33.9 vs. 13.7 h), and reduced clearance (Cl: 0.12 vs. 0.29 L/h).",Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34416320/),[ng] / [h·ml],1784,243604,DB00987,Cytarabine
,34416320,T1/2,"Seven out of 9 patients were PM with a strong impact on the PK parameters, i.e., PM patients showing higher cytarabine levels as compared with EM patients (AUC: 5536 vs. 1784 ng/mL.h), sustained plasma exposure (T1/2: 33.9 vs. 13.7 h), and reduced clearance (Cl: 0.12 vs. 0.29 L/h).",Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34416320/),h,33.9,243605,DB00987,Cytarabine
,34416320,T1/2,"Seven out of 9 patients were PM with a strong impact on the PK parameters, i.e., PM patients showing higher cytarabine levels as compared with EM patients (AUC: 5536 vs. 1784 ng/mL.h), sustained plasma exposure (T1/2: 33.9 vs. 13.7 h), and reduced clearance (Cl: 0.12 vs. 0.29 L/h).",Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34416320/),h,13.7,243606,DB00987,Cytarabine
,34416320,clearance (Cl,"Seven out of 9 patients were PM with a strong impact on the PK parameters, i.e., PM patients showing higher cytarabine levels as compared with EM patients (AUC: 5536 vs. 1784 ng/mL.h), sustained plasma exposure (T1/2: 33.9 vs. 13.7 h), and reduced clearance (Cl: 0.12 vs. 0.29 L/h).",Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34416320/),[l] / [h],0.12,243607,DB00987,Cytarabine
,34416320,clearance (Cl,"Seven out of 9 patients were PM with a strong impact on the PK parameters, i.e., PM patients showing higher cytarabine levels as compared with EM patients (AUC: 5536 vs. 1784 ng/mL.h), sustained plasma exposure (T1/2: 33.9 vs. 13.7 h), and reduced clearance (Cl: 0.12 vs. 0.29 L/h).",Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34416320/),[l] / [h],0.29,243608,DB00987,Cytarabine
,589600,plasma half-life,"[14C]-tetrahydrouridine (THU), a strong inhibitor of cytidine (CR) deaminase, was, after iv administration, rapidly and quantitatively cleared from the blood with a plasma half-life of about 1 hour.",Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/589600/),h,1,244061,DB00987,Cytarabine
greater,7086691,tissue/medium ratios,"Although in both tissues the uptake of [3H] cytosine arabinoside was saturable, neither brain slices nor the isolated choroid plexus achieved tissue/medium ratios greater than 1.0 in 30 min.",Pharmacokinetics and metabolism of cytosine arabinoside in the central nervous system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7086691/),,1.0,244128,DB00987,Cytarabine
,3885117,complete remission rate,A complete remission rate of 47% was achieved.,[High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3885117/),%,47,245839,DB00987,Cytarabine
,2344886,survival,Median survival was 6 months for all patients and 10 months for responders.,High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2344886/),month,6,250407,DB00987,Cytarabine
,2344886,survival,Median survival was 6 months for all patients and 10 months for responders.,High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2344886/),,10,250408,DB00987,Cytarabine
,3995167,steady-state plasma levels,The results demonstrate mean steady-state plasma levels ranging from 1.8 to 6.9 X 10(-8) mol/L.,Clinical pharmacology of low-dose cytosine arabinoside. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3995167/),[mol] / [l],1.8 to 6.9 X 10(-8),251618,DB00987,Cytarabine
,3995167,total drug exposure (area under the curve),The range for total drug exposure (area under the curve) for the 14-day course was 6.5 to 15.9 X 10(-6) mol/L X hour.,Clinical pharmacology of low-dose cytosine arabinoside. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3995167/),[mol] / [h·l],6.5 to 15.9 X 10(-6),251619,DB00987,Cytarabine
,30413669,maximum tolerated dose,"MBC-11 was well tolerated, with an maximum tolerated dose of 5 mg/kg per day and myelosuppression as the principal toxicity.","First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30413669/),[mg] / [kg],5,251897,DB00987,Cytarabine
,7791024,t1/2 alpha,"Pharmacokinetic studies in mice revealed that NHAC had biphasic kinetics in blood with a t1/2 alpha of 16 min and a t1/2 beta of 3.8 h when the drug was formulated in plain liposomes and a t1/2 alpha of 15 min and a t1/2 beta of 9.67 h in PEG liposomes, respectively.",Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791024/),min,16,254481,DB00987,Cytarabine
,7791024,t1/2 beta,"Pharmacokinetic studies in mice revealed that NHAC had biphasic kinetics in blood with a t1/2 alpha of 16 min and a t1/2 beta of 3.8 h when the drug was formulated in plain liposomes and a t1/2 alpha of 15 min and a t1/2 beta of 9.67 h in PEG liposomes, respectively.",Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791024/),h,3.8,254482,DB00987,Cytarabine
,7791024,t1/2 alpha,"Pharmacokinetic studies in mice revealed that NHAC had biphasic kinetics in blood with a t1/2 alpha of 16 min and a t1/2 beta of 3.8 h when the drug was formulated in plain liposomes and a t1/2 alpha of 15 min and a t1/2 beta of 9.67 h in PEG liposomes, respectively.",Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791024/),min,15,254483,DB00987,Cytarabine
,7791024,t1/2 beta,"Pharmacokinetic studies in mice revealed that NHAC had biphasic kinetics in blood with a t1/2 alpha of 16 min and a t1/2 beta of 3.8 h when the drug was formulated in plain liposomes and a t1/2 alpha of 15 min and a t1/2 beta of 9.67 h in PEG liposomes, respectively.",Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791024/),h,9.67,254484,DB00987,Cytarabine
,28240971,Cmax,"PK for 400 mg (day 7) showed Cmax 3.07 μM, Tmax 3.0 hours, t1/2 (half-life) 6.6 hours, CL/F (apparent clearance) 28.9 L/h, and Vd/F (apparent volume) 274 L.",Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28240971/),μM,3.07,256947,DB00987,Cytarabine
,28240971,Tmax,"PK for 400 mg (day 7) showed Cmax 3.07 μM, Tmax 3.0 hours, t1/2 (half-life) 6.6 hours, CL/F (apparent clearance) 28.9 L/h, and Vd/F (apparent volume) 274 L.",Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28240971/),h,3.0,256948,DB00987,Cytarabine
,28240971,t1/2 (half-life),"PK for 400 mg (day 7) showed Cmax 3.07 μM, Tmax 3.0 hours, t1/2 (half-life) 6.6 hours, CL/F (apparent clearance) 28.9 L/h, and Vd/F (apparent volume) 274 L.",Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28240971/),h,6.6,256949,DB00987,Cytarabine
,28240971,CL/F (apparent clearance),"PK for 400 mg (day 7) showed Cmax 3.07 μM, Tmax 3.0 hours, t1/2 (half-life) 6.6 hours, CL/F (apparent clearance) 28.9 L/h, and Vd/F (apparent volume) 274 L.",Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28240971/),[l] / [h],28.9,256950,DB00987,Cytarabine
,28240971,Vd/F (apparent volume),"PK for 400 mg (day 7) showed Cmax 3.07 μM, Tmax 3.0 hours, t1/2 (half-life) 6.6 hours, CL/F (apparent clearance) 28.9 L/h, and Vd/F (apparent volume) 274 L.",Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28240971/),l,274,256951,DB00987,Cytarabine
,28240971,progression-free survival,"In total, 27 patients with liposarcoma had a median progression-free survival of 237 days.",Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28240971/),d,237,256952,DB00987,Cytarabine
,19492871,elimination half-lives,The average elimination half-lives were 56.7 hours for encapsulated cytarabine and 59.3 hours for free cytarabine.,Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19492871/),h,56.7,257497,DB00987,Cytarabine
,19492871,elimination half-lives,The average elimination half-lives were 56.7 hours for encapsulated cytarabine and 59.3 hours for free cytarabine.,Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19492871/),h,59.3,257498,DB00987,Cytarabine
,19492871,elimination half-life,"After intralumbar administration, the elimination half-life of free cytarabine, measured in the ventricular CSF during two courses in one patient, was significantly shorter (32.7 hours).",Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19492871/),h,32.7,257499,DB00987,Cytarabine
,17001183,total body clearance,"Median total body clearance in children 0.5-1.8 (n=4) and 2.3-17.7 years old (n=36) without Down's syndrome was 17.1 and 17.6 ml/min/m, respectively (P=0.96).",Etoposide pharmacokinetics in children treated for acute myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17001183/),[ml] / [m·min],17.1,258624,DB00987,Cytarabine
,17001183,total body clearance,"Median total body clearance in children 0.5-1.8 (n=4) and 2.3-17.7 years old (n=36) without Down's syndrome was 17.1 and 17.6 ml/min/m, respectively (P=0.96).",Etoposide pharmacokinetics in children treated for acute myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17001183/),[ml] / [m·min],17.6,258625,DB00987,Cytarabine
,17001183,clearance,Five children with Down's syndrome had a median clearance of 13.6 ml/min/m (P=0.067 compared with non-Down's syndrome children).,Etoposide pharmacokinetics in children treated for acute myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17001183/),[ml] / [m·min],13.6,258626,DB00987,Cytarabine
,33302031,complete remission rates,"In TP53 wild-type patients, composite complete remission rates were 18.9 % with monotherapy and 35.6 % with combination therapy.",Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33302031/),%,18.9,263057,DB00987,Cytarabine
,33302031,complete remission rates,"In TP53 wild-type patients, composite complete remission rates were 18.9 % with monotherapy and 35.6 % with combination therapy.",Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33302031/),%,35.6,263058,DB00987,Cytarabine
,17241530,bioavailability,The bioavailability of ara-C was about 4% via prodrug administration.,Pharmacokinetic characteristics of L-valyl-ara-C and its implication on the oral delivery of ara-C. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17241530/),%,4,265378,DB00987,Cytarabine
,2990323,terminal-phase half-life,"FIAC was cleared from the plasma primarily by biotransformation in liver, kidney, and peripheral blood, with a terminal-phase half-life of 0.92 to 1.80 h (mean, 1.36 h) after intravenous administration.",Biotransformation and elimination of [2-14C]-1-(2-deoxy-2'-fluoro-beta-D -arabinofuranosyl)-5-iodocytosine in immunosuppressed patients with herpesvirus infections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2990323/),h,0.92 to 1.80,266543,DB00987,Cytarabine
,2990323,terminal-phase half-life,"FIAC was cleared from the plasma primarily by biotransformation in liver, kidney, and peripheral blood, with a terminal-phase half-life of 0.92 to 1.80 h (mean, 1.36 h) after intravenous administration.",Biotransformation and elimination of [2-14C]-1-(2-deoxy-2'-fluoro-beta-D -arabinofuranosyl)-5-iodocytosine in immunosuppressed patients with herpesvirus infections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2990323/),h,1.36,266544,DB00987,Cytarabine
,2990323,terminal-phase half-life,"The terminal-phase half-life for FIAU was 3.32 to 4.49 h (mean, 3.91 h); FIAU was cleared from plasma by renal elimination and further biotransformation.",Biotransformation and elimination of [2-14C]-1-(2-deoxy-2'-fluoro-beta-D -arabinofuranosyl)-5-iodocytosine in immunosuppressed patients with herpesvirus infections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2990323/),h,3.32 to 4.49,266545,DB00987,Cytarabine
,2990323,terminal-phase half-life,"The terminal-phase half-life for FIAU was 3.32 to 4.49 h (mean, 3.91 h); FIAU was cleared from plasma by renal elimination and further biotransformation.",Biotransformation and elimination of [2-14C]-1-(2-deoxy-2'-fluoro-beta-D -arabinofuranosyl)-5-iodocytosine in immunosuppressed patients with herpesvirus infections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2990323/),h,3.91,266546,DB00987,Cytarabine
,21361136,t1/2,"Free ara-C (F-ara-C) was rapidly eliminated from the circulation (t1/2 = 1.43 h), whereas both conventional liposomes and gelliposomes showed prolonged elimination after intravenous injection with t1/2 of 5.88 h and 27.54 h, respectively.",Effects of interior gelation on pharmacokinetics and biodistribution of liposomes encapsulating an anti-cancer drug cytarabine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21361136/),h,1.43,266927,DB00987,Cytarabine
,21361136,t1/2,"Free ara-C (F-ara-C) was rapidly eliminated from the circulation (t1/2 = 1.43 h), whereas both conventional liposomes and gelliposomes showed prolonged elimination after intravenous injection with t1/2 of 5.88 h and 27.54 h, respectively.",Effects of interior gelation on pharmacokinetics and biodistribution of liposomes encapsulating an anti-cancer drug cytarabine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21361136/),h,5.88,266928,DB00987,Cytarabine
,21361136,t1/2,"Free ara-C (F-ara-C) was rapidly eliminated from the circulation (t1/2 = 1.43 h), whereas both conventional liposomes and gelliposomes showed prolonged elimination after intravenous injection with t1/2 of 5.88 h and 27.54 h, respectively.",Effects of interior gelation on pharmacokinetics and biodistribution of liposomes encapsulating an anti-cancer drug cytarabine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21361136/),h,27.54,266929,DB00987,Cytarabine
,11377379,IC(50),"DNA synthesis was selectively inhibited by a 4-hr treatment with CNDAC in CCRF-CEM and ML-1 cells; the IC(50) values were 1 and 0.8 microM, respectively.",Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC). ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377379/),μM,1,267837,DB00987,Cytarabine
,11377379,IC(50),"DNA synthesis was selectively inhibited by a 4-hr treatment with CNDAC in CCRF-CEM and ML-1 cells; the IC(50) values were 1 and 0.8 microM, respectively.",Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC). ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377379/),μM,0.8,267838,DB00987,Cytarabine
,11377379,K(m),Evaluation of the polymerization reaction of a primer on an M13mp19(+) template by human DNA polymerase alpha indicated that CNDACTP was incorporated effectively (K(m) = 0.22 microM) opposite a complementary dGMP in the template strand.,Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC). ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377379/),μM,0.22,267839,DB00987,Cytarabine
,11377379,V(max)/K(m),"CNDACTP competed with the normal substrate, dCTP, for incorporation, and the two nucleotides showed similar substrate efficiencies (V(max)/K(m): dCTP = 0.91; CNDACTP = 0.77).",Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377379/),,0.91,267840,DB00987,Cytarabine
,11377379,V(max)/K(m),"CNDACTP competed with the normal substrate, dCTP, for incorporation, and the two nucleotides showed similar substrate efficiencies (V(max)/K(m): dCTP = 0.91; CNDACTP = 0.77).",Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377379/),,0.77,267841,DB00987,Cytarabine
,11377379,K(i),"Primer extension was potently inhibited by CNDAC triphosphate (K(i) = 23 nM); once the analog had been incorporated, further extension was not observed in vitro, suggesting that primers containing a 3'-terminal nucleotide analog were high K(m) substrates for polymerase alpha.",Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC). ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377379/),nM,23,267842,DB00987,Cytarabine
,20532508,distribution,"The distribution and elimination half-lives, steady-state volume of distribution and clearance values were 0.5 h, 7 h, 181 L and 307 l/h for Ara-C and 4.1 h, 34 h, 118 L and 2.64 l/h for Ara-U, respectively.",Effective clearance of Ara-U the major metabolite of cytosine arabinoside (Ara-C) by hemodialysis in a patient with lymphoma and end-stage renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20532508/),h,0.5,269635,DB00987,Cytarabine
,20532508,elimination half-lives,"The distribution and elimination half-lives, steady-state volume of distribution and clearance values were 0.5 h, 7 h, 181 L and 307 l/h for Ara-C and 4.1 h, 34 h, 118 L and 2.64 l/h for Ara-U, respectively.",Effective clearance of Ara-U the major metabolite of cytosine arabinoside (Ara-C) by hemodialysis in a patient with lymphoma and end-stage renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20532508/),h,0.5,269636,DB00987,Cytarabine
,20532508,steady-state volume of distribution,"The distribution and elimination half-lives, steady-state volume of distribution and clearance values were 0.5 h, 7 h, 181 L and 307 l/h for Ara-C and 4.1 h, 34 h, 118 L and 2.64 l/h for Ara-U, respectively.",Effective clearance of Ara-U the major metabolite of cytosine arabinoside (Ara-C) by hemodialysis in a patient with lymphoma and end-stage renal failure. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20532508/),h,7,269637,DB00987,Cytarabine
,20532508,steady-state volume of distribution,"The distribution and elimination half-lives, steady-state volume of distribution and clearance values were 0.5 h, 7 h, 181 L and 307 l/h for Ara-C and 4.1 h, 34 h, 118 L and 2.64 l/h for Ara-U, respectively.",Effective clearance of Ara-U the major metabolite of cytosine arabinoside (Ara-C) by hemodialysis in a patient with lymphoma and end-stage renal failure. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20532508/),l,181,269638,DB00987,Cytarabine
,20532508,clearance,"The distribution and elimination half-lives, steady-state volume of distribution and clearance values were 0.5 h, 7 h, 181 L and 307 l/h for Ara-C and 4.1 h, 34 h, 118 L and 2.64 l/h for Ara-U, respectively.",Effective clearance of Ara-U the major metabolite of cytosine arabinoside (Ara-C) by hemodialysis in a patient with lymphoma and end-stage renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20532508/),[l] / [h],307,269639,DB00987,Cytarabine
,15020609,disease-free survival,The median disease-free survival in those achieving CR was similar in the two arms (10 versus 9.3 months) as was the patients' overall survival (4.6 versus 5.4 months).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),month,10,270463,DB00987,Cytarabine
,15020609,disease-free survival,The median disease-free survival in those achieving CR was similar in the two arms (10 versus 9.3 months) as was the patients' overall survival (4.6 versus 5.4 months).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),month,9.3,270464,DB00987,Cytarabine
,15020609,overall survival,The median disease-free survival in those achieving CR was similar in the two arms (10 versus 9.3 months) as was the patients' overall survival (4.6 versus 5.4 months).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),month,4.6,270465,DB00987,Cytarabine
,15020609,overall survival,The median disease-free survival in those achieving CR was similar in the two arms (10 versus 9.3 months) as was the patients' overall survival (4.6 versus 5.4 months).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),month,5.4,270466,DB00987,Cytarabine
,15020609,CR rates,The CR rates in MDR+ (69% of patients) versus MDR- patients were similar for those receiving either chemotherapy regimen (16% versus 24%).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),%,16,270467,DB00987,Cytarabine
,15020609,CR rates,The CR rates in MDR+ (69% of patients) versus MDR- patients were similar for those receiving either chemotherapy regimen (16% versus 24%).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),,24,270468,DB00987,Cytarabine
,15020609,CR rate,"The CR rate for unfavorable cytogenetic patients (45% of patients) was 13% compared to the remainder, 28% (P=.09).","Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),%,13,270469,DB00987,Cytarabine
,3589691,initial half-life,A rapid biphasic elimination of the drug from plasma with an initial half-life of 18 minutes was seen after SC injection.,ara-C in plasma and ara-CTP in leukemic cells after subcutaneous injection and continuous intravenous infusion of ara-C in patients with acute nonlymphoblastic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3589691/),min,18,272094,DB00987,Cytarabine
,3589691,half-life,The mean half-life was 2.1 hours.,ara-C in plasma and ara-CTP in leukemic cells after subcutaneous injection and continuous intravenous infusion of ara-C in patients with acute nonlymphoblastic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3589691/),h,2.1,272095,DB00987,Cytarabine
